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Abstract 
Evidence is limited to support decisions on treatment and monitoring requirements in 
the management of hepatitis B virus (HBV) and HIV coinfected patients. The 
antiretroviral drugs lamivudine (3TC), emtricitabine (FTC) and tenofovir (TDF) are also 
active against HBV. 
To assess the evidence for using TDF with 3TC/FTC to suppress HBV viral replication 
in coinfected patients we performed a systematic review and meta-analysis of HBV 
viral suppression from published and unpublished reports. We then carried out a sub-
study of the DART trial (a randomised controlled trial of HIV treatment strategy in 
Africa) to examine HBV epidemiology, viral suppression and associations between 
HBV coinfection and liver status, immunosuppression (CD4 cell count) and death. 
The meta-analysis found: the proportion of coinfected patients with suppressed HBV 
replication after one year of TDF treatment was 57.4%, rising to 85.6% at three years; 
that prior or concomitant 3TC exposure had no effect; but that little data was available 
beyond three years follow-up.  
55.2% of the DART population had evidence of HBV exposure and 9.3% had current 
infection (detectable HBsAg). HBeAg status and HBV viral load (HBV VL), but not 
exposure or current infection, were associated with immunosuppression. After 48 
weeks, HBV suppression was achieved in 81 (56.6%) of 143 with detectable HBV DNA 
at baseline. Suppression was associated with baseline HBeAg status and HBV VL but 
not TDF/3TC versus 3TC alone. Suppression once achieved was durable regardless of 
which treatment was given. If not suppressed at 48 weeks, most treated with both 3TC 
and TDF suppressed by the end of follow-up, but not those treated with 3TC alone. 
Coinfection was associated with an increased risk of exacerbations of liver 
inflammation, HIV progression and death, but deaths were not usually liver-related.  
These studies have implications for the management of HBV coinfection in resource-
poor settings.  
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1 Background 
1.1 Epidemiology 
Over the last three decades, since its discovery, human immunodeficiency virus (HIV) 
infection has grown to become one of the most important infectious diseases in the 
world; an estimated 35.3 million people were living with HIV in 2012 and 1.6 million 
died of AIDS-related causes in 2012 [1]. 
However, in patients with access to treatment, rates both of progression to AIDS and of 
HIV-related deaths declined rapidly after the introduction of Highly Active Antiretroviral 
Therapy (HAART) in 1996 and HIV is now managed as a chronic disease [2-5]. 
UNAIDS estimates that the total number of AIDS-related deaths worldwide peaked at 
about 2.3 million in 2005 and has been declining since [6]. 
Hepatitis B virus (HBV) infection is one of the most common infections worldwide with 
one third of the world’s population showing evidence of prior infection [7]. 
Approximately 360 million people worldwide have chronic HBV (CHB), defined as the 
presence in blood of HBV surface antigen (HBsAg) or HBV DNA for a period of at least 
six months [8]. HBV-related liver disease progresses through a process of inflammation 
and fibrosis and leads to death via cirrhosis and liver failure or via hepatocellular 
carcinoma (HCC), being one of the top 10 infectious causes of death worldwide [9]. It 
has been estimated that HBV caused 786,000 deaths in 2010, most through cirrhosis 
(40%) and hepatocellular carcinoma (43%) [10]. The risk of an individual infected with 
HBV failing to control the virus and developing CHB is related to the age at which 
infection is contracted with rates of chronicity ranging from 80 to 90% in infants born to 
HBeAg positive mothers, 23 to 73% in young children and 5 to 10% in adults (reviewed 
by Hyams [11]) and, to a lesser extent, to the sex of the individual, with males being 
more likely to remain chronically infected [11-14].  
The natural history of CHB infection classically passes through some or all of four 
stages, namely (i) immunotolerance, (ii) immunoactivation, (iii) inactive carrier and (iv) 
reactivation [15]. In those infected at or near birth, the first two phases tend to be 
prolonged until the third or fourth decade [16, 17] while those infected later in childhood 
may have a very brief or absent immunotolerant phase [18, 19]. 
Data on the prevalence of hepatitis B and C (HCV) in HIV-positive adults in sub-
Saharan Africa was recently reviewed by Barth [20]. 60 studies with at least 20 HIV-
infected adults were included. The range of HBsAg prevalence was 3.9 to 70.3% while 
the median prevalence was 12.1% and the mean 14.9%. Some studies in the meta-
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analysis included HIV-negative patients and the risk ratio for HBsAg positivity in HIV-
positive patients compared to HIV-negative was 1.4 (95% confidence interval 1.2 to 
1.7). 
By comparison the cumulative prevalence of HBsAg (proportion ever having had 
detectable HBsAg) in the UK HIV-positive population has been estimated to be 6.9% 
[21]. 
Epidemiology of Hepatitis B and HIV in Uganda and Zimbabwe 
The prevalence of CHB varies worldwide but sub-Saharan Africa, where two thirds of 
those with HIV live, is an area of high CHB prevalence [22]. 
In sub-Saharan Africa few children are infected with hepatitis B at or before birth. There 
are no relevant data from Uganda or Zimbabwe but in a study in northern Namibia 
Botha found only 1% of children under 6 months positive on HBsAg testing but a 
dramatic increase occurred at around 11 months of age with 13% positive thereafter. 
Only 37% of children positive for HBsAg had mothers who were also positive for 
HBsAg, indicating transmission from other sources [23]. 
Global distribution of age-specific HBsAg prevalence was recently estimated regionally 
by the World Health Organisation [24]. Estimates in adults (>20 years) for 2005 were 
between 4.0 and 6.8% for females and 4.3 and 6.8% for males in East sub-Saharan 
Africa (includes Uganda) and between 5.4 and 8.4% for females and 4.2 and 6.4% for 
males in Southern sub-Saharan Africa (includes Zimbabwe). 
The earliest estimates of HBV prevalence in what is now Zimbabwe were performed by 
Cruickshank in the early 1970s with HBsAg prevalence in blood donors of African 
ethnicity in Harare 3.6 to 4.0% and in Bulawayo 4.4%. In blood donors of European 
ethnicity the prevalence was 0.2%. In rural areas the prevalence varied from 0% in 
Nyanga to 5.6% in Kariba [25, 26]. In 1978 Goldsmid also noted ethnic differences, this 
time in the army, with no cases of HBsAg found in 564 soldiers identified as Asian, 
coloured or European whereas the prevalence in those identified as African was 7.6% 
In a subset, the performance of cross-over immune-electrophoresis (CIEP) and direct 
haemagglutination tests were compared with the prevalence being estimated as 6.3% 
with the former and 12.5% with the latter, raising the possibility of underestimation of 
prevalence in the earlier studies which had also used the CIEP method [27]. A national 
seroprevalence survey in 1985 found higher rates in healthy volunteers of between 
13.5% (Kariba) and 19.7% (Masvingo) with 13.7% in Harare [28]. A second national 
seroprevalence survey in 1996 found an overall prevalence of 15.4% with 19.6% in 
Harare but wide regional differences from 2.8% to 36.8% [29]. A study in 1999 of 
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pregnant women delivering at Harare Maternity Hospital found 25.0% carried HBsAg 
[30]. The latest data comes from 2010. A study in pregnant women which also 
examined HIV-1 prevalence found that rates in Harare were lower than in previous 
studies: 2.4% in HIV-negative and 5.8% in HIV-positive women [31]. Another study, a 
multinational cohort from 2 randomised controlled trials, found HBsAg in 11.0% of HIV-
positive participants in Zimbabwe [32]. 
HBV seroprevalence was also first studied in Uganda in the early 1970s. HBsAg was 
detected in 2.1 to 3.1% of inpatients in Kampala [33, 34]. Since then studies have 
found wide variations in prevalence and differences in distribution (Table 2). For 
example, in the largest study prevalence was 23.9% in the northeast region and 3.8% 
in the southwest [35]. Significant gender differences have been found in some studies 
but no difference found in others. 
Immunisation against HBV is effective and its inclusion in childhood schedules has 
been recommended by the World Health Organization since 1992. It was introduced 
into schedules in Zimbabwe in 2000 and Uganda in 2002 [36]. The latest estimated 
coverage from the World Health Organization is that in Uganda 78% of the target 
population (infants), and in Zimbabwe 95%, have received a third dose of HBV vaccine 
[37, 38]. 
UNAIDS estimated the prevalence of HIV in adults aged 15 to 49 years to be 6.5% in 
Uganda and 14.3% in Zimbabwe in 2009 compared to 7.0% and 23.7% respectively in 
2001 [39]. 
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Table 1: Hepatitis B prevalence in Zimbabwe 






Cruickshank[25] 1971 Harare BD NR 25 4.0  
Cruickshank[26] 1972 Harare BD – Af  NR 3,986 3.6  
  Harare BD – Af forces  387 7.2  
  Harare BD – Eu  1,275 0.2  
  Bulawayo BD  228 4.4  
  Nyanga HS and Pt  71 0.0  
  Chitsungo Villagers  652 1.5  
  Chitsunga Villagers  169 4.7  
  Kariba Villagers  144 5.6  
Goldsmid[27] 1978  Army – non-Af  NR 564 0.0  
   Army – Af  262 8.3  
   Army – Af  96 
a
7.6  
   Army – Af  96 
b
12.5  
Tswana[28] 1985 Masvingo HV NR 147 19.7  
  Gweru HV  116 14.7  
  Kariba HV  245 13.5  
  Wedza HV  220 16.8  
  Harare HV  539 13.7  
  Kadoma HV  198 17.2  
  Nationwide HV  1,471 13.7  
Emmanuel[41] 1988 Harare HS NR 226 6.6 48.7 
Mvere[42] 1996 Harare BD NR 198 3.5  
Tswana[29] 1996 Harare HV NR 209 19.6  
  Manicaland HV  381 9.2  
  Matabele S HV  281 21.7  
  Nationwide HV  3,394 15.4 44.6 
Madzime[30] 1999 Harare Pregnant NR 984 25.0  
Mavenyengwa[31] 2010 Chitsungo Pregnant All 59  42.4 
  Chitsungo Pregnant Neg 50 4.0  
  Chitsungo Pregnant Pos 9 0.0  
  Guruve Pregnant All 163  34.4 
  Guruve Pregnant Neg 98 3.1  
  Guruve Pregnant Pos 34 2.9  
  Harare Pregnant All 181  24.3 
  Harare Pregnant Neg 126 2.4  
  Harare Pregnant Pos 52 5.8  
Thio[32] 2010 Harare Pt Pos 227 11.0  
a cross-over immuno-electrophoresis. b direct haemaglutination test (Hepa-test). BD: 
blood donors. Af: African. Eu: European. HS: hospital staff. Pt: patients. HV: healthy 
volunteers. NR: not recorded.  
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Table 2: Hepatitis B prevalence in Uganda 






Maynard[33] 1970 Kampala IP NR 143 2.1  
Anthony[34] 1972 Kampala IP NR 224 3.1  
Sadikali[44] 1973 Kampala IP NR 213 3.3  
Hudson[45] 1988 Kagando  OP All 206 5.3  
  and Kisiizi  Neg 138  58.7 
    Pos 15  80.0 
de Lalla[46] 1990 Kitgum Pt, preg, forces NR 358 10.0  
   Male  213 12.7  
   Female  145 6.2  
Opio [47] 1994 Entebbe OP  1,429 15.7 42.9 
    Neg 1,020 14.6 37.5 
    Pos 409 18.6 55.4 
Nakwagala[48] 2002 Kampala OP All 258 15.5 53.5 
   OP Neg 129 13.2 41.9 
   OP Pos 129 17.8 65.1 
   Bantu NR 238 13.9  
   Nilotic/Hamites NR 20 35.0  
Pido[49] 2005 Kampala Medical students NR 182 11.0 65.9 
Braka[50] 2006 Nationwide HCW NR 311 9.0 55.9 
Pirillo[51] 2007 Kampala Pregnant Pos 164 4.9  
Weidle[52] 2008 Tororo/Busia ART initiation Pos 545 23.5 67.3 
Bwogi[35] 2009 Nationwide Survey NR 5,875 10.3 52.3 
   Male  2,656 11.8 53.6 
   Female  3,219 9.1 51.2 
  North east   473 23.9 87.5 
  Central 
a
   1,023 6.2 38.6 
  Kampala   363 5.3 31.9 
  Southwest   780 3.8 24.9 
Ocama[53] 2010 Kampala ART initiation Pos 470 8.9  
Seremba[54] 2010 Kampala IP All 380 14.5  
   IP – male All 169 14.8  
   IP – female All 211 14.2  
   IP Neg 186 10.8  
   IP Pos 194 18.0  
Ziraba[55] 2010 Kampala HCW  370 8.1 48.1 
   Male  98 9.2 46.3 
   Female  272 7.7 53.1 
Stabinski[56] 2011 Rakai Community   438 4.8  
a includes Entebbe & Rakai. IP: In-patients. OP: Out-patients. Pt: Patients. Preg: 
pregnant. HCW: health care workers. NR: not recorded. ART: antiretroviral therapy. 
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1.2 Hepatitis serology testing 
Serological tests for Hepatitis B detect either viral antigens or antibodies against those 
antigens. Surface antigen is found on the virion envelope and also makes up the 
sphere and filament forms found in the blood of individuals with HBV infection. It is 
produced in 3 forms of varying length from the S domain of the viral DNA; the S domain 
alone, the S plus pre-S1 and the S plus pre-S1 and pre-S2. The C open reading frame 
(ORF) codes for the core antigen and the e antigen. The core antigen is a structural 
protein that forms the 27 nm nucleocapsid. The e antigen is derived from the same 
ORF but with transcription starting at a different codon. It is non-structural and is found 
independent of the virus particles. Its function is unknown though it may play an 
important role in mother to child transmission [57]. Tests used clinically to detect and 
assess HBV infection include surface antigen (HBsAg), e antigen (HBeAg) and 
antibodies against the surface (anti-HBs), e (anti-HBe) and core (anti-HBc) antigens. 
Anti-HBc appears at around 2 months after infection in the majority of patients and 
persists for life. It is therefore a marker of ever having been infected. The HBV proteins 
HBsAg and HBeAg are markers of on-going infection and are not found if an infection 
is cleared. In those who clear HBV, anti-HBs usually becomes detectable around 4 to 5 
months after HBV acquisition as the infection resolves and HBsAg and HBV viral load 
become undetectable [58]. 
HBeAg, discovered by Magnius [59], is a marker of a state with high levels of viral 
replication, high viral load and high infectivity [60]. It appears in blood with HBsAg early 
during acute infection and disappears if the infection resolves [61]. In CHB infection, 
individuals usually seroconvert from HBeAg positive to anti-HBe positive between the 
second and fourth decades of life and then have a lower HBV viral load, low or normal 
ALT and a lower probability of progression [61]. 
1.3 Increasing importance of HBV coinfection in HIV infection 
In countries with widespread access to HAART, rates of HIV-related deaths are 
declining [3-5] and although deaths from AIDS are still more common, a high [62, 63] 
and increasing [64] proportion of deaths in HIV-infected individuals have been from 
liver disease, which is commonly due to coinfection with HBV or HCV (Figure 3) [62, 
65].  
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Figure 3: Cause of death in 3 large multi-centre HIV cohort studies 
 
References: Mortality 2000 [66], D:A:D [62], ATCC [67]  
A French study that attempted to identify a cause for all deaths occurring in 2000 in 
HIV-infected individuals found viral hepatitis to be the second most common cause of 
death after AIDS, causing 11% of deaths, with HBV responsible for 2%. 47% died of 
AIDS-related causes (23% non-Hodgkin’s lymphoma), 11% of non-AIDS and non-
hepatitis cancers, 7% of cardiovascular disease, 6% of bacterial infections, 4% of 
suicide and 1% of adverse reaction to antiretroviral medication [66]. 
Liver-related disease was also the most common non-AIDS-related cause of death in 
an analysis of data (1999-2004) from 11 cohorts in Europe, Australia and the United 
States, causing 15% of deaths. AIDS caused 31%, cardiovascular disease 11% and 
non-AIDS cancers 9%. Liver-related death was found to be associated with viral 
hepatitis infection; 76% of liver-related deaths occurred in patients with HBV and/or 
HCV coinfection. Causes of liver-related deaths included hepatic failure, hepatocellular 
carcinoma, variceal haemorrhage and drug toxicity [62]. 
Another multi-cohort analysis (1996-2006) found a rather lower proportion of deaths 
were attributable to liver disease. 13 cohorts in Europe and North America were 
included and liver disease was responsible for 7.0% of deaths, being the fifth most 
common cause of death after AIDS, non-AIDS malignancies, non-AIDS infections and 
violence and/or drug-related causes. In those who contracted HIV via injecting drug 
use the hazard ratio (HR) for liver death was 6, suggesting again that the relative 
importance of liver death in HIV is related to the prevalence of viral hepatitis coinfection 
[67]. 
At a single site in the United States of America, Bica found liver disease as a cause of 
death to be second to AIDS (23% after 49% with AIDS) but of note found the rate 
increased from 12% in 1991 to 50% in 1998-99 (p=0.003) [64]. 
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Similar results from Catalonia over the period 1997-2004 showed death due to liver-
related causes second (23%) to deaths due to AIDS (40%) with the proportion of 
deaths that were liver-related increasing from 8% in 1997 to 41% in 2004 [68]. 
1.4 Interactions between infection with HIV and HBV 
Despite the announcement of the discovery of a novel virus, later to be called HIV, in 
May 1983 [69], Ravenholt postulated in October of that year that HBV was itself the 
cause of AIDS. This was because of the shared epidemiological pattern, the 
overlapping risk groups and routes of transmission and the development of liver 
disease after a similar latent period [70]. In the same edition of The Lancet McDonald 
suggested that the infectious agent of HIV could be a “strand of nucleic acid residing 
within HBsAg” much like delta virus [71]. The virology of HIV has since been 
characterised and HIV and HBV are distinct viruses with very different life-cycles and 
pathology. They do however have similarities and clinical manifestations of infection 
with the two viruses interact. The mechanisms of such interaction are complex and 
incompletely elucidated.  
1.4.1 Effect of HBV infection on HIV-related disease 
One proposed mechanism whereby HBV could exacerbate HIV-related disease is via 
the increase in HIV replication seen to be caused by the product of the X gene of HBV 
[72]. 
Studies examining the effect of HBV infection on progression of HIV disease have 
given conflicting results. Most have shown no effect of HBV status on progression to 
AIDS [63, 73-83], CD4 rise on HAART [74, 75, 79, 80, 82, 84-88] (including when 
examined at 3 months and later [63, 89]), HIV virological suppression on HAART [63, 
78, 79, 81-87, 89] or on HIV-related deaths [62, 79, 81, 90, 91].  
In contrast some studies have found an increased rate of AIDS [92-94], HIV virological 
failure [80] or HIV-related death [76, 80, 82, 86, 94, 95] and a reduced CD4 rise on 
treatment [81, 96]. 
A meta-analysis including data from 12 studies concluded that HBV has no effect on 
progression to AIDS (effect estimate, calculated from pooled risk ratio, incidence rate 
ratio (IRR), odds ratio (OR), or HR using a random effects model, 0.93, 95% CI 0.75 to 
1.15). All-cause mortality was increased (effect estimate 1.36, 95% CI 1.12 to 1.64) but 
although deaths were not stratified by cause the authors did suggest that reduced 
survival could be due to liver disease secondary to HBV infection rather than to an 
increase in HIV-related deaths [83]. 
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Of course there is a risk of confounding factors being responsible for the association 
found between hepatitis infection and death. For example, in the SMART study HBV or 
HCV coinfection increased the risk of non-AIDS death but the most common causes of 
these deaths were “unknown”, substance abuse and non-AIDS malignancy while only 2 
out of 37 deaths were hepatic and neither of these had HBV [97]. 
These studies were carried out on populations in Europe, North America, Australia, the 
Asia-Pacific region and in South Africa and overall suggest that any effect of HBV 
status on HIV disease is small if it exists at all. 
1.4.2 Effect of HIV infection on HBV-related disease 
In contrast to the lack of effect that HBV has on HIV disease, HIV affects HBV disease 
at several points in its natural history including the probability of remaining chronically 
infected, the level of HBV replication, e antigen status, liver inflammation, fibrosis, 
response to treatment and liver-related death. 
Progression from acute to chronic HBV 
HIV infection decreases the chance that HBV will be cleared after infection. Hadler 
followed HIV-positive and negative men in the USA who contracted HBV while enrolled 
into a HBV vaccine trial and found that the proportion developing CHB was 7% in the 
HIV-negative men and 33% in the HIV-positive (aOR 8.0, p<0.001) [98]. These figures 
are similar to those from Australia published by Bodsworth who found 4% of HIV-
negative and 23% of HIV-positive men who have sex with men (MSM) developed CHB 
after infection (p=0.026) [99]. 
HBV DNA level 
In a study of 132 French MSM, Colin found coinfected patients to have higher HBV 
DNA levels (p=0.01) [100] though this finding was not replicated in a larger French 
population of 477 men and women with HBV infection which found no significant 
difference in DNA level between HIV-positive and negative patients [101]. However in 
the second study more of the coinfected patients received anti-HBV treatment which 
may explain the contrast with the earlier study in which patients were untreated. 
Immunopathogenesis 
The innate immune response to early HBV infection involves natural killer (NK) cells 
which have anti-HBV effects and anti-hepatocyte effects but HBV infection itself 
appears to have immunosuppressive activity. In a study of 8 HIV-negative and 3 HIV-
positive patients with acute HBV infection [102] NK activity was lower in HBV infected 
individuals than in uninfected controls and was similar in 2 of those with HIV. These 2 
had CD4 counts of 495 and 576. The third HIV-positive patient had a CD4 count of 12 
 Chapter 1: Background  Page 28 of 240 
and in contrast in his samples NK activity was markedly raised. This patient had a 
fulminant hepatitis and died. Thus severe HIV-associated immunodeficiency may 
dramatically alter the course of acute HBV. 
Adaptive immune responses also differ in HIV-positive patients. In patients immune to 
HBV (anti-HBs and anti-HBc positive), HBV-specific CD8+ T cell responses were lower 
in those HIV-positive than in those HIV-negative and were found to increase after 
treatment with HAART in 2 of 4 patients examined [103]. 
Hepatic stellate cells in the absence of injury produce type IV collagen which is a 
component of normal basement membrane. These cells can express cell surface 
markers CD4, CCR5 and CXCR4 and when activated can be infected by HIV, though 
this may in fact be independent of such cell surface markers. Once infected by HIV, 
stellate cells switch to producing type I collagen and secrete the pro-inflammatory 
cytokine MCP-1 [104]. MCP-1 secretion and stellate cell chemotaxis are also increased 
directly by the HIV surface molecule gp120 [105]. Thus HBV may activate stellate cells, 
facilitating HIV infection of these cells which leads to increased inflammation and 
fibrosis. 
Evidence for HIV infection of hepatocytes is unclear but it has been shown that gp120 
and HIV virions can both induce hepatocyte apoptosis [106] and sensitise hepatocytes 
to apoptosis in response to other causes of injury [107]. Apoptosis may thus be one 
pathological mechanism whereby HIV infection increases liver damage. 
Only one case of liver disease thought to be directly due to HBV in a patient coinfected 
with HIV has been reported [108] and usually HBV is not cytopathic, the damage to the 
liver from HBV infection being due to the immune response. It may therefore be 
expected that in immunosuppressive disease such as HIV the degree of liver damage 
may be less. 
Consistent with this is the finding that despite a higher number of hepatocytes showing 
HBeAg or HBcAg on microscopic examination of liver biopsy specimens [100, 109], 
coinfected patients had lower alanine transaminase (ALT) levels (p=0.0001) [100]. 
However albumin levels were also lower (suggesting advanced liver disease) and the 
proportion with cirrhosis higher in HIV-positive patients. Lower ALT is associated with 
reduced liver inflammation as a result of less active liver disease but is also associated 
with reduced numbers of remaining hepatocytes in individuals with very advanced liver 
disease. 
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HBeAg to anti-HBe seroconversion 
Coinfected patients are more likely to have persistent HBeAg. In a study that followed 
152 MSM with detectable HBsAg over a mean follow-up period of 2.8 years, Gilson 
found the rate of HBeAg loss to be lower in the coinfected patients with a relative 
hazard of 0.39 (95% CI 0.16 to 0.94) compared with HIV-negative men [77]. 
Similarly other studies have shown lower rates of HBeAg loss [101] and anti-HBe 
seroconversion [101, 110] and higher rates of seroreversion (from anti-HBe positive / 
HBeAg negative to anti-HBe negative / HBeAg positive) [110]. 
Pre-core mutants 
Mutations in the HBV pre-core region are associated with HBeAg negative CHB and a 
high risk of progression to liver fibrosis, failure and death [111]. Whether they occur 
more frequently in HIV-coinfected patients is unclear. In a prospective study of HIV-
positive patients with CHB, Revill found a mutation that gave rise to shortened 
precore/core proteins and higher HBV DNA levels and which occurred at a higher rate 
in coinfected than in HBV monoinfected patients [112]. 
However in another prospective cohort, Cassino found that coinfected patients were 
less likely to have basal core promoter mutations and that precore mutations were no 
more likely than in monoinfected patients [113]. 
Liver flares 
A flare is an acute worsening of liver disease and is marked by a rise in transaminases 
(precise definitions vary – see section 1.7.3). The underlying pathological mechanism 
in HBV-infected patients is a cytotoxic T-cell response against HBV-infected 
hepatocytes. In coinfected patients a flare may arise in several different clinical 
situations and may be fatal [114-116]. Flares associated with treatment may be related 
to an adverse drug reaction or to an improvement in immune status (immune 
reconstitution disease, IRD), which typically occur soon after ART initiation, or to a rise 
in HBV DNA which may occur when treatment is withdrawn or when treatment 
resistance arises. Flares may also occur on HBeAg positive to anti-HBe positive 
seroconversion as hepatocytes producing HBeAg are cleared by the immune system. 
Treatment-related flares are discussed in more detail in section 1.7.3. 
Liver disease progression and mortality 
In some studies cirrhosis has been found at higher rates in coinfected patients [100, 
101] while other studies have failed to show such an association [110, 117]. 
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In those coinfected with HIV and HBV, rates of liver-related death are much higher than 
in those with mono-infection or without either infection [118]. Rates in those uninfected, 
HBV monoinfected, HIV monoinfected and HBV/HIV coinfected were 0.0, 0.8, 1.7 and 
14.2 per 1,000 person years respectively in a prospective cohort of MSM (Figure 4).  
Figure 4: Effect of HBsAg and HIV status on liver-related mortality 
 
Reference: Thio [118] 
Response to treatment 
HIV coinfection decreases the rate of response to interferon treatment. In a randomised 
controlled trial of interferon-α2a for the treatment of CHB 33% of the HIV-negative 
patients responded to therapy (defined as sustained loss of HBV DNA and HBeAg) 
while none of the HIV-positive ones did [109]. Similar results were found in another 
randomised controlled trial of interferon-α2a in which 41% of HIV-negative patients lost 
HBeAg and 17% lost HBV DNA while again no HIV-positive patients responded [119] 
and another in which 39% of HIV-negative patients lost HBeAg and HBV DNA versus 
no HIV-positive patients [120]. 
In another randomised trial the relative risk of a response to interferon (defined as loss 
of HBV DNA and HBeAg and appearance of anti-HBe) was 0.22 in HIV-positive 
patients though confidence intervals on this result were wide (95% CI, 0.03 to 1.78) 
[121]. 
In a French cohort study, 26 HIV-positive and 50 HIV-negative men were treated with 
interferon-α2b for six months. Loss of HBV DNA occurred in 27% of those HIV-positive 
and 56% of those HIV-negative and HBe seroconversion occurred in 11.5% vs. 28% 
respectively, although these differences were not statistically significant [110].  
Another cohort study comparing HIV-positive and negative patients demonstrated a 
marked reduction in response associated with HIV. After a course of interferon of at 
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least 12 weeks, 1 of 23 (4.3%) HIV-positive and 42 of 91 (46.2%) HIV-negative had a 
sustained loss of HBeAg and HBV DNA [122].  
1.5 Treatment 
While HIV and HBV are not closely related, with HIV being a ssRNA-RT (single-
stranded, RNA reverse transcriptase) retrovirus (group VII) and HBV being a dsDNA-
RT (double-stranded, DNA reverse transcriptase) virus (group VI), and have very 
different life cycles, they both make use of a reverse transcriptase enzyme and some 
drugs which target reverse transcriptase have activity against both viruses. 
1.5.1 Treatment of HIV infection 
Drugs currently licensed for the treatment of HIV fall into six classes. In patients who 
have not received prior therapy and virological testing shows no drug resistance, 
guidelines recommend the use of two nucleoside (or nucleotide) reverse transcriptase 
inhibitors (NRTI) together with either a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), a protease inhibitor (PI) boosted with low-dose ritonavir (RTV) or an integrase 
inhibitor [123, 124]. 
The choice of NRTIs is wide but in general either lamivudine (3TC) or emtricitabine 
(FTC) will be used with tenofovir (TDF) or alternatively with either zidovudine (AZT) or 
abacavir (ABC). 
1.5.2 Treatment of HBV infection 
Seven drugs are available to treat HBV [125] and are of two classes: NRTI and 
interferons. 
NRTI act on the HBV DNA-polymerase at one or more of three steps: priming, minus 
strand synthesis and plus strand synthesis. They have differing potencies and patterns 
of resistance. All six NRTIs act on minus strand synthesis. ADV and TDF also inhibit 
priming, 3TC and clevudine inhibit plus strand synthesis and entecavir (ENT) and 
telbivudine inhibit all three stages. 
While a course of interferon of finite duration may lead to a prolonged HBV DNA 
suppression, response rates are low in the context of HIV coinfection (section 1.4.2). In 
HIV-negative patients response rates have been shown to vary by HBV genotype, with 
response (HBeAg and DNA clearance) rates by genotype as follows: A 49 to 66%, B 
39 to 41%, C 15 to 17%, D 25 to 26%, E 36%, F/H 50%, G 20% [126-130].  
In the past, treatment of HBV has been stratified according to HBeAg status, but recent 
guidelines advocate that treatment decisions be made on the basis of liver 
 Chapter 1: Background  Page 32 of 240 
inflammation (ALT) and fibrosis and on HBV DNA level with long-term viral suppression 
the goal [131]. Rates of HBV viral suppression are high with NRTI treatment. Due to 
the interactions between HIV and HBV and the dual action of many treatments (and 
therefore the risk of promoting HIV resistance), current recommendations state that 
coinfected patients should start HAART with a regimen including TDF and 3TC or FTC 
if their CD4 count is <500 cells/mm3. Patients with a higher CD4 count requiring HBV 
treatment are also recommended to start HAART with TDF and 3TC or FTC but 
adefovir (ADV) or interferon (acting only on HBV) can be used in patients who do not 
want or are unable to take TDF as part of HAART [131, 132]. 
1.6 Benefits of treatment in HBV/HIV coinfection 
Treatment guidelines in Europe and North America recommend that HBV status is 
determined for all HIV-infected patients [133, 134]. However HBV testing is not routine 
in resource-poor settings and there is a lack of data on the effect of HBV coinfection on 
clinical outcomes [135]. 
1.6.1 HBV suppression 
Studies have shown the ability of 3TC [136, 137], TDF [138-140], ADV [141], 3TC plus 
ADV [142], 3TC plus telbivudine [143], 3TC plus TDF [114, 139, 140, 144, 145] and 
FTC plus TDF [117, 140, 146] to suppress HBV in HIV-coinfected patients. 
TDF with 3TC has been shown to be more effective than 3TC alone in naïve patients 
[114, 139, 144, 147] and also to be effective in the presence of 3TC resistance [139, 
144]. 
There is very limited data from randomised controlled trials comparing TDF as the only 
HBV-active drug with TDF used in combination with 3TC or FTC. In one such trial (with 
three arms: 3TC, TDF and 3TC plus TDF), Nelson examined suppression at 48 weeks 
and found no difference between groups in terms of the proportion with HBV DNA <400 
copies/mL at 48 weeks [148].  
In a second randomised controlled trial, Matthews compared TDF with TDF plus 3TC in 
naïve patients and also found no difference in suppression rates at 48 weeks [114]. 
1.6.2 Liver disease progression and mortality 
The risk of cirrhosis [149] and hepatocellular carcinoma [150] are related to the level of 
HBV DNA and suppression of HBV has been shown to reduce the risk of disease 
progression [151]. 
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Improved liver function tests and reduced degree of cirrhosis 
Although the development of cirrhosis has been regarded as an irreversible step in the 
progression of chronic liver disease, there have been reports showing that 
improvement is possible. In one case, the liver biopsy improved from Metavir F4 
(cirrhosis) to Metavir F1 after 3 years of HBV suppression on TDF-containing HAART 
[152]. Such reports are of course subject to the limitations inherent in the small sample 
provided by percutaneous liver biopsy. However liver function tests can also improve in 
coinfected patients with cirrhosis, as reported in one study of 7 patients treated with 
TDF in whom HBV DNA was suppressed [153]. 
In another study, 141 coinfected patients were followed on TDF. In those with the most 
severe fibrosis at baseline (F3 or F4) there was a rapid improvement in fibrosis score 
(Fibrometer, which uses age, platelets, prothrombin index, aspartate 
aminotranseferase (AST), alpha-2-microglobulin, urea and hyaluronic acid [154]) during 
the first year and a steady decline in degree of fibrosis up to 3 years [155]. 
An extreme case was described by Guiterrez in which a HBV/HIV coinfected patient 
who had been put on a waiting list for liver transplantation with advanced liver disease 
(including jaundice, ascites and gastrointestinal bleeding) started treatment including 
TDF plus 3TC and 45 months later had improved to such a degree that he was taken 
off the transplant list [156]. 
Decreased mortality 
Highly active antiretroviral therapy (HAART) has greatly improved the prognosis for 
patients infected with HIV, with dramatic declines in the incidence of AIDS and the rate 
of death [157]. However, with this decline in AIDS-related causes of death, liver 
disease has emerged as one of the most common causes of death in HIV-positive 
individuals [158] and is associated with HBV or HCV coinfection in most cases [62]. 
This is primarily due to a lowering of the risk of death in those on HAART rather than 
HAART causing liver deaths. For example, the SMART study showed that the 
incidence of liver disease was lower in those taking HAART continuously compared to 
those who took it intermittently, despite relatively high CD4 counts [159]; this protective 
effect was also seen in HBV and HCV coinfected patients [97]. 
1.6.3 Seroconversion to anti-HBe or anti-HBs 
Typically, HBV replication in carriers falls after a period of immune tolerance (with 
HBeAg-positivity), with seroconversion to anti-HBe and a reduced risk of liver disease. 
HIV coinfection decreases the rate of seroconversion and increases reactivation to 
HBeAg-positivity and the emergence of immune-escape mutations. 
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In a study reported in 1996, Benhamou described 40 patients treated with 3TC or 
3TC/AZT (not HAART) for 1 year, stratified according to baseline HBV DNA level 
(greater or less than 5 pg/mL, or approximately 1.4 x106 copies/mL). Of those with high 
HBV DNA, 5 (17%) lost HBeAg, 3 (10%) of whom developed anti-HBe, all within the 
first 6 months of treatment [136]. 
In Kosi’s study, HBeAg seroconversion was higher (though the difference was not 
statistically significant) in patients treated with TDF/FTC than in those treated with 3TC 
or FTC alone (14.5% vs. 9.2%, p=0.29) [160]. 
Seroconversion of HBsAg to anti-HBs is the most favourable end-point for those with 
HBV infection and represents resolved infection and (in the absence of profound 
immunosuppression) lifelong immunity. 
In Benhamou’s study above, of the 10 with low HBV DNA at baseline, 3 lost HBsAg, 2 
of whom seroconverted to anti-HBs. None of the 30 with high HBV DNA lost HBsAg 
[136]. 
Piroth followed 17 patients with HBV/HIV coinfection over three years from 3TC-
containing HAART initiation. One had HBsAg seroconversion with loss of HBsAg and 
appearance of anti-HBs [161]. 
In a retrospective cohort analysis of HBV/HIV infected patients, Kosi found a higher 
rate of cumulative annual loss of HBsAg (of 6.6% in HBeAg positive patients and 7.9% 
in HBeAg negative patients) and the rate was higher (though again the difference was 
not statistically significant) with TDF plus FTC than with 3TC or FTC (10.3% vs. 6.0%, 
p=0.23) [160, 162]. 
1.7 Limitations of treatment in HBV/HIV coinfection 
1.7.1 Resistance 
Since several drugs used to treat HBV also have activity against the reverse 
transcriptase of HIV they may induce resistance mutations in HIV. Thus these drugs 
should only be used in patients who are on fully suppressive HIV therapy. However HIV 
resistance mutations have been found in patients with HBV treated with 3TC, TDF and 
ENT [163]. In contrast, K65R was not found in seven patients treated with ADV 
monotherapy in Spain and Germany [164]. 
HIV treatment guidelines recommend the use of combinations of drugs with different 
classes (and therefore resistance mutations), at least until HIV is fully suppressed, in 
order to limit the development of resistance. However whether combination therapy is 
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of benefit in treatment of HBV is still unclear. Guidelines for the treatment of coinfected 
patients generally recommend using TDF plus either 3TC or FTC in combination as two 
drugs with HBV activity [125, 134]. However in the past, until TDF became available 
and widely used, 3TC monotherapy has been the norm. Very little data has been 
published comparing combination therapy with monotherapy and none show a 
significantly higher rate of suppression (for detail see meta-analysis results, chapter 3). 
Lamivudine resistance 
HBV resistance to lamivudine is well recognised in coinfected patients and commonly 
arises with mutations at codon 204 in the YMDD (tyrosine methionine aspartate 
aspartate) active site of the HBV reverse transcriptase or at codon 180. In a study of 30 
coinfected patients with resistance after 3TC monotherapy the mean duration of 3TC 
treatment before the emergence of resistance was 3.6 years [165]. 
HBV resistance in coinfected patients was first described by Benhamou in 1999. He 
followed 66 patients with detectable HBV DNA (with a lower level of detection of about 
140,000 IU/mL) who were treated with 3TC as the only active drug against HBV 
reverse transcriptase. Although after 2 months 86% had undetectable HBV DNA, only 
47% remained suppressed after 2 years and only 9% after 4 years of treatment. Of 24 
patients tested, 22 had detectable resistance mutations [166]. 
Some other studies have also found high rates of HBV resistance after 1 to 4 years of 
treatment, for example in the CAESAR study 5 (38%) of 13 had resistance after 1 year 
[167] while in a cohort study including patients from Australia and the USA mutations 
were found in 50% of those treated for less than 2 years and in 94% of those treated 
for over 4 years [168]. 
In contrast, recently published data gives a far lower rate of resistance acquisition. A 
prospective HIV cohort in Thailand included 30 HBV coinfected patients (63% HBeAg 
positive) who commenced 3TC-containing HAART. HBV suppression, defined as an 
undetectable HBV VL (the lower limit of detection was 50 copies/mL) was achieved by 
20 at 12 months (100% of those HBeAg negative and 47% of those HBeAg positive) 
and by 1 more at 38 months. Two others suppressed during the first year but had 
rebounded by 12 months. Of the 23 that reached HBV suppression, 18 (78%) 
maintained suppression to the end of follow-up. The cumulative rate of maintained 
response to 3TC was 80% at 4 years [169]. 
When used in combination with TDF, 3TC resistance is less common though it has 
been detected [144, 170, 171]. 
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Tenofovir resistance 
The mutation A194T was detected in 2 patients treated with TDF for over 6 months and 
was examined in vitro by site-directed mutagenesis, both alone and in conjunction with 
L180M and M204V. The triple mutant was found to have a >10 fold change in the IC50 
for TDF [171]. A second in vitro study confirmed this decrease in susceptibility both 
alone and with other (3TC) resistance mutations and calculated the fold change to be 
between 5 and 6. Of particular note, the replicative capacity of HBV was reduced by 
A194T with and without L180M and/or M204V, whereas this decrease was reversed by 
concomitant mutations in the pre-core or basal core promoter regions [172]. 
Other studies of patients treated with TDF have failed to show any TDF resistance 
mutations [114, 117, 145, 173]. 
1.7.2 HBsAg changes 
The HBV genome contains overlapping reading frames and mutations rtV173L and 
rtM204V/I that may arise in response to 3TC pressure are also sE164D and sI195M or 
sW196S/L/stop in the HBsAg gene. These HBsAg mutations reduce binding affinity of 
antibody against HBsAg in vitro [174]. rtV191I also causes a stop in the surface gene 
(sW182stop) [170]. These stop codons alter the conformation of surface antigen and 
may allow vaccine-escape [175]. Other surface gene mutations that arise in coinfected 
patients during 3TC therapy include sT114R, sP120T, sP120Q, sK122K/N, sQ129R, 
sM133I, sF134L, sT143M and sD144E [168, 176]. 
Stop codons in the surface gene may also interfere with HBV testing. HBsAg is 
frequently used to screen patients and products for the presence of HBV and such a 
modification in HBsAg may lead to false negative screening test results and to 
transmission of HBV [177]. Newer assays avoid this by including more than one 
epitope. 
1.7.3 Flares 
Exposure to HAART is in itself a risk factor for liver disease. Most antiretroviral 
medications are capable of causing liver damage, with in particular high-dose RTV 
[178] and nevirapine (NVP) [179] having a higher risk and although RTV is no longer 
used at high dose, NVP is still frequently used in developing countries. A recent 
systematic review that included over 30,000 adults and children starting first-line 
HAART in 8 randomised controlled trials and 26 cohort studies found that 8.4% of 
those treated with NVP suffered hepatotoxicity with 3.2% having a severe (grade 3 or 
grade 4) reaction. The incidence was lower in those treated with EFV, but 
hepatotoxicity was still reported for 3.6% and severe hepatotoxicity for 2.3% [180]. 
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In patients coinfected with HBV and HIV the risk of liver damage on commencing 
HAART has been shown to be higher. However previous estimates of the rate of 
significant liver damage have varied and studies have been limited by the use of 
different case definitions, low patient numbers and the lack of patients from Africa, 
where the majority of coinfected patients live. 
Different definitions of flare have been used with the most common being the AIDS 
Clinical Trials Group grade 3 definition: a rise in ALT or AST to five times the upper 
limit of normal (ULN) [181]. The ULN is typically around 40 IU/L (see section 1.8.1) and 
on occasion an absolute level of 200 IU/L to represent five times ULN has been used 
[182, 183]. Sometimes additional criteria are used to avoid misclassifying patients with 
raised transaminases at baseline, for example, a rise to 3.6 times the baseline value 
[179] or requiring a rise of at least 100 IU/L [184, 185]. Generally a single value above 
the threshold identifies a flare but it has been argued that a better definition is the 
detection of ALT >200 IU/L on two occasions at least 2 weeks apart to exclude 
transient rises [186].  
Previous studies have found wide variation in rates of flares in HBV/HIV coinfected 
patients starting HAART ranging up to 50% (see Table 3). Of note, rates in many 
studies in Africa have been low (0 to 3%) though African studies have found rates up to 
22.5%. However very few of the studies listed in Table 3 have found deaths associated 
with flares and when they have occurred have rarely been due to liver disease [85, 
187] and often to other causes (such as Kaposi’s Sarcoma or renal failure [184, 187]).  
 
 Chapter 1: Background  Page 38 of 240 









n / N 
Incid. 
(%) 




 15 / 87 20.8 
Saves [189] 2000 France 5x ULN 150
g
 5 / 29 17.2 
Piroth [161] 2000 France NR 1,095 3 / 17 17.6 




 2 / 12 16.7 




 13 / 29 44.8 
Bonfanti [190] 2001 Italy 5x ULN 534
g
 14 / 97 14.4 




 3 / 11 27.3 
Monforte [182] 2001 Italy 200 IU/L 540
f
 8 / 91 8.8 




 15 / 49 30.6 
Law [185] 2003 Thailand 5x ULN
c
 336 9 / 60 15.0 
Livry [193] 2003 France 2.5x ULN 570
f
 6 / 12 50.0 




 18 / 80 22.5 
Ofotokun [194] 2007 USA 2.5x ULN 672 43 / 84
 e
 51.2 
Matthews [114] 2008 Thailand 5x ULN
d
 336 9 / 36 25.0 
Weidle [52] 2008 Uganda 5x ULN 720 0 / 128 0.0 
Idoko [87] 2009 Nigeria 5x ULN 336 8 / 262 3.1 
Moore [195] 2010 Malawi 5x ULN 350 1 / 42
 e
 2.4 
Mbougua [196] 2010 Cameroon 5x ULN 720
f
 0 / 14 0.0 
Kalyesubula [197] 2011 Uganda 2.5x ULN 98 0 / 7 0.0 
Matthews [85] 2011 South Africa 5x ULN 120 10 / 106 9.4 
Wang [198] 2012 China 5x ULN 336 6 / 65 9.2 
Hawkins [199] 2012 Tanzania 5x ULN 554
f
 19 / 1,071 1.8 
a or >200 IU/L 
b or >3.5x baseline if raised at baseline 
c and increase of >100 IU/L 
d or increase of >100 IU/L if raised at baseline 
e
  HBV and HCV combined 
f  median 
g
 mean 
Publ.: publication. Incid.: incidence. NR: not recorded. Shading; studies in sub-Saharan 
Africa. 
Further evidence of liver flares in HIV/HBV coinfected patients includes a cohort of 
2,947 patients, 6.4% of whom were HBsAg seropositive, in which HBsAg had a HR of 
6.0 (p=0.0001) for grade 4 liver events [200]. In another study of 755 patients starting 
HAART, HBsAg seropositivity had an OR of 3.2 (95% CI, 0.9 to 9.09, p=0.04) for 
severe hepatitis (defined as an increase in ALT or AST to >10x ULN or 5 times 
baseline if markedly abnormal) [201]. These studies did not report the proportion 
experiencing flare and so are not listed in Table 3. 
. 
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It is often difficult if not impossible to determine the cause of a flare on starting HAART, 
whether adverse drug reaction, HBV suppression or immune reconstitution, all of which 
have been proposed. 
Adverse drug reaction 
Some studies have analysed the relative probabilities of flares on different antiretroviral 
treatment regimes. Drug-related flares (ALT or AST >5x ULN) were examined by 
Sulkowski in HIV-positive patients starting a new antiretroviral therapy regimen 
including nucleoside analogues and/or protease inhibitors. RTV (given at treatment 
dose rather than the lower dose used to boost other protease inhibitors) was the only 
drug identified as increasing the risk of hepatotoxicity (relative risk 5.6, 95% CI 2.1 to 
15.9) and, while chronic HBV or HCV infection was associated with an increased risk in 
those not prescribed RTV (relative risk 3.7; 95% CI, 1.0 to 11.8), only 2.7% of the 
patients investigated had HBV as opposed to 52% with HCV [178]. 
In another study Sulkowski examined patients exposed to non-nucleoside therapy, of 
whom 8% had HBV and 43% had HCV. A flare was seen in 16% prescribed NVP and 
8% prescribed EFV and, in an adjusted analysis, chronic HBV or HCV infection was 
associated with an increased relative risk (2.1, 95% CI 1.1-3.9) [179]. 
In Thailand a pooled analysis of 8 randomised controlled trials found the relative risk of 
severe hepatotoxicity (ALT >5x ULN) of HBsAg was 3.2 (95% CI 1.1-9.0, p=0.003) and 
NNRTI therapy had a relative risk of 9.8 (95% CI, 3.0-31.5, p=0.0001) whereas there 
was no effect of protease inhibitor therapy, with or without RTV [185]. 
Drug interactions may further increase the risk of hepatotoxicity. In a retrospective 
cohort study of South African patients starting 3TC with AZT and efavirenz (EFV), 
treatment for tuberculosis (TB) increased the risk of a flare (>5x ULN) 8.5 fold [187]. 
Flares on suppression of HBV 
It has been suggested that liver flares can arise as HBV DNA VL is declining and 
becoming suppressed. For example, in ACTG5127 HBV/HIV coinfected patients on 
stable HAART were randomised to receive either TDF or ADV and rates of ALT rise to 
>5x ULN were 11% with TDF and 12% with ADV [141].  
Immune reconstitution disease  
In the Tenofovir in Coinfection trial (TICO), flares (defined as ALT >5x ULN, or a rise of 
>100 IU/L if elevated at baseline) occurred in 25% of patients after a median of 8 
weeks on treatment. 11% of flares resulted in death [114]. Further immunological 
analysis suggests an immune reconstitution response to a high antigenic burden 
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(correlated with HBV DNA) as the cause of early on-treatment flares in coinfected 
patients [202]. 
Also supporting the immune theory of early on-treatment flares is the fact that flares 
have been found to be more common in patients who start therapy with a lower CD4 
count [187] and have been seen in association with rapid rise in CD4 on starting 
HAART [115]. 
Treatment breakthrough/interruption 
Flares have been described in HIV-negative patients with HBV, for example Honkoop 
described a patient (HIV status not mentioned but presumably negative) who had been 
treated with 3TC for six months after which HBV DNA was undetectable. On stopping 
3TC he had a flare with a rise in HBV DNA and a dramatic rise in ALT to 100 times the 
ULN. ALT resolved with HBeAg to anti-HBe seroconversion and a fall in HBV DNA 
[203]. Lim described three cases of patients with fatal flares on treatment cessation 
[204]. In one retrospective cohort study, 10% experienced flares (defined as ALT >10x 
ULN) on NRTI treatment. Three quarters of these flares were associated with 
development of resistance and occurred after a median of 18 months on treatment and 
only in patients taking 3TC or ADV. 10% of flares resulted in the patient’s death. 
Treatment discontinuation flares occurred in 8% after a median of 15 weeks and were 
followed by HBeAg loss in some patients. Unlike on treatment flares, no discontinuation 
flares were fatal [205]. 
In coinfected patients, Bessesen described 5 cases in which flares arose, 2 (1 fatal) 
upon 3TC cessation and 3 upon development of resistance at codons 180 and 204 
(528 and 552 using the older nomenclature) while on 3TC as the only HBV-active drug 
[206]. A patient with a flare associated with a rise in HBV VL on treatment was also 
described in the CAESAR study [167]. 
The STACCATO trial was designed to investigate CD4-guided structured treatment 
interruptions in a Thai population. Patients were treated with TDF plus FTC. There 
were 8 HBV/HIV coinfected patients who had a treatment interruption and 1 (12.5%) of 
these had a flare, which resolved with reintroduction of treatment [146]. 
A retrospective analysis of coinfected patients in the Swiss HIV Cohort Study found 
liver enzyme elevations in 42 (29%) of 147 stopping 3TC, however only 5% were grade 
3 or 4 (>5x ULN). 1 (0.7%) resulted in death [116]. The time to maximum ALT was up 
to 133 days after treatment interruption. Grade 4 flares were most common around 40 
days, but occurred up to 76 days, after treatment interruption 
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A higher rate was found in a Dutch retrospective cohort study; 22% of HBsAg 
seropositive patients stopping 3TC experienced a grade 4 liver enzyme elevation (ALT 
and/or AST >10x ULN and 100 IU/L higher than baseline) within 16 weeks, though 
none died [192]. 
Seroconversion 
Flares may also be associated with HBeAg loss, anti-HBe seroconversion and/or 
HBsAg loss [114, 205]. 
The function of HBeAg is unknown but it has been suggested that it is 
immunosuppressive through favouring tolerance of HBV, either by acting in the thymus 
or by inducing apoptosis (reviewed in Milich [207]). Levels of HBeAg decline on 
initiation of nucleoside treatment and may become undetectable after 8 to 24 weeks 
[208]. Flares may arise as immunotolerance induced by HBeAg declines and the 
immune system better recognises infected hepatocytes, even without anti-HBe 
production. 
1.8 Liver status determination 
1.8.1 Alanine aminotransferase 
Alanine aminotransferase (ALT) is an enzyme that catalyses the reaction shown in 
Figure 5. 
Figure 5: Reaction catalysed by alanine transaminase 
 
 glutamate + pyruvate ⇌ α-ketoglutarate + alanine 
It is mainly found in hepatocytes where the concentration is around 3,000 times higher 
than in serum. On damage to hepatocytes, ALT is released into the blood and as such 
it is a marker of liver inflammation. Common causes of raised ALT include hepatotoxic 
drugs, alcohol, non-alcoholic fatty liver disease and viral hepatitis with other causes 
including autoimmune hepatitis, haemochromatosis, Wilson’s Disease and alpha-1-
antitrypsin deficiency.  
The ULN for ALT is traditionally based upon the local population and, since males 
generally have higher ALT than females, may take sex into account. However, 
although ALT also varies by age and body mass index (BMI), these are not taken into 
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consideration when setting normal ranges. The ULN may be determined using a 
statistical definition, being the upper 97.5th percentile of ALT in healthy subjects. This 
has generally resulted in the ULN being between 30 and 50 IU/L. Using the same 
statistical method applied to a low-risk blood donor population (who tested negative for 
HBsAg, anti-HCV, anti-HIV-1/2 and syphilis and without behavioural contraindication to 
donation) resulted in lower ULN of 19 IU/L for women and 30 IU/L for men [209] and 
these limits are recommended for use in HBV-infected individuals by some experts 
[210]. The ULN may also be defined by following individuals over time and calculating 
the risk of disease or death. One such study which followed 94,000 men for 8 years 
and used death certificates to allocate cause of death determined the ULN for men to 
be 30 IU/L and although the researchers were unable to reliably estimate a limit for 
women they believed it would be lower [211].  
1.8.2 Fibrosis scoring 
The progression of HBV-related liver disease involves an increase in fibrosis; isolated 
fibrotic areas around portal tracts become confluent (bridging) and then the architecture 
of the liver is replaced with fibrotic tissue. The normal blood flow from the hepatic portal 
vein through the venous sinuses is disrupted with shunting and reduction in the ability 
of the liver to remove toxins or to produce clotting factors. The evidence for increased 
severity of HBV-related fibrosis with HIV coinfection is mixed (section 1.4.2). 
Liver biopsy is the gold standard method to determine the degree of liver fibrosis. 
However it has associated risks; mortality rates are around 0.01 to 0.1%, mostly from 
intraperitoneal bleeding [212, 213]. Biopsy may also be inaccurate due to sampling 
error. A biopsy should ideally be 30 mm long (after shrinkage due to formalin fixation), 
be taken with a needle of at least 1.6 mm gauge and contain at least 11 portal tracts 
[212]. However liver fibrosis does not occur uniformly and a biopsy of this size (volume 
about 35 mm
3
) may sample only 1/50,000 of the liver and cirrhosis may be missed in 
10 to 30% of cases [214]. Histological examination of biopsy specimens requires 
specialised training and laboratory facilities. Liver biopsy may not be appropriate in all 
patients in whom fibrosis estimation may be of use. In particular, contraindications to 
liver biopsy include extrahepatic biliary obstruction, bacterial cholangitis, cystic lesions 
in the liver and abnormal coagulation indices (raised prothrombin time (>6 seconds) or 
low platelets (<60,000/mm3)) or recent antiplatelet drugs (e.g. aspirin). 
Transient elastometry (TE, FibroScan®) is a non-invasive alternative to biopsy which 
measures liver stiffness, which increases with fibrosis. The Fibroscan probe delivers a 
physical impulse to the skin which is transmitted through the liver. The speed with 
which this impulse passes through tissues is proportional to the square root of the 
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stiffness and is measured by an ultrasound probe. It is quick and safe and measures a 
larger volume of liver (approximately 3 cm3 with a standard “M” probe). However use of 
TE requires specialist training and the equipment required is expensive and not widely 
available.  
The levels of some markers in blood have been shown to correlate with the degree of 
liver fibrosis. These can be categorised into direct and indirect markers of liver fibrosis 
on the basis of whether they reflect the metabolism of hepatic extracellular matrix 
(ECM) (Table 4). 
Table 4: Direct and indirect serum fibrosis markers 




Prothrombin time  
Total bilirubin  
Albumin 
 Other biochemistry Triglycerides 
Glucose 
 Acute phase protein  Globulins 
α2-macroglobulin  
Haptoglobin  
Apolipoprotein A1  
 Blood cell count Platelets 
Monocytes 
Segmented neutrophils 
 Immunological Chemokine (C-C motif) ligand 5 (CCL5) 
   
Direct ECM component  Hyaluronic acid  
Procollagen III N-terminal propeptide (PIIINP)  
Procollagen I  
Collagen IV  
Laminin  
 ECM enzymes  Chitinase-3-like protein 1 (YKL-40)  
Matrix metalloproteinases (MMP)  
Tissue inhibitors of metalloproteinases (TIMP)  
 Growth factors Hepatocyte growth factor 
Connective tissue growth factor 
GGT: Gamma-glutamyl transferase 
The performance of a test for fibrosis (or any other binary outcome) can be assessed 
using the receiver operating curve (ROC) from which the area under the curve 
(AUROC) can be derived. Values of the AUROC range from 0 to 1, with higher values 
indicating better discrimination. While there is no clear cut-off for an AUROC that 
indicates a good or bad test, it has been suggested that values greater than 0.75 are 
clinically useful [215]. 
Many markers have been assessed as potentially useful measures of fibrosis, either 
alone or in combination with other markers and/or other variables such as age, sex, 
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BMI, spleen size and alcohol intake. Validation has taken place using either liver biopsy 
or TE and in a range of clinical conditions. 
Validation of serum fibrosis scores in hepatitis B and HIV infection 
HBV/HIV coinfection 
Only two studies have been published assessing serum fibrosis scores in patients with 
HBV/HIV coinfection [216, 217]. In the first study, which included 108 patients, liver 
biopsy was used to validate the ability of 11 fibrosis scores to discriminate between the 
presence and absence of significant fibrosis (at least F2), severe fibrosis (at least F3) 
and cirrhosis (F4) [216]. AUROCs are given in Table 5. 
Table 5: Performance of 11 serum fibrosis scores in HBV/HIV coinfected patients 
 F0-1 vs F2-4 F0-2 vs F3-4 F0-3 vs F4 
 AUROC AUROC AUROC 
AST/ALT Ratio 0.48 0.52 0.51 
FIB-4 0.74 0.77 0.8 
APRI 0.73 0.76 0.76 
Hui 0.67 0.67 0.67 
Fibrotest® 0.77 0.8 0.87 
Fibrometer® 0.74 0.83 0.89 
Hepascore 0.74 0.83 0.92 
Zeng 0.75 0.78 0.91 
Forns 0.72 0.77 0.81 
Hyaluronic Acid 0.66 0.72 0.85 
SHASTA 0.65 0.68 0.75 
FIB-4: fibrosis-4 index. APRI: AST to platelet ratio index. SHASTA: serum hyaluronic 
acid, AST and albumin. 
Shading: light grey – can be determined in Ugandan participants in DART; 
dark grey – cannot be determined in DART participants. 
The second study compared Fibrometer® score with biopsy. Fibrometer® generally 
performed well though it failed to detect cases of progression from stage 2 to stage 3-4 
fibrosis [217]. 
HBV monoinfection 
In patients with HBV monoinfection there have been many assessments of over 90 
markers or combinations of serum markers using liver biopsy, TE or both. However 
only 8 validated markers are calculable from the data available from all DART 
participants and a further 4 from data from participants in Uganda (since AST was 
measured in Uganda but not in Zimbabwe) (Table 6). 
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Table 6: Fibrosis markers that can be derived in DART participants 
All participants Ugandan participants 
Age AST 
Platelets or 1/platelets APRI 
API AST/ALT ratio 
ALT FIB-4 
Bilirubin  
Direct bilirubin  
Total bile acid  
White blood cell count  
API: Age and Platelets Index.  
AUROCs published for some markers can vary widely from one study to another, for 
example the AUROC for platelets varies from 0.32 [218] to 0.86 [219]. 
HIV monoinfection 
One small study recruited 24 HIV-positive patients with ALT >50 IU/L, and without HBV 
or HCV infection. Participants underwent TE and had APRI and FIB-4 calculated. 
Enrolled patients did not have advanced liver disease; no patients were found to have 
significant fibrosis on APRI or FIB-4 and out of 24, 21 had “mild fibrosis” and 3 
“progressive fibrosis” on TE. “Moderate concordance” was found between elastometry 
and the serum fibrosis markers. No AUROCs were given but data published allows 
their calculation, although with wide confidence intervals. For APRI the AUROC for 
distinguishing progressive from mild fibrosis was 0.67 (95% CI 0.29 to 1.00) and for 
FIB-4 it was 0.76 (0.42 to 1.00) [220]. 
It has been shown that FIB-4 and APRI were correlated with moderate concordance 
(weighted kappa coefficient = 0.573) in HIV-positive patients in the Italian Standardized 
Management of Retroviral HIV Infection cohort and these were used as markers of liver 
fibrosis [221]. 
It has been suggested that Fibrotest (a marker using age, sex, bilirubin, GGT, 
haptoglobin, α2-macroglobulin and apolipoprotein A1 [222]) is useful in predicting 
fibrosis in conjunction with TE [223] but data was not given on how well Fibrotest 
performed alone. Another study used FIB-4 as a marker for fibrosis in HIV-
monoinfected and HIV/HCV coinfected women [224] and a third similarly used APRI in 
HIV-monoinfected patients [225]. 
FIB-4 has also been shown to correlate with clinical outcome in HIV-positive patients 
with or without viral hepatitis coinfection. In the ICONA cohort (Italian Cohort of 
Antiretroviral Naïve Patients) FIB-4 was strongly associated (relative hazard 4.48 per 
log(FIB-4) higher) with liver-related death [226]. 
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1.9 Conclusion 
HBV coinfection is an increasingly important factor in the management of HIV. Several 
issues remain to be clarified, in particular: the epidemiology of coinfection; the optimal 
treatment strategies in coinfected patients; and, the longer-term outcomes of treatment 
including development of resistance, morbidity and mortality. 
This study is of key importance to the development of future treatment protocols for the 
clinical management of HBV/HIV coinfection in developing countries. The findings may 
have important implications for developing strategies for roll-out of HAART and for 
future antiviral resistance in HBV. 
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2 Hypothesis and aims  
The primary hypothesis we set out to examine was: 
Hepatitis B viral replication is durably suppressed in individuals coinfected 
with HIV and treated with TDF. 
 
To examine this hypothesis we: 
1. performed a systematic review and meta-analysis of published data of HBV 
VL suppression in HIV coinfected individuals treated with TDF, and  
2. examined HBV VL in participants treated with TDF in the DART study. 
 
The DART study also provided an opportunity to consider other research questions 
relevant to the management of HBV/HIV coinfected individuals, including: 
1. What is the prevalence of HBV infection in participants in the DART study? 
2. Is HBV VL suppression more likely and/or more durable when treating HIV 
coinfected patients with TDF plus 3TC than when treating with 3TC as the 
only HBV-active drug? 
3. What is the baseline liver status (inflammation and fibrosis) of participants in 
the DART study and how is it associated with HBV status and other 
characteristics such as age and sex?  
4. How does treatment with ART affect a marker of liver inflammation (ALT) and 
what is the rate of liver inflammatory flares: 
a. on first-line HAART, 
b. on stopping HBV-active treatment, and  
c. during cycles of Structured Treatment Interruption of ART?  
5. Is there an association between HBV status at treatment initiation and CD4 
cell count at baseline and/or over time? 
6. Is HBV status associated with clinical progression to a new WHO stage 4 
event and/or death? 
7. Do the causes of death differ by HBV status, with particular focus on liver 
disease related deaths? 
8. Is there evidence that monitoring or treatment should depend upon a 
patient’s HBV status, and thus that HBV testing should be performed? 
9. Is there evidence that testing patients for ALT would alter a patient’s 
management, and thus that ALT testing should be performed? 
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3 Systematic review and meta-analysis of HBV 
suppression during treatment with tenofovir 
3.1 Introduction 
As discussed in chapter 1 hepatitis B coinfection is common in HIV-infected individuals 
and liver diseases including HBV infection represent a major cause of morbidity and 
mortality [62]. There is evidence that suppression of HBV VL results in improved 
clinical prognosis [151].  
TDF received approval for the treatment of HIV infection from the United States Food 
and Drug Administration (FDA) in October 2001 and from the European Medicines 
Agency in February 2002. (FDA approval for the treatment of CHB infection was 
granted in August 2008.) The first reports of the use of TDF in treating HBV infection 
were presented in 2002. Guidelines now recommend TDF in combination with 3TC or 
FTC as first-line therapy for patients with HIV/HBV coinfection [131, 132]. Many studies 
have reported on the effect of TDF, either with or without 3TC or FTC, in treatment-
naïve or experienced patients, however many studies are small and with relatively 
short follow-up.  
It is uncertain what proportion of patients achieves suppression of HBV DNA (viral load, 
VL) and whether those who do not initially suppress may achieve HBV suppression 
later. It is also unclear to what extent, if at all, those with complete suppression may 
relapse despite continued treatment, e.g. in case of development of resistance 
mutations. Finally, it remains uncertain whether sequential treatment, for example with 
3TC initially and TDF later, compromises the chance of successful treatment with TDF.  
A recent meta-analysis of randomised controlled trials of antiviral treatment for HBV 
excluded patients with HIV coinfection and only compared responses at 12 months 
[227]. Outcomes included both virological and biochemical responses, HBeAg loss or 
seroconversion to anti-HBe, serum HBsAg loss, histological improvement and serious 
adverse events. However only one of the studies included in that meta-analysis 
included patients treated with TDF [228].  
We carried out a complementary meta-analysis of data from patients coinfected with 
HIV to answer the following questions:  
i. what proportion of patients achieve HBV VL suppression on TDF? 
ii. does the rate of suppression differ in those with prior 3TC experience? 
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iii. does the rate of suppression differ in those treated with TDF-3TC/TDF-FTC 
combination therapy compared with TDF monotherapy? 
iv. how common is HBV rebound on TDF? 
We were also able to use patient-level data to further examine loss from follow-up. 
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3.2 Methods 
The systematic review was carried out following the guidance laid out in the PRISMA 
statement [229]. 
3.2.1 Search strategy and selection criteria 
Studies included were those that described HBV/HIV coinfected individuals treated with 
TDF with or without 3TC and/or FTC for a period of at least one year and that reported 
quantitative results of plasma HBV VL at yearly intervals (at a minimum) while on TDF 
treatment. Studies included could be randomised controlled trials or prospective or 
retrospective cohort studies. Patients with undetectable plasma HBV VL at baseline 
were excluded since their inclusion gives a falsely high estimate of the effect of 
treatment. Baseline HBV VL data was not given for 20 patients in three studies (see 
Table 7). The analysis was restricted to patients on TDF treatment, with or without 3TC 
and/or FTC. In this analysis inclusion bias could be considerable if patients who failed 
to suppress either stopped taking TDF or had progressive liver disease and so dropped 
out. This would leave a higher proportion of patients with a good response, 
overestimating the treatment effect. Further analysis of individual patient data was 
carried out where this was available or was provided in the process of performing the 
current analysis (Table 7).  
Web of Science, Embase and Medline were searched, including all years. Conference 
abstracts from The Liver Meeting (American Association for the Study of Liver 
Diseases), The International Liver Congress (European Association for the Study of the 
Liver) and the Conference on Retroviruses and Opportunistic Infections were searched 
for the years 2002-2010. 
To search databases, a combination of key terms was used including “hepatitis”, “HIV”, 
and “tenofovir”, limited to articles with human subjects and written in English (Appendix 
1). Conference abstracts were searched online or by hand. Other publications that 
were discovered from the reference lists in publications reviewed were also included. 
3.2.2 Data collection 
Studies were screened initially by title and then data was collected from the full article 
of all published studies and from conference posters, or conference abstracts if posters 
were not available. Some studies which met the eligibility criteria did not include data 
on the number with undetectable HBV VL at one year, or information on prior or 
concomitant drug exposure. The authors of these studies were contacted by email and 
asked to provide additional data. Additional, unpublished data was obtained from the 
authors of 11 of the 23 sources included (Table 7). Data abstracted consisted of type of 
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study, source of study funding, number of HBV/HIV coinfected participants, number 
HBeAg positive at study entry, prior 3TC/FTC exposure, drug regimens used during 
study period, length of follow-up, type of HBV VL test used and lower limit of detection, 
numbers tested for HBV VL at yearly intervals, and numbers with undetectable HBV 
viral load at yearly intervals. To maximise power and in the absence of any evidence 
suggesting a difference in effect on HBV between 3TC and FTC, exposure to these two 
were grouped together. Patient-level data was available from some studies and this 
was used to analyse loss from follow-up. 
Results were stratified by treatment into four groups. Group A consisted of patients 
who had no prior exposure to 3TC/FTC and who were treated with TDF without 
concomitant 3TC/FTC, Group B those without prior exposure to 3TC/FTC treated with 
TDF in combination with 3TC/FTC, Group C those with prior exposure to 3TC/FTC but 
treated with TDF without 3TC/FTC, and Group D those with prior exposure to 3TC/FTC 
treated with TDF in combination with 3TC/FTC. 
3.2.3 Statistical analysis 
Statistical analysis was carried out using Stata version 10.1. The main outcome 
measure used was the proportion of patients tested who had a HBV VL below the limit 
of detection at each of any available yearly time intervals. 95% confidence intervals for 
these proportions were calculated for each time point in each study and for the 
aggregate results. 
To detect potential sources of bias, assay cut-off was plotted against proportion 
suppressed at one year. Publication bias was examined using funnel plots. Bias from 
patients being lost to follow-up was assessed using patient-level data in those from 
whom it was available. 
Multilevel mixed effects logistic regression (XTMELOGIT command) was used to 
assess the effect of prior exposure to, and combination treatment with 3TC/FTC on the 
probability of viral suppression, with individual studies fitted as a random effect to 
account for clustering (Appendix 2). This implicitly weights each study by the amount of 
information it contains. Since there was no association of assay cut-off with rate of 
suppression the model was not adjusted for cut-off. Between-study heterogeneity was 
assessed by a likelihood-ratio test comparing the mixed effects model with a standard 
logistic regression model which did not include a factor for study. Models were re-run 
with an interaction term between concomitant 3TC/FTC and prior exposure to 
3TC/FTC. Sensitivity analyses were performed (1) including only larger studies 
(reporting at least 10  patients), (2) excluding one study that was an outlier on the 
funnel plot [230], and (3) with a term for study design. 
 Chapter 3: Systematic review – HBV suppression  Page 54 of 240 
3.3 Results 
The initial searches produced 2,110 references which, after duplicates were removed, 
gave 1,607 publications. Publications were then screened by title and if necessary by 
abstract to remove those clearly not meeting the eligibility criteria. This left 379 
published articles. The full text of articles and posters was then checked for eligibility 
(or abstracts if the full article or poster was not available). 356 were removed as 
ineligible (as described in Figure 6) and 23 included in the analysis. Study 
characteristics are given in Table 7. Those studies for which authors were contacted 
and published data augmented by additional information are so labelled in Table 7. 
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 2,110 publications identified 
503 duplicates removed 
Screened 
 1,607 publications 
1,228 excluded on basis 
 of title and abstract 
Assessed for eligibility 
 379 publications 
  300 published articles 
  78 conference presentations 
  1 book 
Included in review and analysis: 
 19 published articles 
 4 conference presentations 
356 removed 
282 published articles 
73 conference presentations 
1 book 
 
Reasons for exclusion: 
115 reviews/comments 
58 no/inadequate HBV viral load data 
50 not tenofovir 
30 no data at yearly time-point(s) 
21 cross-sectional studies 
20 data included elsewhere 
17 case reports 
17 HIV-negative 
15 inclusion criteria 
9 unable to separate into 
 exposure/treatment groups 
4 in vitro only 
 
1 conference presentation replaced with 
recently published article 
  






















Avihingsanon [231] 2010 Thailand RCT 10 6/10 Yes 34 48 W No Ph
1 
Bani-Sadr [232] 2004 France Prospective cohort 6 3/6 Yes 40 96 W Yes
 c
 NS 
Butt [233] 2006 USA Retrospective cohort 5 Unknown Yes 20 36 M No Public
d 










Engell [234] 2011 USA Retrospective cohort 24 18/31 Yes 6 24 M No Public
f  
Gutiérrez [156] 2008 Canada Retrospective cohort 6 Unknown Yes Not given 15-45 M No
 c
 NS 
Jain [235] 2007 USA Retrospective cohort 28 27/28 Yes 400 12-24 M Yes NS 
Kosi [162] 2012 Austria Retrospective cohort 49 35/49 Yes 20 2-171 M Yes
 c
 NS 
Kuzushita [236] 2010 Japan Prospective cohort 16 15/16 Yes 60 6-63 M Yes
 c
 NS 
Lee [237] 2009 USA Retrospective cohort 17 34/43 7/17 
b




Marcelin [238] 2003 France Retrospective cohort 10 9/10 Yes 40 12 M No NS 
Matthews [114] 2008 Thailand RCT 22 13/22 Yes 34 48 W No Ph
1
 
Nelson [148] 2006 UK RCT 39 Unknown Yes 80 48 W No NS 







Peters [141] 2006 USA RCT 18 23/27 Yes 40 48 W Yes Public
i 




Rodriguez [240] 2010 USA Prospective cohort 6 6/6 Yes 25 48 W No Ph
3
 
Schmutz [139] 2006 Europe Prospective cohort 75 75/75 Yes 200 26-206 W Yes NS 
Stephan [241] 2005 Germany Retrospective cohort 23 19/31 Yes 400 48 W Yes NS 
Tan [242] 2009 UK Retrospective cohort 39 39/39 38/39 
b
 100 - 2,000 69-290 W Yes None 
Tuma [243] 2008 Spain Retrospective cohort 38 Unknown 29/38 10 48 W No NS 
van Bommel [244] 2004 Germany Prospective cohort 21 21/21 Yes 80 72-130 W No Public
k 
Footnotes and abbreviations: see next page. 
  
Table 4: Meta-analysis – characteristics of included studies – abbreviations 
 
Pub.: publication. Add.: additional. RCT: randomised controlled trial. W: weeks. M: months. NS: not stated. Ph: pharmaceutical industry.  
Pharma funding: 1: Gilead Sciences. 2: Roche. 3: GlaxoSmithKline.  
a Copies/mL converted to IU/mL by dividing by 5. 
b The limit of detection of the HBV VL assays used fell during the course of follow-up in two studies. 
c Individual patient data available. 
d National Institutes of Health/National Institute on Drug Abuse. 
e Commonwealth Department of Health and Ageing (Canberra, Australia). 
f supported in part by National Institute of Allergy and Infectious Diseases. 
g Medical Student Summer Research Training Program, supported through grants from the National Institutes of Health; Wake Forest 
University School of Medicine Departments, Centers, and Institutes; and private gifts. 
h Swiss National Science Foundation through the Swiss HIV Cohort Study, the Wilsdorf, Sidaide, and de Brocard Foundations, Geneva, 
from the Departments of Social Aﬀairs and Economics, Geneva. 
i In part by the Adult AIDS Clinical Trials Group (ACTG) funded by the National Institute of Allergy and Infectious Diseases; virology support 
funding by the NIH/NIAID and the Adult ACTG Central Group; the Birmingham VA Medical Center, UAB CFAR core clinic and laboratory 
facilities; and NIDDK UCSF Liver Center. 
j Italian Ministry of University. 
k In part by the German BMBF Network of Competence for Viral Hepatitis (Hep Net). 
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Some studies included patients in more than one treatment group (for example both 
patients with and without prior exposure to 3TC), giving 43 study arms (Table 8). 
Table 8: Meta-analysis – results included 
 Year 1 2 3 4 5 6 7 
Group Author S / N S / N S / N S / N S / N S / N S / N 
A 
Nelson 3 / 10       
Matthews 9 / 12       
Kosi 8 / 9 9 / 11      
Tan 0 / 1 1 / 1 1 / 1     
B 
Dore 4 / 5       
Bani-Sadr 5 / 6 6 / 6      
Stephan 4 / 6       
Nelson 2 / 6       
Schmutz 15 / 24 15 / 17 12 / 13 4 / 5    
Jain 7 / 9       
Matthews 7 / 10       
Nüesch 5 / 5 2 / 2      
Tuma 9 / 9       
Kosi 8 / 12 11 / 14      
Lee 2 / 8 2 / 4 5 / 6 2 / 2 1 / 1   
Tan 3 / 6 4 / 6 2 / 4 4 / 4 3 / 3   
Kuzushita 9 / 14 12 / 13 8 / 8 5 / 5 5 / 5   
Avihingsanon 9 / 10       
de Vries-Sluijs 12 / 28 18 / 24 19 / 23 14 / 14 6 / 6 1 / 1  
Rodriguez 3 / 6       
Engell 6 / 10 5 / 5      
C 
van Bommel 11 / 11       
Stephan 1 / 3       
Nelson 4 / 12       
Schmutz 27 / 48 38 / 40 30 / 32 9 / 9    
Lee   1 / 1     
Kosi 1 / 3 2 / 3      
Tan 0 / 2 2 / 2 1 / 1     
D 
Marcelin 3 / 10       
van Bommel 10 / 10       
Stephan 8 / 14       
Nelson 6 / 11       
Peters 7 / 18       
Jain 10 / 19 1 / 2      
Gutiérrez 3 / 6 2 / 2 1 / 1     
Quiros-Roldan 7 / 10 8 / 9 7 / 7 5 / 5 1 / 1   
Tuma 22 / 29       
Lee 2 / 3 3 / 3 2 / 2     
Kosi 11 / 15 13 / 16      
Tan 14 / 20 12 / 15 10 / 14 7 / 8 7 / 9   
de Vries-Sluijs 14 / 50 34 / 49 38 / 47 33 / 38 21 / 23 8 / 8 1 / 1 
Engell 3 / 11 4 / 13      
Butt 2 / 5 3 / 5 3 / 5     
S: number of HBV patients with viral suppression (below the level of detection) 
N: number of patients with a HBV VL test performed 
Groups: A no prior 3TC/FTC treated with TDF alone, B no prior 3TC/FTC treated with 
TDF and 3TC/FTC, C prior 3TC/FTC treated with TDF alone, D prior 3TC/FTC treated 
with TDF and 3TC/FTC. 
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Although data was included from six randomised controlled trials, allocation of TDF vs. 
TDF plus 3TC was randomised in only two [114, 148].  
Studies used assays with widely varying cut-offs for the detection of HBV (Table 7). 
This could have introduced bias, with the use of more sensitive assays resulting in an 
apparent lower rate of suppression. However plotting the proportion undetectable 
against the logarithm of the cut-off value showed no clear pattern (Figure 7). The 
correlation coefficient between log of cut-off and proportion undetectable was 0.11. 
Thus the cut-off was ignored in further analyses. 
Figure 7: Meta-analysis – log of HBV viral load assay cut-off against proportion 
undetectable at one year in each study arm 
 
Note: Lee [237] and Tan [242] are not shown since the cut-off in these studies varied 
during follow-up. 
The overall proportion suppressed was 57.4% (95% CI: 53.0 to 61.7%), 79.0% (95% 
CI: 73.6 to 83.8%), and 85.6% (95% CI: 79.2 to 90.7%) after one, two, and three years 
of treatment with TDF (Table 9 and Appendix 3).  
Baseline HBeAg status could be determined from ten of the included studies [139, 146, 
162, 230, 232, 236, 239, 240, 242, 244]. For HBeAg positive (n=251) and negative 
(n=38) patients respectively the proportion fully suppressed was 51.8%, 82.0%, 86.6% 
and 76.3%, 82.1%, 75.0% at one, two and three years(Figure 8).  
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After one year of treatment, a higher proportion of HBeAg negative than HBeAg 
positive individuals had suppressed HBV VL (p=0.005). However, beyond one year the 
rates of suppression were not significantly different. 
Table 10 shows the effects of prior and concomitant 3TC/FTC on virological 
suppression. Effects are given for all patients and also stratified by prior or concomitant 
treatment with 3TC/FTC as appropriate. Overall, at one year prior exposure to 3TC had 
an OR of 0.69 (95% CI: 0.45 to 1.08) and treatment with 3TC/FTC in addition to TDF of 
1.24 (95% CI: 0.68 to 2.24), neither being statistically significant. The effect of prior 
exposure to 3TC/FTC was similar, but also not statistically significant, at each of one, 
two, and three years. The effect of concomitant treatment with 3TC/FTC favoured dual 
therapy at one year but TDF monotherapy at years two and three, but these effects 
were again not statistically significant. The OR in the stratified analyses were similar to 
the effects overall but with even wider confidence intervals. There was no evidence of 
an interaction between prior and concomitant 3TC/FTC treatment (p=0.98 at 1 year, 
p=0.14 at 2 years and p=0.99 at 3 years). Between-study heterogeneity, allowing for 
the effects of prior and concomitant 3TC/FTC treatment, was significant (p<0.01) at 
year 1 but not at year 2 (p=0.48) or at year 3 (p=1.0). 
 
  
Table 9: Meta-analysis – suppression and effect of prior and current 3TC/FTC at yearly time points 
 Number suppressed / number tested (% suppressed) 
 Group A Group B Group C Group D All 
Year S / N % S / N % S / N % S / N % S / N % 
1 20 / 32 62.5 110 / 174 63.2 44 / 79 55.7 122 / 231 52.8 296 / 516 57.4 
2 10 / 12 83.3 75 / 91 82.4 42 / 45 93.3 80 / 114 70.2 207 / 262 79.0 
3 1 / 1 100 46 / 54 85.2 32 / 34 94.1 58 / 71 81.7 137 / 160 85.6 
S: number of HBV VL test results showing viral suppression (below the level of detection) 
N: number of patients with a HBV VL test performed 
Groups: A no prior 3TC/FTC treated with TDF alone, B no prior 3TC/FTC treated with TDF and 3TC/FTC, C prior 3TC/FTC treated with TDF alone, D 
prior 3TC/FTC treated with TDF and 3TC/FTC. 
 
Table 10: Multivariable logistic regression analysis of effects of prior and concomitant 3TC/FTC on virological suppression 
 Effect of prior 3TC/FTC Effect of concomitant 3TC/FTC 
 Monotherapy Dual therapy Overall 3TC/FTC naive Prior 3TC/FTC exp. Overall 
Year OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
1 0.37 0.09 to 1.59 0.64 0.39 to 1.06 0.69 0.45 to 1.08 1.13 0.40 to 3.15 2.14 0.75 to 6.12 1.24 0.68 to 2.24 
2 0.80 0.06 to 11.50 0.55 0.20 to 1.49 0.69 0.35 to 1.39 0.94 0.19 to 4.70 0.23 0.03 to 1.64 0.37 0.11 to 1.30 
3 - - 0.77 0.30 to 2.03 0.75 0.29 to 1.96 - - 0.28 0.06 to 1.96 0.25 0.05 to 1.14 
Monotherapy: patients treated with TDF without concomitant 3TC/FTC, i.e. groups A and C. 
Dual therapy: patients treated with TDF with concomitant 3TC/FTC, i.e. groups B and D.  
3TC/FTC naïve: patients not previously exposed to 3TC/FTC before TDF treatment, i.e. groups A and B.  
Prior 3TC/FTC exp.: patients previously exposed to 3TC/FTC before TDF treatment, i.e. groups C and D. 
The OR comparing groups A and C and comparing groups A and B in year 3 were non-estimable as there is only one patient in group A. 
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The proportion suppressed increased over time and reached 91.7% (44 of 48) at 5 
years (Table 8). The number of patients in follow-up at each year declined, however of 
the 379 patients in studies with more than one year of follow-up, individual patient data 
was available for 187 (49.3%). The proportion suppressed may have increased in a 
biased fashion if patients failing to suppress dropped out and those that were 
suppressed continued on therapy. However it was more likely at every time point that a 
later HBV VL test result was available for patients with detectable HBV than for those in 
whom HBV VL was fully suppressed (non-significant – data not shown). 
Virological rebound on TDF was rare, with no cases seen in 16 of 23 studies which 
included 374 of the 550 patients in the meta-analysis. Three studies reported a single 
patient with an increase in HBV VL on TDF treatment [114, 239, 242], three had two 
patients [233, 236, 240], and one had three [230] though in three of these studies the 
size of the increases were not reported, in two the increases were very small (0.1 to 0.3 
log), and only two had patients with an increase of at least one log (one in each study) 
[233, 240]. Unfortunately no discussion of these two cases was given; in particular 
there were no data on treatment adherence. 
The funnel plot (Figure 9) shows the standard error against the proportion undetectable 
at one year, with the vertical line marking the summary estimate of the treatment effect 
(derived using fixed-effect meta-analysis) [245]. The plot is symmetrical with no 
suggestion of publication bias. There is larger than expected heterogeneity in the larger 
studies (appearing higher up on the graph with a lower standard error), with one 
apparent outlier with a low proportion undetectable despite large size (de Vries-Sluijs 
[230], Group D). Separate funnel plots of each arm in the analysis also show no 
publication bias (Appendix 5). Repeating the regression analysis after excluding the 
outlier study arm and after excluding small studies (with less than ten patients) made 
no material difference to the results. The model including a term for study design 
showed that this variable had no significant impact on the results, with p values of 0.76, 
0.54 and 0.42 at 1, 2 and 3 years in the overall analysis. 
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Figure 9: Meta-analysis – funnel plot of standard error against proportion 
undetectable at one year – all study arms (with pseudo 95% confidence limits) 
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3.4 Discussion 
This review of HBV/HIV coinfected patients treated with TDF demonstrates durable 
virological suppression of HBV replication to below the level of detection, with the 
proportion suppressed increasing over time, though with small numbers at later time 
points. Few patients experience virological failure on treatment. 
However several reservations should be noted. Firstly most of the studies included 
were cohort studies in which patients who dropped out were not well characterised and 
so measurement of suppression over time could be biased. Secondly, we compared 
different treatment groups though allocation to these was randomised in only two 
studies [114, 148]. Thirdly there was little data beyond three years of treatment with the 
number of patients included in the meta-analysis declining rapidly over time. 
The proportion with undetectable HBV at one year (59%) was lower than the proportion 
found in HIV-negative patients receiving TDF for treatment of HBV infection. For 
example, a multicentre cohort study found that, of 54 HIV-negative patients treated with 
TDF and FTC, 60% of whom were HBeAg positive, the probability of attaining an 
undetectable HBV VL was 76% at one year and 94% at two years [246]. Similarly, in a 
large randomised controlled trial comparing TDF with ADV, Marcellin found 93% of 250 
HBeAg negative and 76% of 176 HBeAg positive patients randomised to TDF had an 
undetectable VL (<400 copies/mL) at 48 weeks (97% and 83% respectively of those 
still on TDF at 48 weeks) [228]. 
In the latter study, ten patients (2.3%) had virological breakthrough (defined in that 
study as detectable HBV after an undetectable result or an increase in HBV VL by a 
factor of 10 from nadir) [228]. Of the 550 patients in the current study, we identified 12 
(2.4%) with a rise in HBV VL on TDF treatment (although at least five of these 12 had 
less than a one log rise from nadir) which is comparable. However other published data 
in coinfected patients have found far higher rates, for example 9 (17%) of 52 patients 
followed up for a median of 34 months in one retrospective cohort study (which was not 
included in the current meta-analysis as data on HBV VL suppression was only given 
at the end of follow-up and not at yearly time points) [247]. 
The high rate of virological suppression and low rate of breakthrough may be related to 
the low chance of developing TDF-resistance mutations. As described in chapter 1, in 
HBV/HIV coinfected patients treated with 3TC as the only drug active against HBV, 
resistance develops in about 90% after four years [166] whereas mutations associated 
with TDF resistance, such as the combination of rtL180M, rtM204V/I and rtA194T [171] 
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or N236T with A181V [248], have only rarely been seen and are of uncertain 
significance [172, 249, 250]. 
No statistically significant effect of prior 3TC/FTC exposure or of concomitant 3TC/FTC 
use was found. However the confidence intervals were wide and we could not exclude 
the possibility of moderately strong effects in either direction. In HIV-negative patients 
TDF monotherapy is as effective for HBV as combination therapy with TDF and 
3TC/FTC with suppression rates (<400 copies/mL) of 81% at one year in both arms of 
an RCT using TDF alone or TDF/FTC combination therapy, and 88% and 85% 
respectively at three years [251, 252]. 
The main concern with sequential treatments that fail to fully suppress the VL is that 
resistance may develop and that cross-resistance could reduce the efficacy of 
subsequent drugs. TDF resistance is yet to be clearly demonstrated but it may be that 
the risk of cross-resistance is higher with drugs that are more similar to TDF in 
structure than 3TC/FTC. However HBV monoinfected patients failing to achieve 
virologic suppression with ADV have also been shown to respond well to TDF [253-
255]. 
A second mechanism by which prior treatment exposure could reduce the apparent 
effectiveness of subsequent TDF is through introducing bias, in that patients failing one 
regimen for reasons other than lack of potency (such as poor adherence to therapy) 
may go on to fail other regimens but again, no such reduction in the effect of TDF in 
those with prior exposure to 3TC/FTC was found and so the effect of any such bias 
must be small. 
As stated above, TDF received FDA approval in late 2001 and thus clinical experience 
to date is limited to just over one decade. Although this review includes data to a 
maximum of seven years, a lack of data limited the main regression analyses to three 
years. Patients with HIV require lifelong treatment and patients with HBV coinfection 
are likely to require the same. The possibility of safe discontinuation of HBV treatment 
may be limited to patients who clear HBsAg. However the probability of HBsAg loss is 
low with a rate of approximately 2.5% per year [256, 257] with the predicted median 
time to HBsAg seroclearance in HBeAg positive patients treated with TDF being 18 
years (IQR 10 to 28 years) [258].  
A limitation of this study is that it does not include analysis of the adverse effects of 
treatment. Future studies with longer follow-up duration will be required to determine 
the risk of treatment associated adverse effects, such as renal and bone toxicity, in 
patients exposed to TDF for many decades. 
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In conclusion, this meta-analysis shows that TDF suppresses HBV to undetectable 
levels in the majority of HBV/HIV coinfected patients, and with little virological rebound 
on treatment. Prior treatment with 3TC/FTC appears not to alter the efficacy of TDF 
treatment. Combination treatment with 3TC/FTC appears to offer no significant benefit 
over TDF alone. 
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4 Development of Antiretroviral Therapy (DART) 
Hepatitis Substudy 
4.1 Summary of the DART study 
The DART Study was an open, randomised, multi-centre trial in Africa, funded by MRC, 
DFID and the Rockefeller Foundation [259]. There were two main research questions, 
(1) is laboratory monitoring required when providing treatment for HIV and (2) can 
treatment be given intermittently, in order to reduce toxicity, but without reducing 
effectiveness? 
To answer the first question there were two primary endpoints, (1) progression to a 
new WHO stage 4 event or death and (2) serious adverse events. This analysis was 
published in 2010 and found that HIV treatment can be safely given without monitoring 
bloods without an increase in serious or grade 3 or 4 adverse events, although from the 
second year of treatment such monitoring did provide a small but statistically significant 
reduction in disease progression to a new stage 4 event or death (Figure 10) [259]. 
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Figure 10: Clinical disease progression and adverse events in the DART study 
 
Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, et al. Routine versus 
clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a 
randomised non-inferiority trial. Lancet. 2010;375(9709):123-31. [259] 
The second question was addressed in a structured treatment interruption (STI) 
substudy in which 813 participants were randomised to either continuous treatment 
(CT) or fixed-duration treatment interruptions of 12 weeks on and 12 weeks off 
medication. Due to concerns with the safety of treatment interruption the STI substudy 
was stopped early in March 2006 [260]. 
The DART study is now complete, with few dropouts, archived blood samples and 
matching laboratory and clinical data. It provides a unique opportunity to answer some 
of the key questions regarding HBV/HIV coinfection. 
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4.1.1 Study Population 
Participants were recruited at 2 sites in Uganda and 1 in Zimbabwe. These are the 
Joint Clinical Research Centre (JCRC), Kampala, the MRC/UVRI Uganda Research 
Unit on AIDS, Entebbe and the University of Zimbabwe Clinical Research Centre, 
Harare. 
Inclusion criteria to DART were: age at least 18 years; CD4 <200 cells/mm3; naïve to 
antiretroviral therapy except for exposure for the prevention of mother-to-child 
transmission. Exclusion criteria were: likely to be unable to attend follow-up; likely to 
have poor compliance; acute infection including intense-phase of TB treatment; 
malignancy requiring chemotherapy; laboratory test result indicative of contraindication 
to ART (including ALT >5x ULN); pregnancy; breastfeeding. 
Patients (n=3,316) were randomised to care including laboratory monitoring of CD4 
(LCM), or relying on clinically driven monitoring (CDM) in which arm laboratory results 
were not returned to clinicians unless they had been requested or the result showed 
evidence of a grade 4 abnormality. 
4.1.2 Consent and ethical approval 
Patients gave informed consent to participate in the main study and substudies. Ethics 
approval was obtained from bodies in Uganda, Zimbabwe and the United Kingdom. 
4.1.3 Timing and follow-up 
The first DART participant was randomised on 15th January 2003 and the last on 28th 
October 2004. Maximum follow-up was for 2,129 days (almost six years). The last day 
of follow-up was 31st December 2008. 
4.1.4 Samples 
Samples were taken and stored at baseline, 4 weeks, and every 3 to 6 months 
subsequently.  
4.1.5 Antiretroviral treatment 
Patients all received AZT and 3TC (Combivir) and either TDF (n=2,469), NVP (n=547) 
or ABC (n=300). Drug allocation was not randomised, except 1:1 to ABC or NVP in a 
sub-group of 600 Ugandan patients. Although other treatment allocations were not 
randomised, group baseline characteristics have been shown to be similar [259]. 
Approximately 10% switched to second-line HAART with switches made on the basis 
of clinical progression (new or recurrent WHO stage 4 event or stage 3 event if clinician 
so decided) or, in the LCM arm, if CD4 was confirmed lower than 100 cells/mm3 on 
ART [259].  
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3TC and TDF have potent activity against hepatitis B [261, 262]. ABC has been shown 
to have weak activity against HBV [263]. The other antiretroviral drugs used in DART 
have no activity against HBV. 
4.1.6 Data available 
Laboratory test data available from DART includes CD4 and liver function tests (LFTs) 
on samples taken at the time-points described above. 
Clinical events data was recorded monthly and is also available. Deaths were recorded 
by clinicians on a standardised form and reviewed by the members of the Endpoint 
Review Committee, who were blinded with respect to study arm. 
4.1.7 Baseline characteristics 
Baseline characteristics of the DART population are shown in Table 11. There were 
more female than male participants and this difference was more pronounced in the 
Ugandan sites. There were fewer participants under the age of 30 in Zimbabwe. WHO 
stage 4 disease was more common in JCRC than either Entebbe or Zimbabwe.  
Table 11: Baseline characteristics of the DART population 
 Entebbe  JCRC  Harare  p 
 N % N % N %  
Total 1,020  1,297  999   
Sex       <0.001 
Male 335 32.8 404 31.1 421 42.1  
Female 685 67.2 893 68.9 578 57.9  
Age       0.004 
18-29 196 19.2 201 15.5 135 13.5  
30-34 251 24.6 309 23.8 236 23.6  
35-39 253 24.8 331 25.5 264 26.4  
40-44 163 16.0 253 19.5 192 19.2  
45-49 91 8.9 118 9.1 104 10.4  
50- 66 6.5 85 6.6 68 6.8  
CD4       0.09 
0-49 330 32.4 465 35.9 314 31.4  
50-99 220 21.6 314 24.2 251 25.1  
100-149 242 23.7 282 21.7 235 23.5  
150-199 228 22.4 236 18.2 199 19.9  
Stage       <0.001 
2 290 28.4 174 13.4 209 20.9  
3 532 52.2 731 56.4 601 60.2  
4 198 19.4 392 30.2 189 18.9  
Drug       <0.001 
TDF 720 70.6 997 76.9 752 75.3  
ABC 149 14.6 151 11.6 0 0  
NVP 151 14.8 149 11.5 247 24.7  
TDF: tenofovir. ABC: Abacavir. NVP: Nevirapine. 
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4.2 Hepatitis serology testing 
In the hepatitis substudy of DART, we aimed to examine the degree and durability of 
HBV viral suppression. We were also able to examine the epidemiology and clinical 
correlates of HBV coinfection and implications for testing and monitoring (see 
Hypothesis and aims – section 2).  
We attempted to retrieve and test baseline samples from all participants for antibody to 
HCV (anti-HCV) and for HBV serological markers according to the algorithm below 
(Figure 11). 
Figure 11: Algorithm for HBV serology testing 
 
HBsAg: HBV surface antigen. anti-HBc: antibody to HBV core antigen. anti-HBs: 
antibody to HBV surface antigen. HBeAg: HBV “e” antigen. anti-HBe: antibody to HBV 
“e” antigen. 
Baseline samples were initially tested for HBsAg and anti-HBc. Those that tested 
positive for anti-HBc but negative for HBsAg were then tested for anti-HBs and those 
that tested positive for HBsAg were tested for HBeAg, anti-HBe and HBV DNA.  
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Anti-HBc, HBsAg, anti-HBs and anti-HCV testing was done at all three sites. Anti-HBe 
and HBeAg testing was done at JCRC and Harare with samples from Entebbe sent to 
JCRC.  
All assays used for HBV serology were commercial enzyme immunoassays and quality 
control used standardised controls supplied with test kits. HBsAg assays used were 
known to be unaffected by recognised HBsAg mutants. 
For HBsAg, anti-HBs and anti-HBc Entebbe and Harare used Murex assays which are 
based on an enzyme immunoassay (EIA) method. JCRC used Roche Elecsys which is 
an electrochemoluminescence assay (ECLIA). All three sites followed a positive 
screening HBsAg test with a confirmatory neutralisation test (Appendix 5). 
Testing for hepatitis B e markers used separate assays for HBeAg and anti-HBe. 
Harare used Murex EIA while JCRC used Roche Elecsys ECLIA. 
For HCV a third generation EIA assay by Innotest was used in Uganda while Murex 
EIA was used in Zimbabwe. 
HBsAg testing was performed on 37 participants during the follow-up period of DART. 
Of these, 3 (8.1%) had a positive result. No other hepatitis serology testing was 
undertaken. Of the 34 with a negative HBsAg result in DART, 32 had negative results 
when tested in the hepatitis substudy. Of the 3 with a positive result in DART, 2 were 
positive and 1 negative in the substudy. In all analyses the baseline result from testing 
undertaken as part of the substudy was used. 
4.3 Hepatitis B DNA viral load testing 
4.3.1 Viral load testing methods 
Hepatitis B DNA viral load testing followed the algorithm below (Figure 12). All 
participants with positive HBsAg had hepatitis B DNA viral load testing at baseline and 
of the last sample taken before any change in HBV-active treatment, i.e. stopping or 
interrupting either 3TC or TDF for ≥30 days or starting TDF in a participant treated 
initially with NVP or ABC. Those participants who had HBV VL quantifiable at baseline 
had testing of samples taken at week 48 with the last sample only being tested if this 
was after 96 weeks. Participants at JCRC with quantifiable HBV VL at baseline had 
additional testing at weeks 4, 12 and 24. 
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Figure 12: Algorithm for HBV viral load (DNA) testing 
 
HBsAg: HBV surface antigen. VL: viral load. JCRC: Joint Clinical Research Centre, 
Kampala, Uganda. ENT: MRC/UVRI Uganda Research Unit on AIDS, Entebbe, 
Uganda. HAR: University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe. 
HBV DNA VL tests were performed at JCRC and Harare, with samples sent from 
Entebbe to JCRC for testing. JCRC used Roche Cobas Ampliprep/Cobas TaqMan 
while Harare used Abbott Realtime HBV after manually preparing samples using the 
mSample Preparation SystemDNA. 
The interpretation of these tests as used (in IU/mL) was as given below (Table 12). 
Table 12: Interpretation of HBV DNA viral load test results 
Test Not detected 






Upper limit of 
quantification 
IU/mL 











Baseline samples at JCRC were diluted 1:4 giving a range of 48 to 440 x106 IU/mL. IU 
can be converted to copies by multiplying by 3.41 (Abbott) or 5.82 (Roche). If HBV VL 
was reported as above the range of the assay the value used in analyses was the 
upper limit of the assay range.  
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Quality control of HBV DNA viral load testing was performed at JCRC and Harare using 
reference samples supplied by the United Kingdom National External Quality 
Assessment Service (UKNEQAS). 
4.4 Statistical analysis 
All analyses were performed using Stata version 12 (StataCorp LP, College Station, 
Texas, USA). 
All logarithms used are to base 10. 
Prevalence of variables was given using proportions and shown on histograms, 
stratified appropriately. Changes in variables over time were shown graphically with 
95% confidence intervals (Stata ci command) also stratified appropriately (e.g. the 
change in ALT was shown stratified by HBsAg status and first-line drug regimen). 
Medians were compared using the Kruskal-Wallis equality-of-populations rank test. 
Associations with categorical variables were examined using Chi squared or Fisher’s 
exact test, as appropriate according to cell size. Chi-squared test for trend (Stata 
command ptrend) was used to examine associations with ordinal variables (age group, 
baseline CD4 cell count group and WHO stage of HIV disease). Unadjusted 
(univariable) and adjusted (multivariable) logistic regression were used to determine 
factors associated with binary outcome variables (e.g. prevalence of HBsAg) and 
unadjusted and adjusted linear regression to examine associations with numerical 
outcome variables, transformed as necessary to approximate normal distributions (e.g. 
the logarithm to base 10 of ALT). Multivariable models included all covariates of 
interest whether or not their effect was statistically significant i.e. no forward or 
backward selection approaches were used. This was vindicated by the large number of 
observations relative to the number of covariates, so that the number of degrees of 
freedom was not an issue. All variables included in models are shown in the results. 
Categorical variables included in multivariable models were examined with global p-
values comparing across groups. 
Concern that correlation between WHO stage and CD4 count at baseline could distort 
the conclusions of models was examined by comparing the standard errors (SE) of the 
coefficients of both factors in univariable and multivariable regressions of one variable, 
namely positive anti-HBc test result. As can be seen in Table 13, the standard errors 
were very similar and so it was concluded that collinearity was not a problem. 
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Table 13: Coefficients and standard errors of baseline WHO stage and CD4 count 
in logistic regression of anti-HBc 
 Univariable  Multivariable 
 Coefficient SE  Coefficient SE 
WHO Stage      
2      
3 -0.013 0.090  -0.000 0.091 
4 -0.069 0.105  -0.043 0.108 
Baseline CD4      
<50      
50-99 0.119 0.094  0.115 0.094 
100-149 0.046 0.094  0.041 0.095 
150-199 0.119 0.099  0.111 0.101 
 
Correlation between variables, e.g. fibrosis markers, was examined using R, the 
Pearson product-moment correlation coefficient.  
Incidence rates were used to compare the incidence of outcomes over time. Survival 
analyses used Kaplan Meier failure estimate curves shown graphically and 
associations were examined using unadjusted and adjusted Cox proportional hazards 
models.  
A significance level of p<0.05 has been used throughout. 
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5 Baseline serology and virology 
5.1 Introduction 
The epidemiology of hepatitis B has been reviewed in chapter 1. Estimates of 
prevalence have varied widely in both Uganda and Zimbabwe. In this analysis we 
characterise the baseline hepatitis B and hepatitis C status of the participants in DART. 
Aims 
The aims were to determine, at entry to the trial, the proportion of participants and 
factors associated with: 
1. evidence of exposure to HBV,  
2. current HBV infection and HBeAg and HBV DNA status,  
3. evidence of exposure to HCV. 
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5.2 Methods 
5.2.1 Statistical methods 
The prevalence of anti-HBc, HBsAg and HBeAg, the percentage with evidence of 
exposure and the percentage of those exposed who had evidence of having cleared 
HBV were shown using histograms stratified by study site, sex and age and the 
distribution of HBV DNA results shown by HBeAg status. 
To examine associations between categorical variables (study site, sex, anti-HBc and 
HBsAg results, HBV DNA detection, anti-HCV result) we used chi-squared tests (or 
Fisher’s exact test as appropriate due to small numbers). We used the chi-squared test 
for trend (Stata command ptrend) to examine associations with ordinal variables (age, 
baseline CD4 cell count and WHO stage of HIV disease). 
Unadjusted (univariable) and adjusted (multivariable) logistic regression were used to 
determine factors that may influence the prevalence of anti-HBc, HBsAg and HBeAg 
positivity. 
All analyses were performed using Stata version 12 (StataCorp LP, College Station, 
Texas, USA).  
5.2.2 Serology and viral load testing 
Current HBV status was classified according to the results of anti-HBc, HBsAg and 
anti-HBs testing as shown in Table 14. Anti-HBs results were classified as positive if 
the assay result was greater than 10 mIU/mL. 
Table 14: Combinations of baseline HBV serology test results used to classify 
infection status 
 Anti-HBc HBsAg Anti-HBs 
Not exposed Negative Negative Neg/Pos/Not tested 
Resolved infection Positive Negative Positive 
Isolated anti-HBc Positive Negative Negative 
Infected Any Positive Any 
Some participants without detectable anti-HBc and/or with detectable HBsAg were 
tested for anti-HBs although this was not required in the algorithm. 
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5.3 Results 
5.3.1 Patients tested  
All 3,316 participants had baseline samples stored and available for HBV testing but 
due to insufficient sample not all tests mandated by the algorithm were performed. 
3,311 were tested for anti-HBc and 3,315 for HBsAg. 1,505 of 1,521 with a positive 
anti-HBc result and a negative HBsAg result had a test for anti-HBs. Of 308 
participants with a positive HBsAg result, 280 (90.9%) had tests for HBeAg and anti-
HBe and 270 (87.7%) were tested for HBV DNA VL. Anti-HCV tests were performed on 
samples from 3,253 participants. 
5.3.2 Test results 
The results of individual tests are summarised in Table 15. All combinations of serology 
results are shown in Appendix 7.  
Table 15: Baseline viral hepatitis tests  
  Positive 
Test N n % 
HBsAg 3,315 308 9.3 
Anti-HBc 3,311 1,774 53.6 
Anti-HBs 1,865 1,004 53.8 
HBeAg 325 107 32.9 
Anti-HBe 325 145 44.6 
HBV DNA VL 270 214
a
 79.3 
Anti-HCV 3,253 77 2.4 
a: detectable 
5.3.2.1 HBsAg and anti-HBc results 
308 (9.3%) and 1,774 (53.6%) participants tested positive for HBsAg and anti-HBc, 
respectively. 
Patients with a positive result for HBsAg would be expected to also have a positive 
result for anti-HBc (except in rare cases of very recent infection). However 54 (17.6%) 
out of 307 patients with detectable HBsAg that had a test for anti-HBc were found to be 
anti-HBc seronegative. 
5.3.2.2 Anti-HBs results 
Of 1,521 participants with results positive for anti-HBc but negative for HBsAg, 1,505 
(98.9%) were tested for anti-HBs and 962 (63.9%) results were positive, consistent with 
a resolved infection and natural immunity.  
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In addition, 360 patients with results other than positive anti-HBc and negative HBsAg 
had anti-HBs testing. Of these, 308 tested negative for both HBsAg and anti-HBc or 
tested negative for one and the other had not been tested; of these, 28 (9.1%) results 
were anti-HBs positive. 52 patients had a positive result for HBsAg (anti-HBc results 
negative in 6 and positive in 46) and were tested for anti-HBs; 14 (27%) had a positive 
anti-HBs result. 
5.3.2.3 HBeAg and anti-HBe results 
325 (280 HBsAg seropositive and 45 HBsAg seronegative) participants were tested for 
HBeAg and anti-HBe; 107 (32.9%) were HBeAg seropositive and 145 (44.6%) were 
anti-HBe seropositive. 7 (2.2%) had positive results on both tests and 80 (24.6%) on 
neither. Of the 280 HBsAg seropositive participants tested for HBeAg, 103 (36.8%) 
were HBeAg seropositive and 127 (45.4%) were anti-HBe seropositive, 56 (20.0%) 
were negative and 6 (2.1%) were positive on both tests.  
5.3.2.4 HBV DNA VL results 
270 (87.7%) of 308 HBsAg seropositive participants were tested for plasma HBV DNA 
VL at baseline; 56 (20.7%) had undetectable DNA, 30 (11.1%) had DNA detectable but 
below the level of quantification (BLQ) and 184 (68.1%) had a quantifiable level of 
DNA. In those with a quantifiable result the median was 7.0 x105 IU/mL (IQR 2.0 x103 
to 2.0 x108).  
5.3.2.5 Anti-HCV results 
77 (2.4%) of 3,253 participants were anti-HCV positive.  
5.3.3 Exposure and current status 
Overall, 1,829 (55.2%) of the 3,316 participants had evidence of exposure to HBV 
(positive HBsAg and/or positive anti-HBc results).  
All but 21 (0.6%) of the 3,316 participants could be categorised as described in 
methods (section 5.2.2). Of those that could be categorised, 1,482 (45.0%) had not 
been exposed to HBV, 962 (29.2%) had evidence of having cleared the infection as 
defined by presence of anti-HBc and anti-HBs but without HBsAg, 308 (9.3%) had 
detectable HBsAg and 543 (16.5%) had isolated anti-HBc (defined as having test 
results positive for anti-HBc and negative for both HBsAg and anti-HBs), which could 
have represented cleared or “occult” infection (Table 16). 
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Table 16: Baseline HBV status - categories 
 Total 
Category n % 
Not exposed 1,482 45.0 
Resolved infection 962 29.2 
Isolated anti-HBc 543 16.5 
Infected 308 9.3 
Total 3,295 100.0 
 
5.3.4 Unusual serological patterns 
5.3.4.1 Positive HBsAg and anti-HBs 
14 participants had positive results for HBsAg and anti-HBs. All 13 tested for anti-HCV 
were anti-HCV negative. 2 were anti-HBc negative; of these 2, HBV DNA was below 
the level of quantification in one and not detected in the other. Of the 12 who were anti-
HBc positive, 10 were tested for HBeAg and anti-HBe; one was positive for HBeAg and 
5 for anti-HBe. 11 of the 12 were tested for HBV DNA – in 7 HBV DNA was not 
detected, in 2 it was below the level of quantification and in 2 HBV DNA was 
detectable, one at a level of 532 IU/mL and the other at 2.6 x107 IU/mL. 
5.3.4.2 Positive HBsAg with negative anti-HBc 
54 participants had positive HBsAg (all confirmed by neutralisation) but negative anti-
HBc. 6 of these were also tested for anti-HBs; 4 results were negative and 2 were 
positive. 48 had tests for HBeAg and anti-HBe; 29 (60%) were negative for both HBeAg 
and anti-HBe, 1 (2%) was positive for both, 15 (31%) were HBeAg positive/anti-HBe 
negative and 3 (6%) were HBeAg negative/anti-HBe positive. 47 were tested for HBV 
DNA; in 23 (49%) HBV DNA was not detected, in 7 (15%) HBV DNA was below the 
level of quantification and in 17 (36%) HBV DNA was detectable and quantifiable, 
ranging from 54 IU/mL to the upper limit of quantification (1 x109 IU/mL). 
5.3.5 Predictors of baseline status 
5.3.5.1 Anti-HBc 
The prevalence of positive anti-HBc was similar in the three sites (Entebbe 51.4%, 
JCRC 53.2% and Harare 56.3%; p=0.09). 
Male sex was associated with a higher prevalence of anti-HBc overall (59.6% vs. 
50.3%), in Harare (65.7% vs. 49.4%) and in JCRC (58.2% vs. 51.0%) but in Entebbe, 
while males again had a higher prevalence of anti-HBc, the difference was not 
statistically significant (53.7% vs. 50.3%). 
Older age was associated with increasing prevalence of anti-HBc in all three sites. 
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The relationship between age and anti-HBc positivity appeared to differ according to 
sex and in the three sites (Figure 13). In a logistic regression model examining the 
effect of site, age and sex on anti-HBc status, while interaction terms between site and 
age and between sex and age were not significant (p=0.28 and p=0.93 respectively) 
the interaction term between site and sex was (p=0.01). 
Figure 13: Anti-HBc seroprevalence at baseline by age, sex and study site 
 
 
In multivariable logistic regression, anti-HBc positivity was higher in males and 
increased with age, but was not associated with site, stage, baseline CD4 or anti-HCV 
status (Table 17).
   
Table 17: Associations with anti-HBc status 
 All anti-HBc positive OR p  aOR 95% CI p 
 n n %       
All 3,311 1,774 53.6       
Site     0.09    0.26 
Entebbe 1,019 524 51.4       
JCRC 1,297 690 53.2 1.07   1.08 0.91 to 1.27  
Harare 995 560 56.3 1.22   1.16 0.97 to 1.39  
Sex     <0.001    <0.001 
Male 1,159 691 59.6       
Female 2,152 1,083 50.3 0.69   0.72 0.62 to 0.84  
Age group     <0.001    0.02 
<30 531 249 46.9       
30-35 794 407 51.3 1.19   1.14 0.92 to 1.43  
35-40 848 454 53.5 1.30   1.21 0.97 to 1.50  
40-45 607 349 57.5 1.53   1.40 1.10 to 1.77  
45-50 312 180 57.7 1.54   1.39 1.04 to 1.85  
>50 219 135 61.6 1.82   1.63 1.17 to 2.26  
WHO Stage     0.54    0.96 
2 673 364 54.1       
3 1,861 1,002 53.8 0.99   0.98 0.82 to 1.18  
4 777 408 52.5 0.94   0.97 0.78 to 1.20  
Baseline CD4     0.32    0.59 
<50 1,107 576 52.0       
50-99 783 431 55.0 1.13   1.10 0.91 to 1.33  
100-149 759 403 53.1 1.04   1.06 0.87 to 1.28  
150-199 662 364 55.0 1.13   1.14 0.93 to 1.39  
Anti-HCV     0.96    0.89 
Negative 3,171 1,700 53.6       
Positive 77 40 51.9 0.94   0.90 0.57 to 1.41  
Not done 63 34 54.0 1.01   0.96 0.58 to 1.60  
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As mentioned above (section 5.3.4.2), in 54 participants HBsAg was detectable but 
anti-HBc was not, a phenomenon which has been linked to increasing 
immunosuppression (see discussion) as well as to acute infection or a false positive 
HBsAg. We observed a non-significant increasing trend in the proportion negative for 
anti-HBc at lower CD4 counts (Table 18). 
Table 18: Anti-HBc status in those HBsAg seropositive, by baseline CD4 
  Anti-HBc positive 
Baseline CD4 N n % 
0-49 98 77 78.6 
50-99 84 69 82.1 
100-149 68 56 82.4 
150-199 57 51 89.5 
Total 307 253 82.4 
Chi-squared test for trend p=0.11. 
5.3.5.2 HBsAg 
The prevalence of detectable HBsAg was three times higher in Harare (16.7%) than in 
the Ugandan sites, where the prevalence was similar (Entebbe 5.5%, JCRC 6.6%; 
Zimbabwe vs. Uganda p<0.001, Entebbe vs. JCRC p=0.29). 
As stated above (section 5.3.2.1) we would expect anti-HBc results to be positive in all 
participants with CHB. In those anti-HBc positive, HBsAg was more prevalent in Harare 
(22.7%) than in Entebbe (8.8%) or JCRC (11.6%; p<0.001) but was no different 
between the 2 Ugandan sites (p=0.11). However HBsAg was also detected in 54 
participants negative for anti-HBc (40 at Harare, 9 at Entebbe and 5 at JCRC).  
Higher prevalence was associated with male sex (12.2% vs. 7.7%; p<0.001) but this 
was seen only at JCRC (10.6% vs. 4.7%; p<0.001) and not at Entebbe (5.7% vs. 5.4%; 
p=0.86) or Harare (18.8% vs. 15.3%; p=0.13). 
There was no clear relationship between the prevalence of HBsAg and age (p=0.78) 
(Figure 14). 
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Figure 14: HBsAg seroprevalence at baseline by age, sex and study site 
 
 
There was also no relationship between HBsAg status and WHO stage (p=0.85), 
baseline CD4 count (p=0.68) or anti-HCV status (p=0.64). 
The median CD4 count at study entry was the same in those without detectable HBsAg 
(86 cells/mm3, IQR 31 to 140) and those with detectable HBsAg (87 cells/mm3, IQR 
31.5 to 137.5; p=1.0). 
In a logistic regression model, HBsAg status was associated with site (p<0.001) and 
sex (p=0.001) with higher prevalence of HBsAg in JCRC (aOR 1.22) and Harare (aOR 
3.41) and lower prevalence in females (aOR 0.65). In adjusted analyses, HBsAg status 
was not associated with age (p=0.29), baseline WHO stage (p=0.99), baseline CD4 
(p=0.66) or anti-HCV status (p=0.34) (Table 19). 
 
  
Table 19: Predictors of HBsAg status 
 All HBsAg positive OR p  aOR 95% CI p 
 n n %       
All 3,314 308 9.3       
Site     <0.001    <0.001 
Entebbe 1,020 56 5.5       
JCRC 1,297 85 6.6 1.21   1.22 0.86 to 1.74  
Harare 997 167 16.7 3.46   3.41 2.48 to 4.70  
Sex     <0.001    0.001 
Male 1,160 141 12.2       
Female 2,155 167 7.7 0.61   0.65 0.50 to 0.83  
Age group     0.78    0.29 
<30 532 46 8.6       
30-35 795 79 9.9 1.17   1.05 0.71 to 1.55  
35-40 848 77 9.1 1.06   0.89 0.60 to 1.32  
40-45 608 63 10.4 1.22   0.99 0.66 to 1.50  
45-50 313 31 9.9 1.16   0.91 0.55 to 1.49  
>50 219 12 5.5 0.61   0.48 0.25 to 0.95  
WHO Stage     0.85    0.99 
2 672 61 9.1       
3 1,864 178 9.5 1.06   1.00 0.73 to 1.37  
4 779 69 8.9 0.97   1.02 0.69 to 1.49  
Baseline CD4     0.68    0.66 
<50 1,109 99 8.9       
50-99 784 84 10.7 1.22   1.21 0.88 to 1.66  
100-149 759 68 9.0 1.00   1.06 0.76 to 1.48  
150-199 663 57 8.6 0.96   1.02 0.71 to 1.46  
HCV Ab     0.64    0.34 
Negative 3,175 298 9.4       
Positive 77 5 6.5 0.67   0.70 0.28 to 1.77  
Not done 63 5 7.9 0.83   0.54 0.21 to 1.38  
 
 Chapter 5: Baseline serology and virology Page 88 of 240 
5.3.5.3 HBeAg 
Among HBsAg-positive participants, HBeAg positivity was higher at JCRC (46.3%) and 
Harare (34.7%) than at Entebbe (27.1%), although these differences did not reach 
statistical significance (p=0.07). 
The proportion HBeAg positive was greater in males than females (44.0% vs. 31.0%; 
p=0.03). There was no relationship with age (p=0.17) (Figure 15). 
Figure 15: HBeAg status by age, sex and study site 
 
 
HBeAg prevalence increased with advancing HIV disease with rates of 24% in stage 2, 
36% in stage 3 and 52% in stage 4 disease (p=0.001). The pattern by CD4 count was 
less clear. There was no association with anti-HCV (p=0.62). 
In multivariable logistic regression there remained no association with site, sex, age or 
anti-HCV status and the relationship with baseline CD4 was no longer significant. 
However HBeAg positivity was more likely with advanced WHO stage of HIV disease 
(p=0.03) (Table 20). In a model including all variables apart from WHO stage, the aOR 
for baseline CD4 cell count did not materially change and remained non-significant 
(p=0.08). 
   
Table 20: Predictors of HBeAg status 
 
All HBeAg positive 
OR p 
 
aOR 95% CI p 
n n %  
All 280 103 36.8       
Site     0.07    0.35 
Entebbe 48 13 27.1       
JCRC 82 38 46.3 2.33   1.55 0.67 to 3.62  
Harare 150 52 34.7 1.43   1.03 0.47 to 2.26  
Sex     0.03    0.12 
Male 125 55 44.0       
Female 155 48 31.0 0.57   0.65 0.38 to 1.11  
Age group     0.17    0.68 
<30 41 10 24.4       
30-35 70 26 37.1 1.83   1.71 0.69 to 4.25  
35-40 67 25 37.3 1.85   1.66 0.67 to 4.13  
40-45 61 27 44.3 2.46   2.19 0.87 to 5.53  
45-50 29 10 34.5 1.63   1.52 0.50 to 4.66  
>50 12 5 41.7 2.21   2.38 0.59 to 9.70  
WHO Stage     0.001    0.03 
2 59 14 23.7       
3 159 57 35.8 1.80   1.67 0.80 to 3.48  
4 62 32 51.6 3.43   3.10 1.33 to 7.25  
Baseline CD4     0.05    0.10 
<50 89 36 40.4       
50-99 74 35 47.3 1.32   1.57 0.81 to 3.06  
100-149 65 16 24.6 0.48   0.60 0.28 to 1.27  
150-199 52 16 30.8 0.65   0.97 0.44 to 2.15  
HCV Ab     0.62    0.32 
Negative 276 102 37.0       
Positive 4 1 25.0 0.57   0.31 0.03 to 3.23  
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5.3.5.4 HBV DNA 
The proportion of those with a positive HBsAg result that had detectable HBV DNA was 
higher in JCRC (91.7%) and lower in Harare (72.3%) than in Entebbe (82.0%; 
p=0.003). 
250 (92.6%) of those with HBV DNA results were tested for HBeAg; 83 (33.2%) were 
HBeAg positive. HBV DNA was detected in more HBeAg positive (96.4%) than HBeAg 
negative (70.1%) participants (p<0.001) and HBeAg positive patients had higher HBV 
DNA results (median 1.1 x108 vs. 2.9 x103, p<0.001) (Figure 16). 
Figure 16: HBV DNA viral load in those quantifiable, by HBeAg status 
 
In a multivariable linear regression model limited to those with quantifiable HBV DNA, 
HBV DNA was associated with site (higher in JCRC) and HBeAg status but was not 
associated with sex, age, WHO stage or CD4 cell count (Table 21). HBV DNA was 
nearly 3 logs higher in those who tested HBeAg positive. 
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Table 21: Linear regression of log(HBV DNA) 
 Unadjusted Adjusted 
 Coeff. 95% CI p Coeff. 95% CI p 
Site       
Entebbe   0.01   0.004 
JCRC 1.21 0.15 to 2.28  0.91 0.01 to 1.80  
Harare 0.04 -0.96 to 1.03  -0.25 -1.10 to 0.60  
Sex       
Male   0.81   0.62 
Female -0.09 -0.66 to 0.85  0.16 -0.47 to 0.78  
Age group       
<30   0.12   0.09 
30-35 1.09 -0.19 to 2.37  1.36 0.31 to 2.41  
35-40 0.30 -1.01 to 1.62  0.67 -0.41 to 1.75  
40-45 0.51 -0.81 to 1.82  0.71 -0.35 to 1.78  
45-50 -0.76 -2.24 to 0.73  0.04 -1.15 to 1.23  
>50 0.51 -1.47 to 2.49  0.98 -0.57 to 2.53  
WHO Stage       
2   0.04   0.78 
3 0.76 -0.23 to 1.74  0.06 -0.76 to 0.89  
4 1.52 0.36 to 2.68  -0.21 -1.20 to 0.78  
Baseline CD4       
<50   0.002   0.10 
50-99 0.54 -0.40 to 1.49  0.41 -0.37 to 1.21  
100-149 -1.37 -2.38 to -0.36  -0.71 -1.59 to 0.16  
150-199 -0.74 -1.80 to -0.31  -0.19 -1.14 to 0.75  
HBeAg       
Negative   <0.001   <0.001 
Positive  2.98 2.35 to 3.61  2.86 2.23 to 3.49  
Coeff: Coefficient. 
5.3.5.5 Exposure to HBV and resolution of infection 
Exposure to HBV (HBsAg and/or anti-HBc positive) was more prevalent in Harare 
(60.1%) than in Entebbe (52.4%) or JCRC (53.6%; p=0.001) and in males (61.4%) than 
females (51.8%; p<0.001). Exposure was more common with increasing age (p<0.001) 
(Figure 17). 
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Figure 17: Percentage with evidence of exposure to HBV by age, sex and site 
 
In multivariable logistic regression analysis, sex and site were associated with 
exposure (p<0.001 and p=0.006) while the association with age approached 
significance (p=0.06). Interaction terms for sex and age and for site and age were not 
significant (p=0.81 and p=0.24) whereas that for sex and site was (p=0.003). 
The proportion of those exposed who had resolved HBV infection (defined as in section 
5.2.2) was higher in JCRC (63.0%) and in Entebbe (50.4%) than in Harare (42.5%; 
p<0.001) and higher in females than in males (56.0% vs. 47.3%, p<0.001). There was 
no association with age (p=0.91). The proportion that had resolved HBV infection is 
shown in Figure 18 by site, sex and age.  
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In logistic regression site and sex predicted resolution whereas age, WHO stage, 
baseline CD4 and anti-HCV status did not (Table 22). However the effects of sex and 
age appeared to vary between the sites (interaction factors between site and sex 
p=0.15, site and age p=0.02, sex and age p=0.16). 
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Table 22: Predictors of resolved HBV infection 
 
All Resolved 
aOR 95% CI p 
n n % 
All 1,829 962 52.6    
Site      <0.001 
Entebbe 534 269 50.4    
JCRC 695 438 63.0 1.71 1.35 to 2.16  
Harare 600 255 42.5 0.78 0.61 to 0.99  
Sex      0.005 
Male 712 337 47.3    
Female 1,117 625 56.0 1.3 1.09 to 1.62  
Age group      0.71 
<30 261 141 54.0    
30-35 423 222 52.5 0.98 0.72 to 1.35  
35-40 468 243 51.9 1.05 0.77 to 1.44  
40-45 359 181 50.4 0.97 0.70 to 1.35  
45-50 183 97 53.0 1.10 0.74 to 1.63  
>50 135 78 57.8 1.34 0.87 to 2.07  
WHO Stage      0.25 
2       
3    0.86 0.68 to 1.10  
4    1.03 0.77 to 1.39  
Baseline CD4      0.28 
<50       
50-99    0.83 0.65 to 1.07  
100-149    1.02 0.78 to 1.32  
150-199    0.83 0.63 to 1.09  
HCV Ab      0.76 
Negative       
Positive    0.86 0.45 to 1.63  
Not done    0.71 0.40 to 1.63  
 
5.3.5.6 HCV serology results 
The prevalence of anti-HCV was similar in the three sites (Entebbe 2.5%, JCRC 2.6% 
and Harare 2.0%; p=0.64).  
There was no difference in prevalence of anti-HCV between those not exposed to HBV 
and those exposed (2.5% vs. 2.2%, p=0.56).  
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5.4 Discussion 
5.4.1 Serology results compared with previously published data 
 
5.4.1.1 HBV 
We found that over half (55.2%) of DART participants had evidence of HBV exposure, 
defined as detectable HBsAg and/or anti-HBc. The probability of exposure was higher 
in males than in females and also higher in Zimbabwe than in Uganda, while rates in 
the two Ugandan sites were similar. 
There was evidence of cleared HBV infection in 29.0% of participants, with detectable 
anti-HBc and anti-HBs but without detectable HBsAg; 9.3% had current infection with 
detectable HBsAg; 16.5% had isolated detectable anti-HBc with both HBsAg and anti-
HBs negative; and 0.6% were unclassifiable due to missing results (i.e. tests not done 
due to insufficient samples). In those with evidence of having been exposed to HBV the 
percentages were: 53.2% cleared HBV; 16.8% HBsAg seropositive; 30.0% isolated 
anti-HBc. Previous studies have reported prevalence of HBsAg and/or anti-HBc rather 
than categories as defined above. We found the prevalence of anti-HBc in the three 
sites to be similar at 51.4 to 56.3%. These figures are consistent with rates found in 
previous studies, though data in HIV-positive patients are limited (chapter 1 Table 1 
and Table 2). In an analysis adjusting for both age and sex, participants in Harare and 
at JCRC were more likely to be anti-HBc positive if male. 
The systematic review of sub-Saharan HIV-positive adults quoted above found mean 
prevalence of HBsAg to be 15%, but with a very wide range from 3.9% to 70.3% [20]. 
Previous studies from both Uganda [48, 52-54] and Zimbabwe[31, 32] have also 
presented widely varying results, both between geographical areas and within the 
same location (chapter 1 Table 1 and Table 2). In this study 9.3% tested positive with 
the prevalence similar at the two Ugandan sites but considerably higher in Zimbabwe. 
In Harare and JCRC HBsAg was more prevalent in males. Our estimates lie within the 
ranges previously described in both Zimbabwe and Uganda. Although recent published 
data in HIV-positive patients in Kampala found HBsAg prevalence of 8.9% (95% CI 6.5 
to 11.9%) at ART initiation [53] and of 18.0% (12.9 to 24.2%) in patients admitted to 
hospital [54], both of which are higher than the prevalence we found in Kampala (6.6%; 
5.2 to 8.0%), the confidence levels overlap. Similarly, although two recent studies of 
patients in Harare found the prevalence in HIV-positive pregnant women to be 5.8% 
(1.2 to 15.9%) [31] and 11.0% (7.3 to 15.8%) [32], both of which are lower than the 
prevalence we found in Harare (16.6%; 14.3 to 19.1%), again our estimate is not 
significantly different. 
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We did not find a relationship between CD4 count or stage of HIV disease and HBsAg 
prevalence, and therefore no evidence that immunosuppression resulted in either (i) 
reduction in the rate of loss of HBsAg over time or (ii) HBsAg reactivation. However, all 
participants had advanced HIV disease and low CD4 cell count at study entry. Thus we 
had no group with higher CD4 counts to compare with and it could therefore also be 
the case that all participants had CD4 count below the level at which these effects on 
HBV natural history appeared. A relationship between CD4 count and HBsAg status 
has been noted in one previous study in Africa, with causation suggested to be acting 
in the other direction, namely of HBV infection lowering CD4 cell count, but we found 
no difference in CD4 cell count at study entry between those with and without 
detectable HBsAg [87]. 
A previous study of mostly HIV-negative, HBsAg seropositive inpatients in Kampala 
found 27% HBeAg seropositive [54]. An earlier study, also of inpatients in the same 
hospital, found 6 (28.1%) of 23 HIV-positive and 3 (17.6%) of 17 HIV-negative patients 
to be HBeAg seropositive [48]. In Harare studies have found widely variable rates of 
HBeAg seropositivity, from 76.5% in jaundiced patients to 3.3% in pregnant women 
[30, 264]. A national survey found the overall rate to be 24.5% [29]. None of these 
three Zimbabwean studies tested for HIV. In HBV/HIV coinfected Zimbabwean patients 
recruited to a randomised controlled trial 54.2% (13 of 24) were HBeAg seropositive 
[32]. In the DART population, of those with detectable HBsAg 36.8% were HBeAg 
seropositive. The prevalence of a positive HBeAg result was higher in those with more 
advanced stage of HIV disease (in contrast to the lack of evidence for such a 
relationship between advanced disease and HBsAg status) which may have been due 
to immunosuppressed patients clearing HBeAg less often, or due to reactivation of 
HBeAg in previously seronegative patients as immunosuppression progressed. This 
relationship between HBeAg status and low CD4 count has been noted previously in a 
study in Nigeria [87]. 
543 participants, 16.4% of the study population and 30.0% of those with evidence of 
HBV exposure, had isolated anti-HBc. Similar rates have been found in Ugandan 
healthcare workers, both nationally (32.1%) [50] and in Kampala (35.4%) [55] and in 
HIV-positive patients elsewhere in sub-Saharan Africa, for example in South Africa 
(35.6%) [265] and in Côte d’Ivoire (42%) [266]. This pattern may be due to false 
positive anti-HBc test results, or be transient and occur during the resolution phase of 
acute HBV after the loss of HBsAg but before the appearance of anti-HBs. Persistent 
isolated anti-HBc may be due to occult HBV infection with negative HBsAg or due to 
loss of anti-HBs in patients who have cleared HBV, possibly related to 
immunosuppression. The testing algorithm used in this study was such that no further 
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testing was planned for individuals with isolated anti-HBc (section 4.2). In fact 10 such 
individuals did have a baseline sample tested for HBeAg and anti-HBe; 4 had 
detectable HBeAg and 7 had detectable anti-HBe, one testing positive for both. While 
we cannot rule out false positive results, this does suggest that all 10 had been infected 
with HBV. Repeat serology testing (to identify false positives and those with acute 
infection) and HBV DNA viral load testing (to identify occult infection) would help to 
determine more accurately the status of the 543 with isolated anti-HBc. 
5.4.1.2 HCV 
The overall prevalence of anti-HCV in sub-Saharan Africa has been estimated at 6.9%, 
though the range was wide, from 0% in studies from Botswana, Burkino Faso and 
Tanzania to 22.2% in Ethiopia [20]. There is very limited data on the prevalence of 
HCV exposure and/or infection in Uganda and Zimbabwe and reported rates are very 
low; only 0.6% of pregnant women in Kampala and 0.8% of those in rural Zimbabwe 
were shown to be positive [51, 267]. In the DART population we found the prevalence 
to be 2.4% and the prevalence was similar in the 3 sites. 
5.4.2 Differences between study sites 
The patterns of HBV test results differed between the sites, and even between 
Kampala and Entebbe which are only 35 km apart, despite the fact that the overall 
prevalence of anti-HBc was very similar. This variation is consistent with the wide 
variation seen in other prevalence studies. Populations geographically close to each 
other, or even living amongst each other, may carry what are in fact distinct endemic 
viruses. For example, it has previously been shown that different ethnic groups within 
Uganda may carry predominantly different types of HBV; Lwanga showed that amongst 
Bantu groups, 19 out of 24 (79%) individuals carried serotype adw whereas in non-
Bantu ethnic groups, only 1 of 10 (10%) carried adw, all others in both groups carrying 
serotype ayw [268]. As noted in the introduction, it is believed that in sub-Saharan 
Africa hepatitis B is most often contracted in early childhood through horizontal routes 
of transmission. These include such culturally determined practices as scarification, 
which varies widely in prevalence, for example between 66% in Kisiizi and 14% in 
Kagando (both in Uganda, see Figure 2) [45]. Thus populations may have different 
prevalent infections and transmission patterns. 
The age at which HBV is contracted is the strongest determinant of the probability that 
infection does not resolve and instead becomes chronic. It also affects the natural 
history of the infection, with those infected near birth showing a longer immunotolerant 
phase and having HBeAg present for longer, often until after the age of thirty. Those 
infected after 1 year of age but before 5 years having a short period of tolerance only 
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until early adulthood and those infected as adults having sometimes no immunotolerant 
phase at all [61, 269]. Sex also has an effect on the risk of chronicity with males being 
more likely to progress to chronic infection, both when infected in childhood and as 
adults [11-14].  
If it were the case that all DART participants were infected at birth or as neonates, the 
expected pattern of results would show that, (1) the prevalence of exposure to HBV 
was constant over the age range of DART, (2) the fraction of exposed individuals that 
had cleared HBV (have evidence of exposure but negative HBsAg, possibly with anti-
HBs) would be only a small minority by the age of 30 and would very gradually rise with 
age, and (3) the proportion HBeAg positive would be high in the 18-30 age group and 
decline until most had lost HBeAg after the age of 40. On the other hand, if it was the 
case that infection predominantly occurred through sexual exposure, the prevalence of 
exposure should rise through adulthood, though perhaps rapidly in early adulthood and 
more slowly in older age, depending on sexual behaviour. The large majority of those 
exposed should have cleared HBV infection and the proportion HBeAg positive should 
be lower. Thus examining the patterns of HBsAg, HBeAg and HBV DNA in those 
exposed to HBV may indicate the age at which HBV is acquired. 
However the results show no clear pattern in any site. This may be due to a change in 
epidemiology over time, as a result of each of the three sites examined including 
diverse populations with different epidemiological patterns that cannot be distinguished 
once aggregated or due to the picture being complicated by HIV-associated 
immunosuppression leading to loss of antibody or reactivation of HBeAg or even 
HBsAg and HBV DNA. 
We found an increase in the prevalence of anti-HBc with increasing age in all three 
sites which may indicate infection during adulthood but this may also be as a result of a 
cohort effect, with historically declining childhood infections (Figure 13). 
The proportion HBeAg positive ranged from 27.1% in Entebbe to 46.3% at JCRC but 
the difference was not statistically significant. The proportion of those with HBsAg that 
had detectable HBV DNA was 72.3% in Harare, 82.0% in Entebbe and 91.7% at 
JCRC. This is similar to the 27 (79%) of 34 HBsAg-positive blood donors in Harare and 
the 50 (91%) of 55 HBsAg-positive inpatients in Kampala that were HBV DNA positive 
in previous studies [54, 270]. The variation between the sites is partly explained by the 
fact that those with positive HBeAg were more likely to have detectable HBV and the 
proportion with positive HBeAg was higher in JCRC (though this difference was not 
statistically significant). However even in those HBeAg negative, more had quantifiable 
HBV DNA VL in JCRC than in the other sites. 
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We also found differences in the relationship between sex and HBV exposure or anti-
HBc prevalence in the three sites. This may also be as a result of differing patterns of 
transmission, either through gender-specific cultural practices (scarification) or through 
differential sexual transmission in adulthood. 
Differences in HBsAg prevalence (chronic infection with HBV) despite very similar anti-
HBc prevalence (HBV exposure) may also reflect genetic differences. It has been 
shown that the chance of clearing HBV is higher with certain single nucleotide 
polymorphisms in or near to the TNF-α gene in the MHC complex on chromosome 6. 
Clearance has been shown to be associated with TNF-α-863 CC and persistence with 
TNF-α-308 GG [271]. Genetic markers were not studied in this population. 
5.4.3 Unusual patterns 
HBsAg was detectable despite undetectable anti-HBc in 54 (1.6% of all study 
participants) and despite detectable anti-HBs in 14 (0.4%), including 12 (0.4%) in 
whom anti-HBc was also detectable. However these unusual patterns of serology are 
not novel and previous studies have found similar atypical patterns. In studies including 
both HIV-positive and negative individuals, the percentage of those with detectable 
HBsAg but undetectable anti-HBc has ranged widely, for example 3.7% in Thailand but 
56.0% in Uganda, while the percentage of those with detectable HBsAg that also had 
detectable anti-HBs has also varied, for example 1.2% in Thailand but 32.5% in Angola 
[47, 272, 273]. One study from Uganda compared HIV-positive and negative patients 
and found a lower prevalence of undetectable anti-HBc (44.7% vs. 62.0%, p=0.01) but 
a higher prevalence of detectable anti-HBs (25.0% vs. 16.9%, p=0.16) in HIV-positive 
than in HIV-negative individuals, though the latter result did not reach significance [47]. 
5.4.3.1 Negative anti-HBc but positive HBsAg 
In 1984 Trepo described patients with non-A, non-B (NANB) hepatitis who had HBsAg 
briefly detectable in serum without anti-HBc. In all these cases HBsAg disappeared 
within 2 weeks to 2 months. These were presumably acute HBV infections occurring in 
patients with other forms of hepatitis including HCV [274]. This pattern of HBV serology 
was also reported in cases of vertical transmission in Taiwan. Since the pattern of 
HBsAg without anti-HBc was not found in a previous epidemiological study in adults 
(also in Taiwan) it was postulated that anti-HBc would develop as the new-borns lost 
their natural immunotolerance [275]. As previously discussed, most HBV transmission 
in sub-Saharan Africa occurs in early childhood and so we expect that few of the 
participants with this serological pattern have acute infection. Follow-up serology would 
help to clarify this. 
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However anti-HBc-negativity has also been found in HBsAg seropositive children in 
Senegal where it has been suggested that infection is with a different type of HBV, 
named HBV2 by the authors, which does not stimulate the usual immune response to 
HBV core antigen. However there has been no subsequent confirmation of this virus 
[276, 277].  
The same pattern has also been reported in an individual with mutations including 
insertion resulting in a change in the location of core transcription initiation and a stop 
codon in the pre-core region, though in that case the lack of anti-HBc was postulated to 
be due to pre-existing HIV and immunosuppression [278].  
It has been suggested that the relationship with immunosuppression may be dynamic 
in HIV-positive individuals, for example anti-HBc may be absent when the CD4 count is 
<50 and appear if CD4 rises in response to antiretroviral treatment [277] although 
successful treatment does not always result in development of anti-HBc [279]. In some 
cases anti-HBc may be present in small amounts due to other defects of the immune 
system, as described by Lazizi [280]. These patients may have high levels of viral 
replication with high HBV DNA and high levels of HBcAg circulating in the blood. The 
HBcAg then complexes with the little anti-HBc that is present and so tests that require 
uncomplexed anti-HBc will give a false negative result. 
5.4.3.2 Positive anti-HBc, HBsAg and anti-HBs 
The classical picture of evolution of HBV serology results states that HBsAg becomes 
detectable during acute infection and then persists, either for less than 6 months in 
cases of resolving acute hepatitis B infection or for greater than 6 months in cases of 
CHB, until seroconversion occurs at which point anti-HBs becomes detectable. 
However this picture of only one of either HBsAg or anti-HBs being detectable in the 
blood at any one time is overly simplistic. 
Shulman was the first to detect both HBsAg and anti-HBs occurring together as 
immune complexes [281]. Trepo reported that the presence of both HBsAg and anti-
HBs indicated a poor prognosis in patients with fulminant hepatitis [282].  
Sometimes anti-HBs is directed at HBsAg from a different subtype of HBV than the one 
found circulating concurrently and thus both may exist together [283]. In some patients 
the antigenic ‘a’ determinant of HBsAg (the site of anti-HBs binding) has increased 
variability which may allow immune escape [284].  
In patients who had HBsAg, anti-HBs and anti-HBc simultaneously detectable, Carman 
found a mutation in the gene for HBsAg (G145R) which affected the ‘a’ determinant. In 
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these cases anti-HBs was as a result of immunisation and so bound to a form of 
HBsAg without this mutation [175]. In the Thai study mentioned above patients with this 
pattern also had G145A [272]. 
A second mutation, consisting of a deletion after 21 amino acids of the S gene, was 
also found in a patient with positive HBsAg, anti-HBs and anti-HBc. This mutation 
caused a shift in reading frame and a stop codon which resulted in a severely truncated 
HBsAg in which the antigenic ‘a’ determinant was entirely missing. HBsAg occurs in 
three forms, encoded by the S gene alone, the S gene plus pre-S2 and the S gene plus 
pre-S2 and pre-S1. HBeAg and HBV DNA were detected in the serum and 
morphologically normal viral (Dane) 42nm particles and 22nm spheres were seen on 
electron microscopy, although there was an absence of 22nm filaments. It has been 
shown that such a truncated HBsAg should not have been able to form into intact viral 
particles. Also, since the open reading frames for the S gene and the P gene that 
encodes the viral polymerase overlap, this deletion and associated frame shift should 
have produced an ineffective enzyme incapable of effective viral replication. It was 
postulated that a minority population with a wild-type S gene probably accounted for 
HBsAg and polymerase production [285]. 
5.4.4 Limitations 
One important caveat is that in general we assume that HBsAg is a marker of chronic 
infection with HBV. It is likely that a small proportion of individuals in fact have acute 
HBV. These cases could be identified by repeating HBsAg tests at least six months 
after study entry or by testing for anti-HBc IgM. Unfortunately neither was available in 
this study. It would be very interesting to repeat HBsAg tests at the end of follow-up 
and to derive an incidence rate in those susceptible since there are no published data 
on adult HBV incidence in HIV-positive individuals in sub-Saharan Africa. 
A high proportion of DART participants (16.5%) had the HBV serological pattern of 
isolated anti-HBc. This result may represent a false positive, resolved and cleared 
infection or chronic infection with a very low rate of viral replication (occult HBV 
infection). For example in a previous study in Uganda, 14.6% of HIV-positive patients 
with negative HBsAg had detectable HBV DNA [54]. A positive HBV DNA result in an 
individual with isolated anti-HBc defines occult HBV infection. The clinical implications 
of occult HBV infection are unclear, but it is generally accepted that individuals with 
detectable plasma HBV DNA may be infectious and may also be at risk of HBV 
reactivation and inflammatory liver flares [286]. Thus clarifying the clinical situation of 
these individuals is important. Unfortunately, in this study, only patients with positive 
HBsAg were tested for HBV DNA. Alternatively repeating anti-HBc and anti-HBs tests 
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after some time on HAART or after HBV vaccination may show some patients to have 
resolved infection if anti-HBs which had been lost as a result of profound 
immunosuppression reappeared on immune reconstitution or after challenge with 
vaccine.  
The data is insufficient to determine the age of acquisition of HBV in this cohort. 
Examining the age-specific HBV prevalence in those aged between birth and 18 years 
would be very informative, particularly if many or most infections occur between these 
ages. As the data in this study is cross-sectional it only gives us a snapshot of the 
distribution at one time. Any future attempt to clarify the epidemiological patterns may 
be limited by increasing HBV vaccination rates. 
The different distributions of serological results may also be due to infections with 
different genotypes of HBV [61]. Unfortunately no genotypic sequence data is available 
in this study. Even if all HBV-infected participants carried the same genotype, 
sequence data would also allow phylogenetic analysis which may show to what extent 
patterns are due to independent networks of HBV infection.  
Clearly the three sites include distinct populations with different patterns of HBV 
epidemiology. In this study we have attempted to discover some of the factors that are 
associated with HBV status.  
5.4.5 Conclusion 
We found that just over half the DART participants carried anti-HBc and just fewer than 
10% carried HBsAg at study entry; both were more common in males than in females. 
Although the prevalence of anti-HBc was similar in the three sites, HBsAg prevalence 
was 3 times higher in Zimbabwe than in Uganda.  
We were unable to deduce the patterns of transmission in the DART populations from 
the serological results available. Data that could better characterise these patterns 
could include results from those aged less than 18, from repeated tests in the same 
participants after time and from performing additional tests, for example HBV DNA 
assays on those with isolated anti-HBc. 
An important conclusion is that HBV serological patterns in one population cannot be 
simply applied to other populations in sub-Saharan Africa or even other populations 
geographically close to each other. In so far as HBV prevalence may determine clinical 
policy, determination of local epidemiology is crucial. 
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6 Longitudinal analysis of plasma HBV DNA levels  
6.1 Introduction 
In a proportion of those infected with hepatitis B virus, infection leads to liver fibrosis, 
hepatocellular carcinoma, liver failure or death. The prognosis can be improved by 
treatment that reduces inflammation, fibrosis and the amount of HBV in the blood [149, 
150]. Markers of treatment success include normalisation of liver transaminase activity 
levels, HBeAg to anti-HBe seroconversion, reduction in fibrosis and reduction in HBV 
DNA viral load in plasma [287]. These markers are associated with the improvement in 
prognosis although HBV remains in hepatocytes and is not entirely cleared from the 
body. 
Current treatment approaches are either to inhibit virus replication directly or to 
enhance the immune response responsible for suppressing viral replication in most 
patients. Drugs for the treatment of HBV fall into two groups, interferons and 
nucleoside (or nucleotide) reverse transcriptase inhibitors. Interferon treatment is given 
for a limited duration, usually 12 months, and then stopped, with a successful outcome 
being such that hepatitis B remains either undetectable or at a low level (HBV DNA 
<2,000 IU/mL) in the patient’s blood with normalisation of ALT, preferably with loss of 
HBeAg and seroconversion to anti-HBe if HBeAg positive at baseline and a persistently 
negative HBsAg, ideally with a positive anti-HBs [288]. These serological changes are 
prognostic markers of a sustained response. 
Treatment with reverse transcriptase inhibitors can similarly result in HBeAg and 
HBsAg loss and anti-HBe and anti-HBs seroconversion, which if maintained may allow 
treatment for HBV to be stopped. However in individuals with HIV coinfection such 
seroconversions are less likely and if they do occur are also less likely to be durable on 
stopping treatment and so generally guidelines recommend that once treatment is 
started it should be continued indefinitely [125] although some guidelines state that 
treatment can be stopped in certain circumstances [289]. 
The probability of treatment success is lower in coinfected patients (see chapter 1) and, 
it is sometimes suggested, with advanced immunosuppression [110, 140, 287] 
although some studies examining the effect of reverse transcriptase inhibitors have 
found no association with baseline CD4 count [85, 139, 147, 290]. In DART all 
participants had advanced HIV disease with CD4 cell counts below 200 cells/mm 3. 
Guidelines recommend treating individuals with more advanced HIV disease for both 
infections with a regimen that includes TDF and either 3TC or FTC, while those with a 
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need for HBV treatment but less advanced HIV disease could be treated with drugs 
that have no significant activity against HIV, such as interferon, ADV or telbivudine 
[123, 125, 133, 134, 287]. Recent guidelines recommend a CD4 cut-off of 500 
cells/mm3 for the initiation of HIV treatment in coinfected patients (and in the latest 
WHO guideline, all patients) [132-134]. Patients with a CD4 count greater than 500 
cells/mm3 with normal ALT, no fibrosis and HBV DNA viral load less than 2,000 IU/mL 
do not require treatment and should be monitored closely [125, 133, 287]. 
Previous published data have shown that regimes containing 3TC [136, 137], TDF 
[138-140], 3TC plus TDF [114, 139, 140, 144, 145] and FTC plus TDF [117, 140, 146] 
are able to suppress HBV in HIV-coinfected patients. There is evidence that virological 
suppression is more likely with 3TC plus TDF than with 3TC alone in patients on first 
line therapy [114, 139, 144, 147]. The suppressive effect of 3TC and TDF may be 
similar but rates of virological rebound lower when TDF is used [147]. 
All patients in DART initiated antiretroviral therapy with at least one drug active against 
HBV (3TC) and approximately three quarters with two active drugs (3TC and TDF). 
However, in coinfected patients treated with 3TC as the only HBV-active drug, 
resistance to 3TC emerges with continued use [291] and has been reported to occur in 
60% after two years [292] and as much as 90% after four years [166]. However a 
recent small study in Thailand found resistance in only 20% at four years [169].  
Resistance to TDF has not been definitively described. Two coinfected patients were 
found to have acquired the reverse transcriptase mutation A194T after approximately 
one year of treatment, one on TDF as the only HBV-active drug and one while taking 
TDF plus 3TC and this mutation was found to lower HBV susceptibility to TDF in vitro 
by a factor of about 10 [171]. It has also been shown that A194T reduces the viral 
replication rate but that this can be overcome by the acquisition of mutations in the 
precore/core region [172]. However in other studies patients with A194T responded 
well to TDF [250, 293] and the mutation was not found to confer TDF resistance in vitro 
[249, 294].This mutation has also been found in patients without a history of exposure 
to TDF [295, 296]. The mutation R192P has also been put forward as a possible TDF 
resistance mutation [297]. It is located close to A194 and the switch from arginine to 
proline induces a large kink in what is otherwise a straight section of the reverse 
transcriptase protein and it is suggested that this causes resistance via a change in 
protein conformation. 
There is limited published data on long-term follow-up of HBV/HIV coinfected 
individuals on treatment (chapter 3). DART provides long term follow-up of a large 
cohort of well-characterised HIV/HBV coinfected participants, and thus provides an 
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excellent opportunity to examine the durability of virological suppression on therapy 
including 3TC with or without TDF.  
In the meta-analysis reported in chapter 3, TDF treatment was associated with 
suppression of plasma HBV viral load below the level of detection at a rate of 57%, 
79% and 86% after 1, 2 and 3 years respectively. The meta-analysis only included 
patients treated with TDF so the effect of 3TC without TDF could not be examined. 
There was no additional benefit to using 3TC in addition to TDF, or any effect of prior 
exposure to 3TC. . 
Aims 
1. To determine the proportion of participants with HBV VL quantifiable at baseline 
that achieved HBV virological suppression at 48 weeks on first line HBV-active 
treatment. 
2. To examine any association between the proportion suppressed and specific 
drug treatment. 
3. To examine associations between the proportion suppressed and baseline 
characteristics including WHO stage, CD4 count, HBeAg status and HBV VL. 
4. In a subset of participants with HBV VL quantifiable at baseline, to examine viral 
load dynamics between 4 and 48 weeks. 
5. To examine durability of suppression and the rate of virological rebound. 
6. To confirm that patients with suppressed HBV VL at baseline remained so 
during treatment. 
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6.2 Methods 
6.2.1 HBV DNA viral load testing 
HBV DNA viral loads were tested as described in chapter 4 at baseline, week 48 and 
the latest sample available before any change in HBV-active treatment (the last sample 
if there had been no such change) provided this was at week 96 or later. For 
participants who underwent STI, the eligible period for this HBV VL study was 
terminated at the onset of the first STI. In addition, samples from weeks 4, 12 and 24 
were tested in participants at JCRC only, as shown in Figure 12.  
6.2.2 Statistical Methods 
Analyses in this chapter grouped participants treated with ABC and NVP as the focus is 
on drugs with potent activity against HBV (section 4.1.5). In view of the testing strategy 
described above, all analyses are “on treatment” rather than “intention to treat”.  
To look for evidence of bias, those tested were compared with those eligible but not 
tested using Fisher’s exact test for categorical characteristics (including sex, site, 
baseline HBeAg status, baseline HBV VL higher or lower than 107 IU/mL and use of 
TDF) and using the chi-squared test for trend (Stata command ptrend) with ordinal 
variables (age, baseline WHO stage of HIV disease and CD4 cell count group), 
stratified by baseline characteristics. 
Three different definitions of viral suppression were examined: (A) undetectable viral 
load, (B) viral load below the limit of quantification (12 IU/mL) and (C) viral load <1,000 
IU/mL, to enable comparisons with earlier literature. In quantitative analyses, viral load 
was examined on a log 10 scale. 
In participants with quantifiable HBV VL at baseline, HBV VL was examined at 48 
weeks and at the latest time point using graphical methods. Associations with the 
proportion with HBV VL below the level of quantification were examined using Fisher’s 
exact test and the chi-squared test for trend as above. Logistic regression was used to 
examine the association of undetectable HBV VL at 48 weeks with both HBeAg status 
and high/low baseline HBV VL together.  
HBV VL suppression was examined over the first 48 weeks on treatment in participants 
at JCRC in both aggregate form and individually. Kruskal-Wallis equality-of-populations 
rank test was used to compare HBV VL in those treated with or without TDF at time 
points during the first 48 weeks. 
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All viral load rebounds, including subsequent VL values to examine re-suppression, are 
shown graphically. Adherence data was reviewed and participant histories examained 
to see if prior breaks in treatment of less than 30 days may have predisposed to HBV 
VL rise or if rises were associated with flares in ALT. The association of treatment with 
the proportion with rebound after achieving undetectable HBV was examined using 
Fisher’s exact test. 
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6.3 Results 
6.3.1 Baseline  
308 participants (9.3%) were HBsAg positive at baseline, of whom 270 (87.7%) had 
sufficient sample for measurement of HBV DNA VL. Results of HBV VL at baseline are 
presented in chapter 5 and in Figure 19 (below).  
Figure 19: Flowchart of samples tested for HBV VL at baseline 
 
 
6.3.2 Outcomes of participants with quantifiable HBV VL at baseline 
6.3.2.1 Samples tested 
At baseline, 184 participants (67.5% of those tested) had a HBV VL result above the 
lower limit of quantification of whom 135 received a first line antiretroviral regimen that 
included TDF. Of these 184, 36 (19.6%) stopped, changed or interrupted either 3TC 
and/or TDF treatment before 48 weeks (Table 23). Of the remaining 148, 123 (83.1%) 
had HBV VL measured at 48 weeks.  
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Table 23: Participants with a change in treatment before week 48 
n Reason for treatment interruption / change before week 48 
19 Died 
4 STI at 24 weeks as part of the STI pilot study 
3 Stopped due to adverse event 
2 Switched NVP to TDF due to starting TB therapy 
2 Switched NVP to TDF due to adverse event 
2 Interrupted due to participant unable to attend 
2 Stopped due to patient decision 
1 Switched to second line therapy 
1 Switched due to pregnancy 
 
A further 26 participants died, switched or interrupted treatment between 48 and 96 
weeks (Table 24). 
Table 24: Participants who changed treatment between weeks 48 and 96 
n Reason for treatment interruption / change between weeks 48 and 96 
2 Died 
13 STI at 52 weeks as part of the STI study 
4 STI at 76 weeks as part of the STI study 
4 Switched to second line therapy 
1 Switched NVP to TDF – reason not given 
1 Interrupted due to participant unable to attend 
1 Stopped due to patient decision 
 
Of the remaining 122 participants, only 70 (57.4%) had a test at or after 96 weeks, 
primarily due to difficulties with assay procurement in Zimbabwe.  
6.3.2.2 Length of follow-up 
In this chapter, “follow-up” refers to the time from baseline until the last HBV VL result 
available. This may be significantly shorter than the time a participant was followed up 
in DART.  
In those with quantifiable HBV VL at baseline, median follow-up was 48 weeks and 
total follow-up was 19,328 participant weeks, 14,299 of which were on TDF. Follow-up 
was 0 weeks for 42, 4 to 24 weeks for 14, 48 weeks for 58 and ranged from 96 to 276 
weeks for 70 with 62 (45 on TDF) having at least 192 weeks and 41 (36 on TDF) at 
least 240 weeks of follow-up. 
6.3.2.3 Baseline demographics 
Baseline demographics, apart from site, did not significantly predict whether or not a 
participant had a HBV VL test at week 48 or end of treatment (Table 25). As stated 
above, in Harare more samples were found at 48 weeks but assays ran out before 
testing at the end of treatment could be completed.  
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Table 25: Baseline demographics of participants with quantifiable baseline HBV 
viral load testing/not testing at week 48 and at or after 96 weeks 
  Week 48 At or after week 96 
  Tested  p Tested  p 
   n %  n %  
All   123 83.1   70 57.4   
Site Entebbe 15 57.7 <0.001 14 70.0 0.005 
  JCRC 36 81.8   30 73.2   
  Harare 72 92.3   26 42.6   
Sex Male 58 79.5 0.28 36 55.4 0.72 
  Female 65 86.7   34 59.6   
Age 18-30 25 89.3 0.42 14 65.0 0.57 
  30-35 29 82.4   15 53.6   
  35-40 27 81.8   18 58.6   
  40-45 26 78.1   13 48.1   
  45-50 10 83.3   8 70.0   
  >50 6 83.3   2 40.0   
WHO Stage 2 23 79.3 1.00 15 60.0 0.32 
3 76 85.4   44 59.7   
4 24 79.3   11 45.8   
Baseline 
CD4 
<50 40 87.0 0.77 21 53.8 0.48 
50-99 30 72.5   19 52.9   
100-149 28 87.5   17 63.0   
150-199 25 86.2   13 60.0   
Monitoring 
strategy 
LCM 66 88.0 0.13 36 61.0 0.47 
CDM 57 78.1   34 54.0   
Initial drug 
regimen 
TDF 90 84.1 0.82 50 56.8 0.22 
ABC 11 78.6   10 47.6   
NVP 22 81.5   10 76.9   
 
6.3.2.4 Virological suppression 
HBV VL at 48 weeks  
Figure 20 shows log(VL) at week 48 plotted against baseline log(VL) in 123 
participants. Values “below the level of quantification” have been set to 12 IU/mL and 
values “below the level of detection” to 1 IU/mL for the purpose of illustration. 
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Figure 20: Log(HBV viral load) at week 48 against baseline 
 
Participants treated with 3TC without TDF: red circles.  
Participants treated with 3TC and TDF: blue triangles. 
A single participant with baseline HBV VL above the limit of quantification failed to 
achieve a decline of at least 2 log in HBV VL (or to below the level of quantification) 
after 48 weeks on treatment. This participant had baseline HBV VL of 352 IU/mL, with 
a similar value at 48 weeks (265 IU/mL) within the range of assay variability. The 
participant was treated with TDF and reported good adherence.  
Overall, 91 (74.0%) of 123 participants had a VL at week 48 that was either 
undetectable (n=63; 51.2%) or detectable below the level of quantification (n=28; 
22.8%) and this was more likely in those with low baseline HBV VL and those who 
were HBeAg negative. In the 82 (66.7%) with baseline HBV VL below 10
7
 IU/mL, VL at 
week 48 was below 12 IU/mL or undetectable in 76 (92.7%) compared to 15 (37%) in 
the 41 participants with baseline HBV VL above 107 IU/mL (p<0.001). Baseline HBeAg 
results were available in 116. HBV VL at week 48 was undetectable or below the level 
of quantification in 63 (93%) of 68 HBeAg negative participants compared with 22 
(46%) of 48 HBeAg positive participants (p<0.001).  
Using the other viral load cut-offs described in methods (undetectable and below 1,000 
IU/mL), both negative HBeAg status and low baseline HBV VL remained predictive of 
having an undetectable HBV VL at 48 weeks (Table 26). 
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Table 26: Viral load suppression at 48 weeks by HBeAg and baseline HBV VL 
 
 Week 48 HBV viral load 
 A B C 
N n % P n % p N % p 
All 123 63 51.2  91 74.0  116 94.3  
HBeAg 
Negative 68 45 66.2 <0.001 63 92.6 <0.001 68 100.0 <0.001 





  82 56 68.3 <0.001 76 92.7 <0.001 82 100.0 <0.001 
≥10
7
  41 7 17.1  15 36.6  34 82.9  
VL: viral load. BL: baseline. 
(A) undetectable viral load 
(B) viral load below the limit of quantification (12 IU/mL) 
(C) viral load <1,000 IU/mL 
As described earlier, baseline HBV VL was higher in those with detectable HBeAg 
(chapter 5, Figure 16). In those with baseline HBV VL below 107 IU/mL, the proportion 
having an undetectable HBV VL at week 48 was similar between those HBeAg 
negative (42 of 60, 70%) and those HBeAg positive (11 of 17, 65%; p=0.77). In those 
with HBV VL above 107 IU/mL, the difference by HBeAg status was again not 
statistically significant (3 of 8, 38%, vs. 4 of 31, 13%; p=0.14).  
There was no association between undetectable HBV VL at week 48 and baseline CD4 
status (p=0.94), WHO stage (p=0.14) or initial drug regime; 48 (53%) of 90 participants 
treated with TDF and 3TC had undetectable HBV VL compared to 15 (45%) of 33 
participants treated with 3TC alone (p=0.54).  
In a multivariable logistic regression model including HBeAg status, baseline HBV VL, 
drug treatment, WHO stage and baseline CD4 group, baseline HBV VL remained 
significant (OR 0.12, p<0.001) but HBeAg status did not (OR 0.63, p=0.34). Drug 
treatmend had an adjusted OR of 1.75 but this was not significant (p=0.26) Advanced 




Table 27: Predictors of viral load suppression at 48 weeks 
 All Undetectable VL OR p  aOR 95% CI p 
 n n %       
All 123 63 51.2       
HBeAg     0.001    0.59 
Negative 68 45 66.2       
Positive 48 15 31.3 0.23   0.77 0.26 to 2.27  
Not done 7 3 42.9 0.38   0.40 0.06 to 2.57  
Baseline DNA     <0.001    <0.001 
Low 82 56 68.3       
High 41 7 17.1 0.10   0.07 0.02 to 0.22  
Drug treatment     0.44    0.54 
No TDF 33 15 45.5       
TDF 90 48 53.3 1.37   1.75 0.65 to 4.70  
WHO Stage     0.11    0.13 
2 23 13 56.5       
3 76 42 55.3 0.95   0.92 0.29 to 2.90  
4 24 8 33.3 0.38   0.27 0.06 to 1.25  
Baseline CD4     0.94    0.27 
<50 40 21 52.5       
50-99 30 15 50.0 0.90   0.89 0.26 to 3.04  
100-149 28 14 50.0 0.90   0.30 0.09 to 1.07  
150-199 25 13 52.0 0.98   0.52 0.15 to 1.86  
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In those with baseline HBV VL >107 IU/mL, treatment with 3TC alone was associated 
with a smaller decline in VL at 48 weeks (-5.5 log10 IU/mL for 3TC alone vs. -6.5 log10 
IU/mL for 3TC with TDF, p=0.01). While in participants with low baseline HBV VL there 
was no association of treatment with the proportion suppressed, in those with baseline 
HBV VL >107 IU/mL more suppressed when treated with TDF (Table 28).  
Table 28: VL suppression at 48 weeks by baseline HBV VL and drug treatment 





 A B C 
N n % p n % p n % p 
All 3TC 33 15 45.5 0.54 25 75.8 1.00 28 84.8 0.02 
 3TC+TDF 90 48 53.3   66 73.3   88 97.8   
<10
7
 IU/mL 3TC 24 15 62.5 0.60 23 95.8 0.67 24 100.0 1.00 
 3TC+TDF 58 41 70.7  53 91.4  58 100.0  
≥10
7
 IU/mL 3TC 9 0 0.0 0.32 2 22.2 0.45 4 44.4 0.003 
 3TC+TDF 32 7 21.9  13 40.6  30 93.8  
(A) undetectable viral load 
(B) viral load below the limit of quantification (12 IU/mL) 
(C) viral load <1,000 IU/mL 
Last evaluable HBV viral load 
Samples were tested at a time at least 96 weeks after treatment initiation in 70 
participants with quantifiable HBV VL at baseline, 65 of whom also had a test at 48 
weeks. These samples were taken at times ranging from 96 to 276 weeks after 
treatment initiation, as described above. HBV VL was undetectable in 48 (69%), 
detectable below the level of quantification in 9 (13%) and quantifiable in 13 (19%).  
There was no association between the proportion with undetectable HBV VL and 
HBeAg status at baseline (HBeAg positive 18 of 28, 64% vs. HBeAg negative 28 of 39, 
72%; p=0.60) but there was an association with baseline HBV VL (baseline HBV VL 
<107 IU/mL 35 of 45, 78% vs. VL ≥107 IU/mL 13 of 25, 52%; p=0.03). There was no 
association with drug treatment (3TC alone 12 of 20, 60% vs. 3TC with TDF 36 of 50, 
72%; p=0.40). 
62 (89%) of 70 had HBV VL less than 1,000 IU/mL. There was an association between 
HBV VL below 1,000 IU/mL and treatment group with 15 (75%) of 20 treated with 3TC 
alone and 47 (94%) of 50 treated with 3TC with TDF achieving suppression below 
1,000 IU/mL (p=0.04). 
17 participants with quantifiable HBV VL at 48 weeks had a subsequent test after 96 
weeks. Figure 21 shows an apparent effect of treatment. HBV VL increased in all 4 
participants treated with 3TC alone compared with only 3 (23%) of 13 in those treated 
with TDF (p=0.02). All participants with rises in HBV VL after week 48 reported good 
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adherence; none reported having missed a dose of antiretroviral treatment in the month 
before the last measurement. 
 
Figure 21: Evolution of HBV viral load in participants with quantifiable HBV VL at 
48 weeks 
 
Participants treated with 3TC without TDF: red.  
Participants treated with 3TC and TDF: blue. 
Baseline HBeAg results were available for 16 of the 17 shown in Figure 21; 1 (33%) of 
3 HBeAg negative and 5 (38%) of 13 HBeAg positive participants had undetectable 
HBV VL at the last result (p=1.0). There was also no association between final HBV VL 
and baseline HBV VL (p=0.52). 
Of 53 participants with either VL below the level of quantification (n=18) or 
undetectable VL (n=35) at 48 weeks, only 5 had quantifiable VL at their last 
measurement (Figure 22 and Figure 23). HBV VL at or after 96 weeks was quantifiable 
in 2 treated with 3TC without TDF and 3 treated with both 3TC and TDF. Viral load 
when quantifiable was generally low (HBV DNA less than 10,000 IU/mL). 
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Figure 22: Subsequent HBV VL in those with HBV VL detectable below the level 
of quantification at 48 weeks 
 
See below for legend. 
Figure 23: Subsequent HBV VL in those with undetectable HBV VL at 48 weeks 
 
Participants treated with 3TC without TDF: red circles.  
Participants treated with 3TC and TDF: blue triangles. 
Overlapping markers: N,N indicates number of participants treated with 3TC alone, 
3TC with TDF. 
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Thus, the proportion of those with undetectable HBV VL at 48 weeks that maintained 
suppression at or after 96 weeks was 89%, with only 9% having a quantifiable HBV VL 
(Table 29). 
Table 29: Subsequent HBV VL in those with HBV VL undetectable or detectable 
below the level of quantification at 48 weeks 
HBV VL at 
48 weeks 
HBV VL at or after 96 weeks 
Undetectable Detectable BLQ Quantifiable Total 
N % N % N % N 
BLQ 11 61.1 5 27.8 2 11.1 18 
Undetectable 31 88.6 1 2.9 3 8.6 35 
 
As with the analysis at week 48, there was no association between baseline CD4 cell 
count or WHO stage and detectable HBV VL at or after week 96 (p=0.80 and p=0.34). 
HBV VL during the first 48 weeks of treatment 
Participants at JCRC with quantifiable HBV VL at baseline underwent additional testing 
during the first 48 weeks on treatment (Table 28).  






0 59 59 100 
4 58 36 62.1 
12 54 34 63.0 
24 48 35 72.9 
48 44 36 81.8 
 
Mean log(HBV VL) fell from 5.9 at baseline to 1.4 at week 48. Again 12 IU/mL was 
used for values “below the level of quantification” and 1 IU/mL for values “below the 
level of detection”. There was no difference in the pattern of decline of HBV VL 
between those treated with 3TC alone and those treated with 3TC with TDF (Figure 
24). 
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Figure 24: Mean log(HBV VL) over the first 48 weeks 
 
Participants treated with 3TC without TDF: red.  
Participants treated with 3TC and TDF: blue. 
The proportion with undetectable HBV VL increased with time: 11%, 38%, 40% and 
61% at 4, 12, 24 and 48 weeks respectively (Table 31). Again, there was no evidence 
that this was affected by treatment. Overall, 31 (53%) participants achieved an 
undetectable HBV VL at some time during the first 48 weeks. 
Table 31: HBV VL results over first 48 weeks (JCRC only) 
 3TC without TDF 3TC with TDF All  
  Undetectable  Undetectable  Undetectable  
Week N n % N N % N   p 
0 11     48     59     
4 6 1 16.7 30 3 10.0 36 4 11.1 0.54 
12 7 4 57.1 27 9 33.3 34 13 38.2 0.39 
24 6 3 50.0 29 11 37.9 35 14 40.0 0.66 
48 9 5 55.6 27 17 63.0 36 22 61.1 0.71 
Any 11 7 63.6 48 21 43.8 59 31 52.5 0.32 
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6.3.2.5 Virological rebound on treatment 
25 participants had an increase in HBV VL while on HBV-active treatment (Figure 25). 
Of these, 15 were treated with 3TC and TDF and 10 were treated with 3TC alone. 15 
were HBeAg negative and 10 HBeAg positive at baseline. 23 participants had a single 
rise in HBV VL (1 at each time point unless stated) occurring at weeks 4 (n=2), 12 
(n=3), 24 (n=3), 48 (n=4), 132, 168, 192, 204, 216 (n=2), 240 (n=2), 264 and 276 (n=2); 
2 participants had 2 rises each at weeks 4 and 48 and at weeks 24 and 144.  
  
Figure 25: HBV VL over time in participants experiencing a rise in HBV VL 
 
Participants treated with 3TC without TDF: red. Participants treated with 3TC and TDF: blue. 
All results at or after 96 weeks shown at 96 weeks for ease of comparison. 
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A rise by a factor of ten (1 log) is usually taken as the definition of virological rebound 
or breakthrough; 6 rises were only from HBV VL being undetectable to being below the 
level of quantification, 6 were by less than 1 log, 7 by between 1 and 2 log, 2 between 
2 and 3, 1 between 3 and 4, 2 between 4 and 5 and 1 by over 6 log.  
4 (17%) of 23 had rebound at 48 weeks after having previously achieved full 
suppression. A further 4 (11%) of 35 had undetectable HBV at 48 weeks with rebound 
later during follow-up which was to at least 192 weeks after initiation in 30 (22 treated 
with TDF) and to at least 240 weeks in 21 (17 treated with TDF). Treatment was 
associated with rebound at 48 weeks (TDF: 0 of 14, 0% vs. 3TC: 4 of 9, 44.4%; 
p=0.01) but not after (3 of 26, 11.5% vs. 1 of 9, 11.1%; p=1.0).  
As discussed in the methods, treatment interruptions of 30 days or more were 
interpreted as a change in treatment. However some participants had breaks in 
treatment of less than 30 days which could conceivably result in viral load rebound. Of 
the participants with a rise in HBV VL, 7 had a break followed by a rise. These are 
shown in Table 32. 
Table 32: Rises in HBV VL coming immediately after treatment interruptions of 
less than 30 days 
Duration of interruption 
(days) 
Week HBV VL 
Test before Interruption start Test after Before After 
7, 6, 6, 8 48 124, 204, 228, 252 264 UD BLQ 
5 24 4 48 UD BLQ 
7 12 5 24 UD BLQ 
4 48 256 276 UD 954 
5 0 168 252 UD BLQ 
14 0 8 12 1,352 71,512 
14 48 199 216 146 1,190 
 
Eleven (37.9%) of the 29 participants with a rise in HBV VL subsequently suppressed 
such that the last HBV VL measured was undetectable, and a further 6 had a final HBV 
VL that was detectable but below the level of quantification. 
Only 1 rise in HBV VL was associated with a rise in ALT to above the ULN. This was 
grade 3 (i.e. >5x ULN [181]) and resolved on treatment. The participant had HBV VL of 
4.4 x108 IU/mL at baseline, which fell to 53 IU/mL at week 4. Baseline ALT was 34 IU/L 
and at week 4 was 33 IU/L but rose to 222 IU/L at week 12 before falling to 36 IU/L at 
week 24 and remaining below 36 IU/L until the end of follow-up. HBV VL rose to 1,400 
IU/mL at week 12 and fell to detectable below the level of quantification at week 24. 
The final HBV was undetectable at week 276. 
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6.3.3 Participants with baseline HBV below the level of 
quantification 
A test was performed at the end of follow-up in 31 (82%) of 38 participants with 
baseline HBV VL below the level of quantification and in 20 (36%) of 56 with 
undetectable baseline HBV VL. 46 (90%) had undetectable HBV VL and the remaining 
5 (10%) had HBV VL detectable below the level of quantification. No participants had 
quantifiable HBV VL. Of those with undetectable HBV VL at baseline, 1 had a result 
that was detectable below the level of quantification at 252 weeks. This participant was 
treated with TDF and reported very poor adherence, only taking between 20 and 50% 
of prescribed doses within the preceding 3 months. 
6.3.4 Participants with baseline detectable HBV VL  
In section 6.3.2 above, the analysis of HBV VL suppression was restricted to those with 
quantifiable HBV VL at baseline. However many published studies examine HBV VL 
suppression in all participants with detectable HBV VL at baseline, i.e. including both 
those with quantifiable, and those with detectable HBV VL but below the level of 
quantification, for example many of those studies included in the meta-analysis 
(chapter 3). The analysis was therefore repeated with this wider entry criterion. 
As stated above, in the DART study 214 participants had detectable HBV VL at 
baseline: of these 143 (66.8%) had a test at 48 weeks. 81 (56.6%) had undetectable 
HBV VL at 48 weeks. The probability of undetectable HBV VL was associated with 
baseline HBV VL less than or greater than 107 IU/mL (72.6% vs. 17.1%, p<0.001) and 
baseline HBeAg status (72.4% vs. 30.6%, p<0.001) though in a logistic model, while 
baseline HBV VL remained significant (OR 8.7, p<0.001), HBeAg status was no longer 
significant (OR 2.1, p=0.10). Treatment with TDF was not associated with the 
probability of undetectable HBV VL (p=0.45) whereas HBV VL <1,000 IU/mL was more 
likely in those treated with TDF (79.8% vs. 59.0%, p=0.02). 
55 (69.6%) of 79 with a test at or after 96 weeks had undetectable HBV VL which was 
not associated with HBeAg status at baseline (p=0.31) or use of TDF (p=0.79) whereas 
an undetectable HBV VL was more likely in those with low HBV VL at baseline (78% 
vs. 52%, p=0.03). 
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6.4 Discussion 
This study provides a significant addition to the published data on HBV suppression in 
HIV/HBV coinfected patients treated with TDF, as seen in the meta-analysis in chapter 
3. Previous studies included in the meta-analysis reported a total of 550 patients with 
each study reporting a maximum of 78 patients (Table 7). Collectively, while 516 were 
tested at 1 year, only 90 were tested at 4 years and 48 at 5 years (Table 8). 
Considering those with HBV VL above 48 IU/mL at baseline we found that, after 48 
weeks of treatment, HBV VL was undetectable in 15 (45%) of 33 participants treated 
with a first-line regimen containing 3TC without TDF and in 48 (53%) of 90 participants 
treated with 3TC and TDF (p=0.54). The proportion of those treated with TDF achieving 
undetectable HBV VL at 48 weeks is similar to the 110 (63.2%) of 174 individuals with 
detectable HBV VL at baseline included in the meta-analysis (p=0.15). When 
comparing with other studies, assay cut-off is important since when using a higher cut-
off samples with low levels of HBV will be reported as undetectable. Cut-off was lower 
in the DART study than in most of the studies included in the meta-analysis. For 
example, of the studies in the meta-analysis, the two that gave data on the largest 
number of participants at 1 year included 24 and 28 participants and found 63% and 
43% fully suppressed, respectively [139, 230]. In these studies the cut-offs used were 
about 200 IU/mL (about 1,000 copies/mL) and 20 IU/mL respectively. Many of those in 
DART with detectable HBV VL at 48 weeks had low level viraemia; using a cut-off of 
1,000 IU/mL, the proportion suppressed on treatment with TDF was 98%.  
There was no association between use of TDF and the proportion suppressed at 48 
weeks (45% vs. 53%, p=0.54) or at the end of follow-up (60% vs. 72%, p=0.40). We 
thus found no evidence that treatment with TDF and 3TC is more likely to suppress 
HBV than treatment with 3TC alone. There was also no evidence of TDF resulting in 
quicker suppression with a similar proportion of each group achieving an undetectable 
HBV VL at each time point during the first 48 weeks. 
Only 2 previous studies directly compare the HBV response to treatment with 3TC vs. 
3TC with TDF in HIV coinfected patients. Study 903 enrolled naive patients in Western 
Europe, North America and Australia with HBV DNA >106 copies/mL and randomised 
to treatment with EFV plus 3TC and either D4T or TDF [144]. At week 48, HBV viral 
suppression (HBV DNA <1,000 copies/mL) was achieved by 1 (17%) of 6 treated with 
3TC and D4T and 4 (80%) of 5 treated with 3TC and TDF (p=0.08). Mean DNA 
declined by 3.0 log vs. 4.7 log, respectively (p=0.06). In TICO, 36 naive patients in 
Thailand were randomised to receive EFV plus one of: AZT with 3TC (n=13), AZT with 
TDF (n=12) or 3TC with TDF (n=11) [114, 147]. Median change in HBV DNA was 4.07 
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log, 4.57 log and 4.73 log, respectively (p=0.70). 6 (46%) of 13, 9 (75%) of 12 and 7 
(64%) of 11 suppressed HBV DNA to <170 copies/mL at week 48 (p=0.65). Using a 
cut-off of 1,000 copies/mL the proportions suppressed were 46%, 92% and 91% 
(p=0.013). The subject who failed to suppress to <1,000 copies/mL on 3TC and TDF 
and 1 of those on TDF alone had been lost to follow-up while the other on TDF alone 
had a fall followed by a rise in HBV DNA at the same time as a rebound in HIV VL. 
Poor adherence or malabsorption were suggested. There was no difference in HBV 
viral dynamics by treatment over 48 weeks. These results are comparable to those in 
DART. Although we found a higher rate of suppression in those treated with TDF this 
was only significant when using 1,000 IU/mL as the cut-off. 
One important question in clinical practice, in those regions where HBV VL monitoring 
is available, is what to do when HBV VL does not suppress after a period on treatment; 
should treatment be continued or switched? In this study the number of participants 
who failed to suppress at 48 weeks and had a subsequent test is low (4 on 3TC and 7 
on 3TC and TDF) and so conclusions must be drawn with caution. The data suggests 
that if a patient is treated with 3TC as the only active drug and fails to suppress at 48 
weeks then continuing the same treatment will not lead to suppression. For patients 
treated with 3TC and TDF, 10 (77%) had HBV VL that continued to decline on 
continuing the same treatment and only 3 (23%) had a rise in HBV VL. In view of the 
lack of prior demonstration of HBV resistance to TDF and of evidence for another 
strategy it may be argued that continuing 3TC and TDF is reasonable.  
An undetectable HBV VL is a surrogate marker for treatment success. When managing 
patients we are in fact concerned about disease progression and complications. Since 
HBV-related disease tends to occur over many years as liver fibrosis progresses, it 
may be that durability of suppression (i.e. whether a successful suppression of HBV is 
maintained over time or whether rebound in VL occurs, whether through development 
of antiretroviral resistance or by another mechanism) is more important than 
achievement of undetectable VL. It may be the case that a brief period of undetectable 
VL followed by rebound may not inhibit development of liver-related morbidity and 
mortality. Of those with fully suppressed HBV replication (undetectable VL) at 48 weeks 
and a subsequent test follow-up was of at least 192 weeks in 30 and 240 weeks in 21. 
Even more surprisingly than the similarity of the response to 3TC treatment with and 
without TDF, we found that suppression of HBV was as durable when treatment was 
with 3TC as the only HBV-active drug as with TDF and 3TC used in combination 
(p=1.0). Almost 90% of those treated with 3TC alone and with an undetectable VL at 
48 weeks maintained this through until the end of treatment. This is surprising as high 
rates of HBV resistance development have previously been described in coinfected 
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individuals treated with 3TC alone. For example, Benhamou found only 9% of 
coinfected patients treated 3TC alone had fully suppressed HBV at 4 years [166]. Our 
results are more in keeping with the much lower rate of resistance seen in a more 
recent study from Thailand [169].  
Rebound, when it occurred, was very rarely associated with a flare in ALT. Only one 
participant had a rise in ALT above the ULN at the same time as a rise in HBV VL and 
this resolved on treatment. Subsequent HBV VL was undetectable. This rise in ALT 
occurred early after treatment initiation (at 12 weeks) and so may have been related to 
adverse drug reaction rather than being as a result of HBV rebound. 
Similarly to previous data (chapter 3, Figure 8), we found that suppression at 48 weeks 
was more likely in those HBeAg negative at baseline (66% vs. 31%, p<0.001), but that 
the proportion with suppressed HBV was similar later (72% vs. 64%, p=0.60). This may 
be largely explained by the fact that baseline HBV VL tends to be much higher in 
HBeAg positive individuals (chapter 5, Figure 16). Few participants had negative 
HBeAg with high baseline HBV VL (n=8) or positive HBeAg with low baseline HBV VL 
(n=17). Although the OR for the effect of HBeAg status on HBV VL suppression when 
controlling for baseline HBV VL was 1.58, this may be due to chance (p=0.34) and the 
observed effect of HBeAg driven by HBV VL. 
As all participants received antiretroviral combinations that included 3TC, we are 
unable to assess outcomes when TDF is given as monotherapy. A consideration in 
comparing participants treated with and without TDF is that while this was a 
prospective study, allocation to treatment with TDF was not randomised and so any 
apparent difference in response may be subject to selection bias.  
As described earlier, the design of the hepatitis substudy was such that analyses are 
“on treatment” rather than “intention to treat”. Thus we could postulate that participants 
with more advanced disease would either die or switch due to treatment failure and that 
this would bias the population tested at times after initiation, giving an inaccurately high 
degree of treatment success. However, we found no evidence of baseline 
characteristics (apart from site) being associated with the chance of being included or 
not (untested) at 48 weeks or after. The association with site was due to the order in 
which testing was performed at each location and to the availability of stored samples 
and assays. 
In the DART study all participants had advanced HIV disease with CD4 cell count less 
than 200 cells/mm3 and results may not be applicable to patients started on treatment 
with less advanced immunosuppression, as guidelines recommend. 
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6.4.1 Conclusion 
Approximately half of the participants achieved an undetectable HBV VL at 48 weeks 
and two-thirds by the end of treatment and there was no statistically significant 
difference between those treated with or without TDF. Baseline HBeAg status and HBV 
VL were predictive of the probability of achieving an undetectable HBV VL, although 
the association with HBeAg was at least partly explained by higher HBV VL in those 
testing HBeAg positive.  
Once achieved, suppression of HBV VL to undetectable levels was maintained to the 
end of treatment in the vast majority of participants and again 3TC performed as well 
as 3TC plus TDF. These results do not support the consensus that treatment of 
HBV/HIV coinfected patients with 3TC as the only HBV-active drug is inadequate for 
reasons of poor durability. Participants in whom HBV VL was fully suppressed after 48 
weeks on 3TC alone were as likely to have remained suppressed to the end of the 
study as those treated with TDF, while those on 3TC alone that failed to supress at 48 
weeks all had an increase in HBV VL over time.  
We found no evidence of HBV VL rebound being associated with a rise in ALT. Thus 
monitoring of ALT is unlikely to be useful in predicting HBV virological treatment failure. 
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7 Liver inflammation and fibrosis 
7.1 Introduction 
The DART trial provides a useful opportunity to examine the effect of HBV on the liver 
in HIV-positive individuals and to determine the incidence and consequences of liver 
injury associated with initiating, continuing and interrupting highly active antiretroviral 
therapy (HAART) in HBV/HIV coinfected participants. 
A liver inflammatory flare is an acute worsening of liver disease and is marked by a rise 
in transaminases (ALT and AST). Studies have found that up to half of all HBV-
coinfected patients starting HAART experience a liver flare, but interestingly data from 
Africa indicate much lower rates (Table 3). The aetiology of flares occurring on initiation 
of HAART is unclear and may be due to adverse drug reactions to components of 
HAART, to improvement in immune status (IRD) or even as a response to HBV viral 
suppression. Liver flares may also occur in other situations, of note (i) on HBV 
rebound, whether due to virological breakthrough or treatment interruption, (ii) as a 
result of reaction to other drugs, particularly drugs used to treat TB and (iii) on HBeAg 
seroconversion.  
In patients coinfected with HBV and HIV the risk of liver damage on commencing 
HAART has been shown to be higher than in those with HIV alone [85, 178, 179, 187, 
191, 193] although some studies have not found this to be the case [182, 190, 195]. 
However previous estimates of the rate of significant liver damage have varied and 
studies have been limited by the use of different case definitions and low numbers of 
patients, particularly in Africa. 
Aims 
1. To determine the baseline liver status of participants in the DART study and 
examine associations with other characteristics. 
2. To determine the change in ALT and rate of liver inflammatory flares: 
a. on first-line HAART, 
b. on switching to second-line ART with change in HBV treatment and 
c. during Structured Treatment Interruption cycles. 
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7.2 Methods 
7.2.1 Participants and samples 
It is of note that although baseline ALT over five times the ULN was an exclusion 
criteria in DART, two participants with ALT greater than five times the local ULN were 
enrolled into DART; one had baseline ALT of 198 (ULN 37) and the other had baseline 
ALT of 332 (ULN 44). 
Participants were excluded from all analyses if HBsAg was not tested. According to the 
protocol, ALT was tested at baseline, at weeks 4 and 12, and every 12 weeks 
thereafter. As with all tests, results were returned to the clinician if the patient was in 
the LCM arm. Results in the CDM arm were returned only if they had been requested 
for a clinical reason or if there was grade 4 toxicity (ALT >10 x ULN). Samples from 17 
participants were also taken at 2 weeks. Over and above testing once at weeks 0, 4, 12 
and 12-weekly thereafter, 2,885 extra tests were done in a total of 1,213 participants. 
Since we were interested in ALT as a marker for the occurrence of inflammation, all 
available results were included. In the DART structured treatment interruption (STI) 
substudy ALT was measured 8 weeks after treatment changes. In participants with 
more than one result at the time of an analysis, the highest was used. Week 2 results 
(which in no cases were materially higher than the corresponding week 4 result) were 
dropped except for 4 participants with no week 4 result, when the week 2 result was 
used as the week 4 result in the analyses. Data were censored at the first change in 
treatment combination, excluding breaks of less than 4 weeks and switches from AZT 
to stavudine (D4T).  
The effect of stopping TDF was examined in all participants with ALT results after a 
switch from a TDF-containing regimen to second line HAART that contained neither 
TDF nor 3TC.  
Most single, isolated high ALT values are likely to have been the result of data entry 
errors. We therefore deleted observations if ALT was five times greater than the 
preceding and following ALT result, except if (i) AST measured at the same time was 
greater than 1.5 times the ULN, or (ii) a participant had more than one such isolated 
high ALT value. A total of 36 (0.05%) of 70,066 ALT results were dropped following 
these rules. 
7.2.2 Definition of a flare 
The three laboratories used different ULN for ALT; JCRC used 40 IU/L, Harare used 44 
IU/L and Entebbe used 37 IU/L for females and 55 IU/L for males. Where ULN is 
referred to in analyses it is the local ULN that was used for participants at each site. 
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Previous studies of flares in HBV/HIV coinfection have used a variety of definitions of a 
flare (Table 3). For simplicity a single value for males and females across all three sites 
of 200 IU/L, with a rise of at least 100 IU/L from baseline, was used to define a flare. 
For the analysis of flares after a switch to second line HAART “baseline” was time of 
switch. A flare was considered to have resolved if ALT decreased to less than 40 IU/L.  
7.2.3 Fibrosis scoring methods 
Of the components of serum fibrosis markers that have been used, those available in 
all DART participants are platelets, ALT, bilirubin, white blood cell count and age. In 
published studies these five have been used as markers alone. Age and platelets have 
also been used in combination as the Age and Platelets Index (API). 
Of these six serum fibrosis markers that could be used for all DART participants, none 
have been validated in HBV/HIV coinfection or in HIV monoinfection and in HBV 
monoinfection API performs the best. 15 different assessments with AUROCs ranging 
from 0.68 to 0.93 have been published. 
API can range from 0 to 10 and is calculated by adding together a point score for each 
of age and platelets as shown in Table 33. A score of 6 is taken as a marker of 
significant fibrosis [298]. 







 / L) 
Points 
<30 0  >225 0 
30-40 1  200-225 1 
40-50 2  175-200 2 
50-60 3  150-175 3 
60-70 4  125-150 4 
>70 5  <125 5 
 
AST was also tested in DART participants in Uganda. Using AST with the markers 
above several more serum fibrosis markers are calculable, of which AST, AST/ALT 
ratio, FIB-4 and APRI have been validated in HBV positive patients. Three of these 
were evaluated in HBV/HIV coinfected patients and, of these 3, FIB-4 was consistently 
the most discriminating (Table 5). 
FIB-4 was calculated as described by Sterling [299]: 







Age in years, AST and ALT in IU/L and platelets in 109/L. 
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The cut-off commonly used for FIB-4 to determine advanced fibrosis (Ishak score 4-6) 
is 3.25 [299]. 
7.2.4 Statistical Methods 
The analysis of baseline ALT used graphical and descriptive methods and the Kruskal-
Wallis equality-of-populations rank test to compare median values by HBsAg status 
and other predictors. The Chi-squared test or Fisher’s exact test were used to compare 
the distribution of categorical variables, as appropriate. Baseline ALT distribution was 
positively skewed. Box-Cox transformation indicated that the logarithm of baseline ALT 
had a distribution that was close to normal and so this was used in subsequent 
analyses. Unadjusted and adjusted (i.e. univariable and multivariable) linear regression 
were used to determine which baseline factors were associated with baseline ALT. 
Distribution of baseline platelet count was shown graphically. Correlation of platelet 
count with age and platelets index (API) and with FIB-4 was calculated. In the case of 
FIB-4, the score was transformed to achieve a more normal distribution by taking the 
logarithm. The proportion of participants with significant fibrosis used published cut-offs 
and was examined by HBsAg status using Chi-squared tests [298, 299]. 
The rate and predictors of ALT flares on first-line treatment were examined using 
incidence rates, survival analysis and Cox regression. Only the first flare, if any, for 
each participant was included. 
To examine those who stopped TDF and 3TC during a switch to second line HAART 
mean ALT was plotted for one year before and one year after switch and flares 
examined using survival analysis. 
In the STI substudy, baseline characteristics were examined using Fisher’s exact tes t 
or Kruskal-Wallis equality-of-populations rank test as appropriate. The rate of flare was 
examined by study arm and by HBsAg status using Fisher’s exact test. 
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7.3 Results 
7.3.1 Participants 
Of 3,316 participants in DART, 3,315 had baseline HBsAg testing. 326 (9.8%) were on 
TB therapy at baseline and 400 (12.1%) started TB therapy during follow-up. Of the 
3,315 participants with an HBsAg result, 2,468 (74.4%) were started on TDF, 300 
(9.0%) on ABC and 547 (16.5%) on NVP. BMI was determined in 3,282 of whom 605 
(18.4%) were underweight (BMI<18.5) and 116 (3.5%) were obese (BMI>30). 
7.3.2 ALT at baseline 
The median ALT at baseline was 25 IU/L (IQR 18-36) (Table 34). It was marginally 
higher in Harare, in males, in those HBsAg seropositive and in those on TB treatment.  
Table 34: Baseline ALT (IU/L) 
 n 
Mean  
Median IQR p 
Arithmetic Geometric  
All 3315 30.9 25.8  25 18 to 36  
Site       <0.001 
Entebbe 1020 28.3 23.2  23 15 to 35  
JCRC 1297 31.0 26.0  25 17 to 37  
Harare 998 33.2 28.5  26 20 to 37  
Sex       <0.001 
Male 1160 34.7 29.1  28 20 to 40  
Female 2155 28.8 24.1  23 17 to 34  
BMI       0.06 
<18.5 605 33.3 27.0  26 18 to 40  
18.5 to 30 2561 30.3 25.4  25 18 to 36  
>30 116 29.7 26.2  27 19 to 34  
HBsAg       <0.001 
Negative 3007 30.4 25.4  25 17 to 36  
Positive 308 35.5 30.2  28 21 to 40  
TB treatment       <0.001 
No 2989 30.5 25.4  24 18 to 36  
Yes 326 34.6 29.0  29 20 to 41  
  
ALT at baseline was above the local ULN in significantly more participants testing 
HBsAg positive than HBsAg negative (22.4% vs. 16.8%, p=0.01).  
The distribution of ALT at baseline is shown in Figure 26, Figure 27 and Figure 28. 
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Figure 26: ALT distribution at baseline – All 
 
 
Figure 27: ALT distribution at baseline – HBsAg seronegative 
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Figure 28: ALT distribution at baseline – HBsAg seropositive 
 
 
In unadjusted and adjusted linear regression analysis, higher baseline ALT was 
associated with site, male sex, younger age, low baseline CD4, WHO stage 4 disease, 
positive HBsAg status, baseline platelet count and TB treatment (Table 35). BMI was 
not associated with baseline ALT (p=0.10) and was excluded in the adjusted analysis 
in order to include those participants without a BMI measurement. 
The magnitude of the changes were similar for site (up to 19.5% change), sex (15.5%), 
age (18.1%) and CD4 cell count (16.6%) and these were all larger than the effect of 
HBsAg positivity (12.6%). The magnitude of the effects of WHO stage, baseline platelet 
count and TB treatment were less (up to 9.8%). 
 
  
Table 35: Linear regression analysis of predictors of baseline log(ALT) 
   Unadjusted Adjusted 
 Factor n 
% difference 
in ALT 
95% CI p 
% difference 
in ALT 
95% CI p 
Site Entebbe 1020   <0.001   <0.001 
 JCRC 1297 12.0  6.9 to 17.4  9.9  4.8 to 15.1  
 Harare 998 22.8  16.8 to 29.2  19.5  13.6 to 25.6  
Sex Male 1160   <0.001   <0.001 
 Female 2155 -17.3  -20.6 to -13.8  -15.5  -18.9 to -11.9  
Age group <30 532   <0.001   <0.001 
 30-35 795 -5.3  -11.1 to 0.9  -7.2  -12.8 to -1.3  
 35-40 848 -5.1  -10.8 to 1.1  -7.8  -13.3 to -2.0  
 40-45 608 -6.4  -12.5 to 0.1  -10.5  -16.2 to -4.4  
 45-50 313 -15.7  -22.3 to -8.6  -18.1  -24.4 to -11.4  
 >50 219 -10.7  -18.5 to -2.2  -13.7  -21.0 to -5.6  
BMI Per kg/m2 3282 -0.4  -0.9 to 0.1 0.10    
WHO Stage Stage 2 672   <0.001   0.01 
 Stage 3 1864 9.7  4.2 to 15.4  3.7  -1.5 to 9.0  
 Stage 4 779 16.6  9.8 to 23.8  8.1  1.8  to 14.9  
Baseline CD4 <50 1109   <0.001   <0.001 
 50-99 784 -13.1  -17.6 to -8.4  -11.9  -16.4 to -7.2  
 100-149 759 -16.7  -21.0 to -12.2  -13.3  -17.8 to -8.6  
 150-199 663 -20.9  -25.1 to -16.4  -16.6  -21.1 to -11.8  
HBsAg Negative 3007   <0.001   0.001 
 Positive 308 19.2  11.4 to 27.6  12.6  5.3  to 20.4  
Anti-HCV Negative 3175   0.11   0.44 
 Positive 77 3.8  -9.0 to 18.3  4.7  -7.8 to 18.9  
 Not done 63 16.2  0.6 to 34.4  8.1  -6.1 to 24.5  
Baseline log(platelet count) 3315 -15.0  -23.0 to -6.1 0.001 -9.8  -18.1 to -0.5 0.04 
TB treatment No 2989   <0.001   0.006 
 Yes 326 13.8  6.5 to 21.6  9.5  2.6 to 16.9  
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7.3.3 Markers of liver fibrosis at baseline  
Platelets results at baseline are available for all DART participants. The median platelet 
count was 204 and the interquartile range was 157 to 260 x109 /L. Median platelet 
count was higher in Entebbe and lower in Harare (p<0.001) (Table 36).  
Table 36: Distribution of platelet count by site 
 N Median IQR 
All 3,315 204 157 to 260 
Entebbe 1,020 214 157 to 273.5 
JCRC 1,297 204 158 to 259 
Harare 998 195 154 to 245 
 
Platelet count declines with advanced liver fibrosis. In this population, 720 (21.7%) had 
a platelet count at baseline below the lower limit of normal (150 x10
9
 /L). The proportion 
with a low platelet count at baseline did not vary between the sites (p=0.70) (Figure 
29). Low platelet count was associated with HBsAg status, with 26.6% of HBsAg 
seropositive participants having a count below 150 x10
9
 /L compared to 21.2% of 
HBsAg seronegative participants (p=0.03). 
Figure 29: Distribution of platelet count at baseline by site 
 
 
The median API was 3 and the interquartile range was 1 to 5. For 510 (15.4%) of the 
3,316 participants API was greater than 6 consistent with significant fibrosis. The 
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proportion with advanced fibrosis by API was higher in those HBsAg seropositive than 
in those HBsAg seronegative (19.5% vs. 15.0%, p=0.04). In participants from Uganda, 
344 (14.8%) of 2,317 had an API greater than 6. AST results at baseline were available 
for the 2,317 participants in Uganda. The median FIB-4 in these 2,317 was 1.28 (IQR 
0.90 to 1.87). In 180 (7.8%) FIB-4 was greater than or equal to 3.25, indicating 
advanced fibrosis and again the proportion was higher in those HBsAg seropositive 
(12.8% vs. 7.4%, p=0.02). 
Platelet count, API and FIB-4 (Ugandan participants only) were correlated (platelets 
and API; R=0.80, p<0.001: platelets and FIB-4; r=0.81, p<0.001: API and FIB-4; 
R=0.78, p<0.001). Of 180 with severe fibrosis determined by FIB-4, 151 (83.9%) had 
severe fibrosis by API. However of 344 Ugandan participants with severe fibrosis by 
API, only 151 (43.9%) had severe fibrosis using FIB-4. 
Since the markers were correlated and since age was also included separately in all 
analyses, baseline platelet count was chosen as the most appropriate marker of 
fibrosis in all subsequent analyses. Baseline ALT was weakly correlated with baseline 
platelet count (R=0.06, p=0.001) (Figure 30). 
Figure 30: ALT vs. platelet count at baseline 
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7.3.4 ALT results on first-line therapy 
The number of participants with ALT results available declined from 3,315 at baseline 
to 2,625 at 48 weeks, 1,624 at 192 weeks and 1,062 at 240 weeks, as shown in Table 
37. 
Table 37: Availability of ALT results on first-line treatment 
Week  0 48 96 144 192 240 288 
Total available 3,315 2,625 2,044 1,832 1,624 1,062 47 
% complete  100 98.9 98.4 98.8 98.5 97.3 97.9 
 
The first participant was randomised in January 2003 but all participants randomised 
before January 2004 received TDF. All participants were followed until the end of 2008 
and thus maximal follow-up was longer for TDF (2,129 days) than for ABC (1,764 days) 
or NVP (1,765 days). 
The decline in the number of available ALT results over the course of the study was not 
due to missing data but rather to later study entry or change in drug treatment (and, to 
a lesser extent, deaths). 
7.3.5 Change in ALT on first-line treatment 
The mean ALT increased by 5 IU/L from baseline to 4 weeks and then declined to 
below the baseline value, reaching 2 IU/L below baseline by 24 weeks and 4 IU/mL 
below baseline by 48 weeks (Figure 31).  
This was not driven purely by a few large values. Median ALT also increased at 4 
weeks.  
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Although mean ALT was higher at week 4 than at baseline, the majority of participants 
not only had a normal ALT at baseline (using the local upper limits of normal) but also 
had an ALT less than 50 at baseline and throughout the first 4 weeks (Table 38); this 
was also true of those HBsAg seropositive (Table 39). In each 50 IU/L band few (347, 
10.5%) had an ALT in a higher band within the first 4 weeks of treatment than at 
baseline. 
Table 38: Peak ALT after baseline and within 4 weeks 
 Peak ALT after baseline within 4 weeks  
Baseline ALT 0-49 50-99 100-149 150-199 ≥200 Total 
0-49 2,608 246 29 12 20 2,915 
50-99 179 115 24 7 4 329 
100-149 25 14 12 2 3 56 
150-199 6 2 3 2 0 13 
≥200 2 0 0 0 0 2 
Total 2,820 377 68 23 27 3,315 
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Table 39: Peak ALT after baseline and within 4 weeks in HBsAg seropositive 
participants 
 Peak ALT after baseline within 4 weeks  
Baseline ALT 0-49 50-99 100-149 150-199 ≥200 Total 
0-49 223 28 2 0 7 260 
50-99 18 14 3 0 1 36 
100-149 4 5 2 0 1 12 
150-199 0 0 0 0 0 0 
≥200 0 0 0 0 0 0 
Total 245 47 7 0 9 308 
 
The majority of participants (1,789, 54.0%) had normal ALT throughout follow-up. Only 
275 (8.3%) had at least one grade 1 (>2.5x ULN) ALT rise during follow-up and only 26 
(0.8%) had an ALT rise of grade 4 (10x ULN [181]). 
Factors affecting change in ALT on first-line treatment 
The change in ALT is shown stratified by HBsAg status in Figure 32, by drug in Figure 
33, and then by drug limited to those HBsAg seropositive in Figure 34. The rise at week 
4 was more pronounced in those treated with NVP than with TDF or ABC (Figure 33) 
and in those HBsAg seropositive than those HBsAg negative (Figure 32). Late in 
follow-up there appears to be a greater relative decrease in ALT for those HBsAg 
seropositive. There is an early decline in ALT in those treated with ABC compared with 
those treated with TDF or NVP but this is not sustained (Figure 33) and this is not seen 
in those HBsAg seropositive (Figure 34). 
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Figure 32: Mean change in ALT from baseline over 240 weeks by HBsAg status 
 
 
Figure 33: Mean change in ALT from baseline over 240 weeks by drug 
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Figure 34: Mean change in ALT from baseline over 240 weeks by drug in those 
HBsAg seropositive only 
 
 
The decline in mean ALT over time in those HBsAg seropositive could have been due 
to participants with higher ALT dropping out of the analysis by switching to second line 
antiretroviral therapy. However the decline was also apparent in an intention to treat 
analysis which included all ALT results, even after a switch from first-line antiretroviral 
treatment (Figure 35).  
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Figure 35: Mean change in ALT from baseline over 240 weeks by HBsAg status 
(including results after switch off first-line treatment) 
 
 
A pronounced increase in mean ALT at weeks 84 and 96 in those HBsAg seropositive 
is entirely driven by a single participant who developed cryptococcal disease and 
switched to lopinavir, RTV and NVP at week 76. ALT rose from 23 IU/L at week 72 to 
1,348 IU/L at week 84 and 1,632 IU/L at week 96. Antiretroviral drugs were stopped 
and ALT fell to 12 IU/L at week 108. ALT remained normal after antiretroviral 
medication was restarted with a regimen of lopinavir, RTV and EFV. In comparison, the 
median change in ALT did not show a rise at weeks 84 and 96, with the rise in ALT in a 
single participant having no effect on the median change (Figure 36). 
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Figure 36: Median change in ALT from baseline over 240 weeks by HBsAg status 
 
Graph shows median change in ALT. Bars show interquartile range. 
7.3.6 Flares on first-line treatment  
The analysis of flares was restricted to those participants with results of all variables 
used in the regression models; 33 participants were excluded as they had no baseline 
BMI result available and 5 as they had no follow-up. Using the definition of flare 
described above (section 7.2.2), 80 (2.4%) of 3,277 had a flare with 26 occurring by 
week 4, 13 between weeks 4 and 12, 9 between weeks 12 and 24, 6 between weeks 
24 and 48 and 26 after week 48.  
The incidence of flares is clearly much higher early after treatment initiation and was 
relatively stable after 24 weeks. 
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Figure 37: Cumulative incidence of ALT flares - all participants 
 
 
Factors associated with flares 
In unadjusted Cox regressions of flare, advanced WHO stage, HBsAg positivity and 
higher baseline ALT were associated with an increased risk while site, sex, age, BMI, 
baseline CD4 count, anti-HCV status, lower baseline platelet count, monitoring strategy 
and drug regimen were not (Table 40). 
In the adjusted model, WHO stage, HBsAg positivity and baseline ALT remained 
significant (Table 41). Site and drug regimen were also significant with a higher risk of 
flare in Entebbe and a lower risk in Harare and with use of NVP associated with higher 
and ABC with lower risk of flare than TDF. The HR for log of baseline ALT was 5.0 
meaning the risk of flare was 5.0 times higher per 10 fold increase in baseline ALT.  
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Table 40: Unadjusted analysis of factors associated with flare (Cox regression) 
  N Flare 
Hazard 
Ratio 
95% CI p 
Site Entebbe 991 32 1  0.15 
 JCRC 1289 28 0.67 0.40 to 1.11  
 Harare 997 20 0.61 0.35 to 1.07  
Sex Male 1146 34 1  0.14 
 Female 2131 46 0.72 0.46 to 1.12  
Age 18-30 525 14 1  0.25 
 30-35 785 22 1.06 0.54 to 2.06  
 35-40 836 22 0.98 0.50 to 1.92  
 40-45 604 11 0.68 0.31 to 1.50  
 45-50 310 7 0.83 0.34 to 2.06  
 >50 217 4 0.68 0.22 to 2.06  
BMI 
kg/m2 
Per unit 3277  0.97 0.91 to 1.03 0.26 
WHO Stage Stage 2 660 9 1  0.003 
 Stage 3 1841 42 1.72 0.84 to 3.53  
 Stage 4 776 29 2.88 1.36 to 6.08  
Baseline CD4 <50 1096 31 1  0.36 
 50-99 774 16 0.70 0.38 to 1.28  
 100-149 752 19 0.86 0.48 to 1.52  
 150-199 655 14 0.72 0.38 to 1.35  
HBsAg Negative 2971 61 1  <0.001 
 Positive 306 19 3.20 1.91 to 5.35  
Anti-HCV Negative 3137 77 1  0.90 
 Positive 77 2 1.04 0.26 to 4.23  
 Not done 63 1 0.63 0.09 to 4.52  
Baseline log(ALT) 
IU/mL 
Per log 3277 80 6.20 2.78 to 13.82 <0.001 
Baseline log(PLT) 
 
Per log 3277 80 0.47 0.17 to 1.26 0.13 
Monitoring 
strategy 
LCM 1633 39 1  0.81 
CDM 1644 41 1.05 0.68 to 1.64  
Drug TDF 2433 59 1  0.11 
 ABC 298 3 0.44 0.14 to 1.40  
 NVP 546 18 1.46 0.86 to 2.48  
TB treatment No 2702 65 1  0.71 
 Yes 575 15 1.11 0.63 to 1.95  
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95% CI p 
Site Entebbe 1  0.004 
 JCRC 0.54 0.32 to 0.92  
 Harare 0.38 0.21 to 0.69  
Sex Male 1  0.45 
 Female 0.83 0.51 to 1.35  
Age 18-30 1  0.47 
 30-35 1.12 0.57 to 2.22  
 35-40 0.99 0.50 to 1.96  
 40-45 0.74 0.33 to 1.66  
 45-50 0.98 0.39 to 2.50  
 >50 0.82 0.26 to 2.53  
BMI 
kg/m2 
Per unit 1.01 0.94 to 1.08 0.83 
WHO Stage Stage 2 1  0.005 
 Stage 3 1.78 0.85 to 3.75  
 Stage 4 2.90 1.32 to 6.41  
Baseline CD4 <50 1  0.80 
 50-99 0.85 0.46 to 1.57  
 100-149 1.09 0.60 to 1.97  
 150-199 1.03 0.53 to 2.01  
HBsAg Negative 1  <0.001 
 Positive 3.44 2.00 to 5.92  
Anti-HCV Negative 1  0.97 
 Positive 1.01 0.25 to 4.13  
 Not done 0.78 0.11 to 5.74  
Baseline log(ALT) 
IU/mL 
Per log 5.04 2.17 to 11.72 <0.001 
Baseline log(PLT) 
IU/mL 
Per log 0.61 0.22 to 1.64 0.32 
Monitoring 
strategy 
LCM 1  0.97 
 CDM 1.01 0.65 to 1.57  
Drug TDF 1  0.05 
 ABC 0.43 0.13 to 1.41  
 NVP 1.69 0.98 to 2.92  
TB treatment No 1  0.70 
 Yes 0.89 0.50 to 1.60  
  
HBsAg seropositive participants had 3.4 times the risk of a flare compared to those 
without HBsAg. The effect of HBsAg positivity increasing the risk of flare was apparent 
very early after treatment initiation (Figure 38). 
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Figure 38: Kaplan-Meier failure estimate - by HBsAg status 
 
 
The effect of drug was also apparent within the first months after starting treatment and 
maintained throughout follow-up (Figure 39). Flares were more common in those 
treated with NVP than in those treated with TDF, and were twice as common with TDF 
as with ABC, though the confidence intervals included 1 (Table 41). 
 Chapter 7: Liver inflammation and fibrosis Page 150 of 240 
Figure 39: Kaplan-Meier failure estimate – by drug treatment 
 
 
The risk of flare was higher in Entebbe than at the other two sites and was more than 
twice as high as in Harare. 
HBeAg 
The effect of HBeAg was examined in the subset of participants with detectable 
HBsAg. The unadjusted HR for HBeAg was 1.38 (95% CI 0.55 to 3.50; p=0.49) and the 
aHR was 1.27 (95% CI 0.42 to 3.83; p=0.67).  
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Flare incidence rate  
The incidence of flare over the whole of follow-up on first-line therapy was 0.56 (95% 
CI: 0.45 to 0.70) per 100 person years. The incidence rate was higher in those HBsAg 
seropositive at 1.55 (95% CI: 0.99 to 2.44) with an IRR of 3.3 (95% CI: 1.86 to 5.60; 
p<0.001). 
The incidence was higher in those treated with NVP (0.84, 95% CI: 0.53 to 1.33) than 
in those treated with TDF (0.54, 95% CI: 0.42 to 0.70) or ABC (0.25, 95% CI: 0.08 to 
0.79) but these differences were not statistically significant. However, of note, the effect 
of HBV infection on the rate of flare differed with drug regimen used. The IRR for 
HBsAg seropositive vs. HBsAg seronegative participants was 4.1 (95% CI: 2.1 to 7.3; 
p<0.001) in those treated with TDF, 6.2 (95% CI: 0.1 to 119.1; p=0.11) in those treated 
with ABC but only 1.1 (95% CI: 0.1 to 4.6; p=0.43) in those treated with NVP. Thus the 
association with HBsAg appeared to be only statistically significant in those on TDF. 
To examine whether the effect of HBsAg-status was different in participants according 
drug used, we performed a Cox regression with interaction factor between HBsAg and 
drug. This test indicated that there was no interaction (p=0.24). 
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The incidence of flare declined over time. For the first 24 weeks on ART, the incidence 
was 3.22 (95% CI: 2.42 to 4.28) flares per 100 person years, while over the rest of 
follow-up it was 0.31 (95% CI: 0.22 to 0.42) flares per 100 person years. In the latter 
case the IRR for HBsAg seropositive vs. seronegative was 1.57 (95% CI: 0.48 to 4.03), 
consistent with there being no association with HBsAg status once treatment has been 
given for 24 weeks. 
Clinical course after flare 
Of the 80 participants with a flare on first-line antiretroviral therapy, 15 (19%) died. 6 of 
these deaths occurred within a week of the flare and one other after 15 days while the 
other 8 deaths were between 3 months and 4 years later.  
One patient had an ALT of 399 IU/L that was then normal on the next sample (taken 12 
weeks later) and remained normal for all other samples until death 19 months later. 
The cause of death was given as “traumatic”. One patient died of disseminated TB 2 
years and 8 months after the first flare with normal ALT results in between although 
ALT rose again on the last sample taken before death, one week after starting TB 
therapy. Three others also had normal ALT after flare while the other 10 participants all 
had abnormal ALT results from the time of flare until their death (although in one case 
ALT declined to 41 IU/L on the day they died having been persistently abnormal since 
the flare 15 weeks earlier). Liver failure was given as a cause of death for 5 of the 10 
(the one who died after 15 weeks and 4 who died at the time of flare). For the other 5 
with persistently abnormal ALT until death, 1 died of pancreatitis, 1 of “HIV-related CNS 
disease” and 1 of cryptococcal meningitis, and in 2 the cause of death was uncertain 
(Table 42). 
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Table 42: Cause of death after flare on first-line therapy 
Patient HBsAg Cause of death 
Time from 





1 Neg Liver failure 1 No 
2 Neg Liver failure 2 No 
3 Neg Septicaemia / acute hepatitis 2 No 
4 Neg Liver failure 3 No 
5 Neg HIV-related CNS disease 3 No 
6 Pos Uncertain 3 No 
7 Neg Cryptococcal meningitis 15 No 
8 Neg Septicaemia / liver failure 104 No 
9 Neg Pancreatitis 148 No 
10 Pos Uncertain 241 No 
11 Neg Traumatic 583 Yes 
12 Neg Sepsis 873 Yes 
13 Neg Disseminated TB 991 Yes 
14 Neg Alcohol related 1216 Yes 
15 Neg Uncertain 1325 Yes 
  
After a flare, ALT returned to normal in most participants, being subsequently normal at 
some point in 65 (81.3%). In 44 ALT was normal within 12 weeks, and in another 18 
within 48 weeks. Of the 15 without a normal ALT after the flare, 10 died before the end 
of follow-up. 
Most flares did not appear to result in any change in therapy. 25 (31.3%) of the 80 were 
followed by a change or interruption in treatment within 12 weeks. Of these 25, 13 were 
in the LCM arm and 12 in the CDM arm of DART. In 18 of the 25, the reason for the 
change in therapy was given as “hepatotoxicity”, “raised LFTs” or, in 1 case, “cirrhosis”. 
In these 18, median time to a change in treatment was 5 days (IQR 3.25 to 20.75 
days). 8 participants stopped their therapy but then restarted the same regimen after a 
median of 21.5 days (IQR 12.25 to 32 days, range 7 to 43 days). 8 switched NVP to 
TDF, 1 switched TDF to NVP and 1 switched NVP to EFV. 
7.3.7 Flares on switch off TDF to second line therapy 
402 participants switched from a regimen that included TDF and 3TC to a regimen that 
included neither and had ALT test results on the second regimen. Baseline 
demographics (i.e. at entry to DART) for these patients are shown in Table 43. 
Switching to second line occurred when indicated by clinical progression or, in the LCM 
arm only, by low CD4 cell count [259]. Switching was more frequent in the LCM arm 
from 2 to 3 years after treatment initiation but similar before and after that period. 
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Table 43: Baseline demographics of those switching off tenofovir to second line 
  
HBsAg negative HBsAg positive 
p 
n % n % 
All  363  39   
Site Entebbe 99 27.3 6 15.4 0.189 
 JCRC 139 38.3 15 38.5  
 Harare 125 34.4 18 46.2  
Sex Male 157 43.3 19 48.7 0.611 
 Female 206 56.7 20 51.3  
Age 18-30 61 16.8 8 20.5 0.065 
 30-35 88 24.2 12 30.8  
 35-40 92 25.3 6 15.4  
 40-45 64 17.6 12 30.8  
 45-50 27 7.4 1 2.6  
 >50 31 8.5 0 0.0  
WHO Stage Stage 2 51 14.0 6 15.4 0.859 
 Stage 3 220 60.6 22 56.4  
 Stage 4 92 25.3 11 28.2  
Baseline CD4 <50 209 57.6 20 51.3 0.771 
 50-99 86 23.7 10 25.6  
 100-149 47 12.9 6 15.4  
 150-199 21 5.8 3 7.7  
Monitoring strategy LCM 199 54.8 23 59.0 0.735 
 CDM 164 45.2 16 41.0  
Anti-HCV Negative 8 2.2 2 5.1 0.381 
 Positive 20 5.5 1 2.6  
 Not done 335 92.3 36 92.3  
  
Mean ALT at the time of switch was 33.6 IU/L and there was no difference by HBsAg 
status (p=0.47). After switch, mean ALT declined in those HBsAg negative to 26.1 IU/L 
at 12 weeks while in those HBsAg seropositive mean ALT rose dramatically to 82.0 
IU/L at 12 weeks, returning to 33.1 IU/L at 24 weeks after switch (Figure 41). The large 
increase at week 12 in HBsAg seropositive participants was driven by 3 participants 
with ALT over 200 IU/L. Of these 3, in 1 ALT continued to rise after another 12 weeks 
but treatment was then switched again and ALT fell to normal 12 weeks later, while in 
the other two ALT fell after the rise 12 weeks after switch but both patients died while 
ALT was still abnormal (both 36 weeks after switch). The mean ALT in the other 35 
participants with detectable HBsAg was 34.6 IU/L at switch and 34.5 IU/L at week 12. 
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Figure 41: Mean ALT before and after switch to second line 
 
 
Using the definition of flare of an ALT ≥200 IU/L with a rise of at least 100 IU/L from 
baseline (time of switch), 12 (3.0%) participants had a flare on switching to second-line 
ART including 4 (10.3%) of those with detectable HBsAg, 1 of whom had detectable 
HBeAg. 3 of these flares in HBsAg seropositive participants were at 12 weeks 
(described above) while the other was at 48 weeks after switch. The Kaplan Meier 
failure estimate is shown in (Figure 42). In Cox regression analysis the HR for flare of 
HBsAg positivity was 4.45 (p=0.02). 
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Figure 42: Kaplan Meier failure estimate of risk of flare by HBsAg status 
 
 
There was no difference in the risk of flare by monitoring strategy arm (unadjusted HR 
1.4, p=0.53). 
Of the 8 HBsAg negative participants with a flare, 4 died; 2 the day after flare, 1 10 
days later and one 60 days later. For 2 the cause of death was recorded as liver failure. 
In the HBsAg seropositive participants with flare 3 out of 4 died; one after 47 days, 1 
after 241 and 1 after 248. Liver failure was recorded as the cause of death in 2 (Table 
44). 
Table 44: Timing and cause of death in those with flare after switch 
HBsAg 
Time of death 
after flare (days) 
Cause of death 
Negative 1 Pancreatitis 
Negative 1 Liver failure 
Negative 10 Liver failure 
Negative 60 Pneumonia / pulmonary hypertension 
Positive 47 Liver failure 
Positive 241 Uncertain 
Positive 248 Liver failure 
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In participants who switched to second line therapy and did not experience an ALT 
flare, 33 (8.5%) of 390 died before the end of follow-up, which was less than the 
proportion of those with flare that died (p<0.001). 
7.3.8 Flares during and after Structured Treatment Interruption 
A total of 813 participants were randomised in the STI substudy. Baseline 
demographics are shown in Table 45. HBsAg was positive in 68 (8.4%) of whom 41 
and 27 were randomised to CT and STI respectively.  




n % n % 
All  405  408  
Site Entebbe 164 40.5 167 40.9 
 JCRC 111 27.4 109 26.7 
 Harare 130 32.1 132 32.4 
Sex Male 106 26.2 112 27.5 
 Female 299 73.8 296 72.5 
Age 18-30 69 17.0 74 18.1 
 30-35 102 25.2 100 24.5 
 35-40 93 23.0 106 26.0 
 40-45 74 18.3 64 15.7 
 45-50 43 10.6 32 7.8 
 >50 24 5.9 32 7.8 
WHO Stage Stage 2 93 23.0 103 25.2 
 Stage 3 238 58.8 219 53.7 
 Stage 4 74 18.3 86 21.1 
Baseline CD4 <50 58 14.3 57 14.0 
 50-99 83 20.5 73 17.9 
 100-149 113 27.9 114 27.9 
 150-199 151 37.3 164 40.2 
HBsAg Negative 364 89.9 381 93.4 
 Positive 41 10.1 27 6.6 
Drug TDF 264 65.2 257 63.0 
 ABC 53 13.1 36 8.8 
 NVP 88 21.7 115 28.2 
Monitoring strategy LCM 208 51.4 207 50.7 
 CDM 197 48.6 201 49.3 
Anti-HCV Negative 393 97.0 392 96.1 
 Positive 8 2.0 8 2.0 
 ND 4 1.0 8 2.0 
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One participant was randomised to CT but the wrong allocation was sent to the 
clinicians and she underwent 3 interruptions. 4 in the STI arm had clinical reasons for 
not stopping only identified after randomisation. The numbers of participants that 
underwent each of 0, 1, 2, 3 or 4 structured treatment interruption cycles through to 
early termination of the study by the Data Monitoring Committee in March 2006 are 
shown in Table 46. 







0 404 4 
1 0 86 
2 0 148 
3 1 139 
4 0 31 
  
Flares occurred in 7 (0.9%) participants, 4 in the STI arm (3 HBsAg seronegative and 1 
HBsAg seropositive) and 3 in the CT arm (2 HBsAg seronegative and 1 HBsAg 
seropositive); 1 HBsAg seropositive participant in the STI arm had two flares (Table 
47). 
Only a single HBsAg seropositive patient in the STI arm (on AZT/3TC/TDF – see 
Figure 43) experienced a liver flare (two episodes, both during “on” cycles). In the CT 
arm there was also a single HBsAg seropositive participant with a flare (on 
AZT/3TC/NVP – see Figure 44).  
 
Figure 43: ALT – HBsAg seropositive 
with flare in STI arm 
 
Off-treatment periods shown shaded  
Figure 44: ALT – HBsAg seropositive 
with flare in CT arm 
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The rate of flare in HBsAg seropositive participants in the STI arm (1 out of 27, 3.7%) 
was no higher than the frequency observed in the CT arm (1 out of 41, 2.4%, p=1.0). 
Taking both arms together, there was a trend towards flares being less common in 
those HBsAg negative (5 out of 745, 0.7% vs. 2 out of 68, 3%, p=0.08).  
Monitoring strategy arm had no effect on the rate of flare, either overall (LCM 0.5% vs. 
CDM 1.3%, p=0.28) or in those in the STI arm (0.5% vs. 1.5%, p=0.37). 






Third drug Participants with flare 
TDF ABC NVP n % 95% CI 
CT 
Negative - 364 239 51 74 2 0.5 0.1 to 2.0 
Positive 34.2 41 25 2 14 1 2.4 0.1 to 12.9 
STI 
Negative - 381 242 34 105 3 0.5 0.1 to 1.9 
Positive 20.0 27 15 2 10 1 3.7 0.1 to 19.0 
  
One participant with a flare during the STI substudy died during follow-up; this 
participant was HBsAg negative, in the CDM arm of DART and the STI arm of the 
substudy and underwent one STI without event from weeks 0 to 12. However a second 
STI was stopped after 1 week when the substudy was terminated by the Data 
Monitoring Committee. 1 year later non-Hodgkins lymphoma (NHL) was diagnosed, TB 
treatment started and AZT/3TC/NVP changed to AZT/3TC/EFV. ALT flared 2 weeks 
later and ART was stopped. Death from NHL occurred two months after flare with ALT 
remaining abnormal until death. Thus death was unlikely to have been related to STI. 
There were no deaths during or within 72 weeks of the end of the STI study among 
HBsAg seropositive participants. 
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7.4 Discussion 
While HBsAg status is associated with higher baseline ALT and with increased risk of 
flare these effects are generally of little clinical significance. 
7.4.1 Liver status at baseline 
Baseline ALT was higher in males as was expected. Surprisingly ALT fell with age until 
50 years and then rose slightly which is the inverse of what has been described in 
healthy subjects [300, 301]. It was higher in those with more advanced WHO stage of 
HIV disease and in those with lower CD4 count. Baseline ALT was higher in those 
HBsAg seropositive, but the magnitude of this effect was similar to that of several other 
factors, including sex, age, and CD4 count. ALT was lower than the local ULN in most 
(83.2%) participants, including those who were HBsAg positive (77.6%).  
Results of the baseline platelet count and the two serum fibrosis markers were highly 
correlated but, when used to categorise those with severe fibrosis, use of API allocated 
approximately twice as many to the F3/4 group as FIB-4. These correlations are 
unsurprising, not only because the scores attempt to measure the same thing, but also 
because both composite methods include the platelet count, with fibrosis score 
increasing as platelet count decreases. 
Low platelet count and severe fibrosis determined by both API and FIB-4 were weakly 
associated with HBsAg status. The proportion with significant fibrosis determined by 
API was similar to the 17% found in a Ugandan study which measured fibrosis using 
TE [56]. That study found the prevalence in HBsAg seropositive individuals to be 2 
times higher whereas we found the difference to be only one third. Unfortunately they 
did not also report platelet count or any serum fibrosis marker. There are no studies 
examining the association of TE and serum fibrosis markers and only two comparing 
biopsy with serum markers in HIV-HBV coinfected patients. The studies that utilised 
biopsy did not compare serum markers that rely only upon widely used blood tests 
such as ALT and platelet count [216, 217]. Although TE is portable it remains 
expensive and rarely available. Further studies comparing TE and/or biopsy with serum 
markers would be valuable and allow the further assessment of the predictive value of 
such fibrosis markers. 
7.4.2 Change in ALT on first-line treatment 
Mean ALT rose slightly at 4 weeks after HAART initiation before falling to below 
baseline. This increase has only rarely been noted in previous studies of first-line 
HAART [198]. There were apparent trends towards the rise in ALT early in treatment 
being higher in those treated with NVP and in those HBsAg seropositive who were 
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treated with TDF, but no significant interaction was found between HBsAg status and 
drug treatment. 
It could be postulated that a small change like this represents an increase in the degree 
of liver inflammation after starting HAART. However the clinical significance of any 
such small change is unclear. Taking the mean change in ALT averages across those 
with no change, those with small and clinically insignificant changes and those with 
large changes indicating severe inflammation and hepatocyte damage. Table 38 may 
give a more useful picture, in that it shows that the majority of participants do not have 
a clinically significant increase in ALT and the majority of those with raised ALT at 
baseline subsequently have a decline (though of course this may simply be a 
regression to the mean). A similar decline in the proportion of both HBsAg seropositive 
and seronegative patients with abnormal ALT was seen over the first few months of 
HAART in a study in Gambia [88]. Of note, in that study there was a transient but 
marked increase in the proportion of those with occult HBV who had an abnormal ALT 
at 1 month after initiation. Another study, from Ghana, also found a reduction in the 
proportion with raised transaminases after treatment initiation [96]. 
The decline in ALT was greater in those treated with ABC during the first year of follow-
up but there was no difference later. Why this should be is unclear. The number of 
participants treated with ABC was low and perhaps the confidence intervals 
unrealistically narrow since many comparisons are made in these graphs. The decline 
in ALT gradually increased in those HBsAg seropositive and continued to diverge from 
those HBsAg seronegative. This could have been due to sicker patients with higher 
ALT dropping out (switching off first-line) over time. However an intention to treat 
analysis, in which ALT results were included including after a switch to second line 
antiretroviral therapy, showed a very similar pattern. 
7.4.3 Flares on first-line antiretroviral therapy 
This is the largest study to determine the incidence of liver flares in HBV/HIV coinfected 
individuals. We found flares on starting first-line HAART occurred at a similar rate to 
previous studies in populations in sub-Saharan Africa, though substantially lower than 
previously reported in resource-rich countries. Why this difference between rates 
should exist is unclear.  
The overall proportion of patients experiencing a flare is a rather crude measure in the 
light of widely varying length of follow-up in different studies. We found the incidence 
rate was ten times higher in the first 24 weeks after starting HAART than subsequently 
but that flares continued to occur for the rest of follow-up. 
 Chapter 7: Liver inflammation and fibrosis Page 162 of 240 
As has been reported in previous studies, flares were more common in those with 
higher baseline ALT. This is unsurprising since those with pre-existing liver 
inflammation are likely to be at higher risk of further damage. Flares were also more 
common in those HBsAg seropositive, in those treated with NVP and in those with 
WHO stage 4 HIV disease. Flares were less common in Harare than in the Ugandan 
sites but again the reason for this is unclear. We did not find an association between 
baseline platelet count (a marker of advanced liver disease) and the risk of flare. 
In most of those who experienced a flare on first line treatment the ALT subsequently 
returned to normal. Mortality was low and in those that died only one third were known 
to have died of liver disease. This is similar to previously published data. In a Malawian 
study of 300 participants with advanced HIV, 7% of whom were coinfected with HBV, 
all flares on starting antiretroviral treatment resolved without clinical incident [195]. In 
another study which enrolled 5,832 participants (hepatitis status unknown) in Kenya 
and Mozambique the investigators found no increase in mortality in the 124 (2.4%) with 
flare on starting HAART [302]. 
The aetiology of the flares in DART participants is unknown. The higher rate in those 
treated with NVP suggests drug reaction to be responsible for some at least. We did 
not find that HBV coinfection significantly increased the sensitivity to NVP-related liver 
flare. In future, NVP may be a less frequent cause of flare since its use is declining 
worldwide as alternatives become more widely available and as guidelines recommend 
starting HAART at higher CD4 counts, when NVP is contraindicated due to an even 
higher risk of hepatotoxicity [303]. Detectable HBsAg appeared to be associated with 
an increased risk of flare only in the first 24 weeks after starting HAART, suggesting 
that once on stable HBV-active therapy, flares are not related to HBV. If flares on 
treatment-initiation are due to IRIS then in future the incidence of flare may also decline 
in frequency as participants are started at higher CD4 counts. 
In view of the fact that the majority of flares in this population were without serious 
clinical sequelae and resolved spontaneously, routine lab monitoring of ALT in order to 
detect flares may not be of significant benefit, as suggested by Moore [195] and Chu 
[302]. The DART trial did report better outcomes in those who had routine monitoring 
but this is likely driven by other monitoring tests done (i.e. FBC, CD4/CD8, bilirubin, 
urea and creatinine) [259]. 
7.4.4 Flares on switch off TDF to second line therapy 
A switch to second line therapy from a regimen that contains TDF and 3TC to one that 
contains neither allows examination of the effect of stopping therapy for HBV while 
continuing therapy for HIV. 
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A flare in ALT occurred in 10.3% (4/39) of HBsAg seropositive but only 2.2% (8/363) of 
HBsAg seronegative participants (HR 4.45) during second-line therapy. In the HBsAg 
seronegative group there was no significant change in ALT at or after the time of 
switch. However in HBsAg seropositive participants the mean ALT was 34.3 IU/L at 
switch but 73.2 IU/L 12 weeks later. This change was in fact driven by 3 with a flare at 
12 weeks while in the remaining 36 participants there was no change in mean ALT.  
A high proportion of those with a flare on switch died, both in the HBsAg seronegative 
and seropositive groups. Liver failure was commonly recorded as cause of death 
regardless of HBsAg status though allocation of cause of death may have been subject 
to bias, in that liver disease could have been decided upon as a probable cause of 
death as a result of the high ALT.  
There are limited data previously published on stopping HBV-active treatment while 
maintaining HAART. HAART was continued in approximately half of 147 3TC 
interruptions in 109 participants in the Swiss Cohort Study [116]. Follow-up was limited 
to 6 months, during which time 29% of interruptions led to liver enzyme elevation, 5.4% 
to flare and 1 (0.7%) to death from liver failure. Flares occurred a median of 5 to 6 
weeks after discontinuation of HBV-active treatment. No association was found with 
age, sex, CD4 count or whether ART was continued when 3TC stopped. 
Discontinuation of 3TC was also identified as a risk factor for flare in a cohort in 
Amsterdam, with 22% having a grade 4 rise in liver enzymes (10x ULN), though it was 
unclear how many had stopped all antiretroviral treatment at the same time as 3TC 
[192]. These studies concluded that HBV-active treatment, once started, should be 
continued. Our data supports this, since although we found death was common after 
flare in both those with and without detectable HBsAg, the rate of flare was higher in 
those coinfected with HBV. 
7.4.5 Flares during and after Structured Treatment Interruption  
The SMART study showed that treatment interruption in HAART leads to an increased 
risk of opportunistic infection or death although earlier, smaller studies had not shown 
such increased risks [159, 304, 305]. In SMART, coinfection with viral hepatitis (mostly 
HCV) was found to increase the risk of death but no data has been reported on liver 
enzyme changes [97]. 
In DART, flares were rare during the STI substudy and there was no significant 
difference between the rate of flare in the two arms. As in the first-line antiretroviral 
therapy analysis, there was a higher rate of flare in those HBsAg seropositive, though 
this difference was not statistically significant in the STI substudy. There was only one 
death in a participant with a flare during the STI substudy. This occurred over a year 
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later and there was no suggestion that liver disease or STI played any contribution. 
Thus, brief treatment interruptions of 12 weeks duration were not associated with an 
increase in liver flares in coinfected participants. The higher risk of death in those with 
flare after switch than in those with flare after STI is likely to be due to the fact that 
those undergoing switch were often doing so because their clinical situation was 
deteriorating while those undergoing STI were a selected group that were doing well on 
treatment. The risk of death in those switching who did not have a flare was lower but 
still considerable at 8.5%. 
In contrast, a trial of CD4-guided STI that recruited participants in Thailand, Switzerland 
and Australia (STACCATO) included 6 HBV/HIV coinfected patients who underwent 
structured treatment interruptions [146]. Of these 6, 5 had a rise in ALT and 1 had a 
flare. The authors stated that ALT in those without flare rose but this was to a 
maximum of only 43 IU/L. Again the authors concluded that HBV-active treatment 
should not be interrupted in HIV/HBV-coinfected patients. 
One potential cause of liver enzyme elevation is HBeAg to anti-HBe seroconversion 
which can occur in association with treatment interruption [116, 146]. Unfortunately we 
have hepatitis B serology only at entry to DART. 
7.4.6 Limitations 
In DART, ALT was measured every 3 months with additional tests as requested by 
clinicians. We found that the majority of flares on first-line therapy were without clinical 
sequelae, as were flares during the STI substudy, while flares on a switch to second 
line therapy were frequently followed by death. Over one third of DART participants 
had extra ALT testing performed and these tests are likely to have been performed if 
participants were sick. Thus the probability of finding a flare may be increased in those 
sick purely through the increase in testing frequency. As such, it may be that 
participants who were at increased risk of dying through other pathology may have 
been at increased risk of having a flare detected. Brief asymptomatic flares may have 
been missed, reducing the apparent incidence of flare in those who were well and 
introducing bias to any association found between flare and death. 
It is well recognised that flares can also occur at the time of HBeAg seroconversion. 
Unfortunately we do not have HBV serology results for time points after study entry. 
For a full investigation of flares in HBV/HIV coinfected individuals this would also be 
interesting to examine. 
Despite DART being a large cohort with a moderately high rate of HIV-HBV coinfection, 
there is still a need to include more individuals to examine factors associated with rare 
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events, such as coinfected patients experiencing flare after switch to second-line 
therapy. 
7.4.7 Conclusions 
The effects on liver inflammation and fibrosis of HBV coinfection in HIV infected 
individuals are limited in public health significance, but include an increase baseline 
ALT, increases in the rise in ALT and the risk of flare on first-line HAART and an 
increase in the risk of flare on stopping HBV-active treatment. HBV does not 
significantly increase the risk of flare in participants on stable HAART after the initial six 
months and in DART did not increase the risk of flare during 12 week treatment 
interruptions.  
Flares were usually without clinical importance although they were frequently followed 
by death when they occurred after a switch to second line.  
These analyses support the recommendations from DART and elsewhere that routine 
ALT monitoring is not of benefit, even in HBV/HIV coinfected individuals, but 
demonstrate that HBV status should be determined before stopping HBV-active 
treatment and such treatment should be continued in coinfected patients.  
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8 CD4 count changes and clinical disease progression 
8.1 Introduction 
In HIV-positive patients with access to antiretroviral medication liver disease is one of 
the leading non-AIDS causes of death [62, 66, 67]. Liver-related and all-cause mortality 
are higher in HBV coinfected patients [82, 83, 118]. Most studies examining the effects 
of HBV coinfection on HIV outcomes have not shown any effect on CD4 rise on ART, 
on progression to AIDS or on HIV-related death (reviewed in chapter 1). However 
published data is mixed, with some studies showing deleterious effects on all three 
outcomes. 
HIV management guidelines, including those from the UK, the USA and the WHO, 
recommend the use of two drugs with anti-HBV activity in HBV/HIV-coinfected patients 
who require treatment for HIV [123, 133, 134]. It is unknown whether this strategy 
abrogates the excess mortality associated with HBV-coinfection documented in some 
earlier studies. 
The DART population provides a valuable opportunity to examine the effect of HBV 
infection on the clinical and immunological responses to HIV treatment. 
Aims 
1. To examine the association between HBsAg status at treatment initiation and 
change in CD4 cell count over time 
2. To determine the predictors of clinical progression to new WHO stage 4 event 
and death 
3. To examine causes of death and determine the proportion of deaths due to 
liver-related causes 
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8.2 Methods 
8.2.1 Analyses 
Baseline CD4 was defined as the last measurement before treatment initiation.  
The examination of mean CD4 at 12 week intervals was stratified by baseline HBsAg 
status. The analysis was truncated at 288 weeks as very few HBsAg seropositive 
individuals had data beyond that point. 
Clinical outcomes were examined using two endpoints, the first being a composite one 
of new WHO stage 4 disease or death and the second being limited to death.  
All deaths were reviewed by an Endpoint Review Committee (ERC) which allocated a 
cause of death where possible. Causes of death were then reviewed by hand to 
determine which were liver-related. In two cases the cause of death was then 
questioned and in one case was re-allocated to a liver cause. 
8.2.2 Statistical Methods 
The effect of HBsAg status on CD4 cell response was examined using graphs and 
confidence intervals and assessed by a global test accounting for within-patient 
correlation (Stata regress command with option cluster()). 
Two clinical endpoints of new WHO stage 4 disease or death and death alone were 
examined using survival analysis methods, including regression and and Kaplan-Meier 
plots, truncated at 288 weeks due to small numbers. Analyses were stratified by 
HBsAg status and adjusted for initial drug regimen, age, sex, country, baseline WHO 
stage, CD4 count, HCV antibody status, liver fibrosis (estimated using baseline platelet 
count or FIB-4) and monitoring strategy. Platelet count was available for all participants 
but AST results were not available for participants in Harare and so FIB-4 could only be 
calculated on participants at Ugandan centres. To determine the effect of HBsAg in 
each drug and monitoring group models were rerun with an interaction factor. 
The associations between the two end points and HBV DNA and HBeAg status were 
also examined using survival analysis, but restricted to participants who were HBsAg 
seropositive. In the analysis using HBV DNA, a cut off of HBV DNA greater or less than 
2,000 IU/mL was used since this is used to inform treatment decisions in published 
guidelines [131]. 
Median ALT and CD4 count at death were compared using the Kruskal-Wallis equality-
of-populations rank test.  
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8.3 Results 
3,315 of 3,316 randomised patients who were tested for HBsAg were included in this 
analysis. 308 (9.3%) were HBsAg seropositive. 
8.3.1 Change in CD4 
The number of participants in this analysis declined with time from HAART initiation 
(Figure 45). Only 9% (including only 14 HBsAg seropositive participants) had samples 
after 288 weeks and 3% after 300 weeks. The analysis of change in CD4 was thus 
limited to the first 288 weeks. Overall, mean CD4 was 88 cells/mm3 at baseline and 12 
weeks after HAART initiation rose to 181 cells/mm3. At 48 weeks it had risen to 222 
cells/mm3. However, mean CD4 count and change in CD4 count from baseline did not 
differ by baseline HBsAg status as shown in Figure 45 (p=0.51) and Figure 44 
(p=0.61). 
Figure 45: Mean CD4 count after treatment initiation 
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Figure 46: Change in CD4 count after treatment initiation 
 
 
8.3.2 Progression to WHO stage 4 event or death 
823 (24.8%) of 3,315 patients (731 HBsAg seronegative, 92 HBsAg seropositive) either 
had a new WHO stage 4 event or died over a median follow-up of 4.9 years (IQR 3.6 to 
5.4 years).  
Figure 47 shows the cumulative probability (1 minus the survival probability) of a new 
WHO stage 4 event or death following HAART initiation; Figure 46 shows the same 
curves limited to the first 48 weeks of follow-up. 
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The curves diverge between 8 and 24 weeks and appear to remain approximately 
parallel thereafter.  
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Figure 48: Cumulative probability of WHO stage 4 event or death by HBsAg 
status (first 48 weeks) 
 
 
The IRR and aHR for the effect of HBsAg positivity on death over the initial 48 weeks 
after HAART initiation are shown in Table 48. The aHR was calculated using a Cox 
model adjusted for sex, age, site, drug regimen, monitoring strategy and baseline CD4. 
The IRR was significantly different from 1 during the first 12 weeks but not between 12 
and 48 weeks. The aHR was greater than 1, though this was only statistically 
significant during weeks 12 to 24 and weeks 36 to 48 (Figure 49). 
Table 48: Incidence rate and adjusted hazard ratios for HBsAg on WHO stage 4 




IRR 95% CI P aHR 95% CI p 
0 to 12 1.30 1.04 to 1.62 0.02 1.21 0.80 to 1.84 0.37 
12 to 24 1.29 0.98 to 1.66 0.06 1.99 1.05 to 3.77 0.03 
24 to 36 1.20 0.88 to 1.59 0.22 1.81 0.80 to 4.10 0.15 
36 to 48 1.17 0.85 to 1.58 0.31 2.69 1.08 to 6.72 0.03 
Incidence rates were calculated using participant-weeks. 
 Chapter 8: Clinical progression Page 173 of 240 
Figure 49: Adjusted hazard ratio for HBsAg on WHO stage 4 or death over the 
intial 48 weeks 
 
 
To attempt to further determine the timing of the effect of HBsAg on the incidence of a 
new WHO Stage 4 event or death we examined a plot of the hazard function (not 
shown) but this did not provide any further information. 
Table 49 shows the IRR and aHR for the effect of HBsAg positivity on death over the 
whole of follow-up. Both the IRR and HR were significantly different from 1 during the 
first 48 weeks and between 192 and 240 weeks. 
Table 49: Incidence rate and adjusted hazard ratios for HBsAg on WHO stage 4 




IRR 95% CI P aHR 95% CI p 
0 to 48 1.53 1.11 to 2.06 0.008 1.54 1.13 to 2.11 0.007 
48 to 96 0.85 0.40 to 1.61 0.64 0.95 0.49 to 1.84 0.88 
96 to 144 0.72 0.30 to 1.47 0.38 0.61 0.28 to 1.33 0.21 
144 to 192 0.90 0.38 to 1.85 0.82 0.81 0.38 to 1.69 0.57 
192 to 240 2.21 1.08 to 4.18 0.02 2.00 1.02 to 3.91 0.04 
240 to 288 1.81 0.55 to 4.76 0.24 1.76 0.66 to 4.70 0.26 
Incidence rates were calculated using participant-weeks. 
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Figure 50: Adjusted hazard ratio for HBsAg on WHO stage 4 or death over the 
whole of follow-up 
 
 
In an adjusted Cox regression model, HBsAg-positivity was associated with a 30% 
(adjusted; 95% CI 4 to 62%; p=0.02) increased risk of a new stage 4 event or death 
(Table 50). Age, site, anti-HCV status, baseline ALT, baseline platelet count and drug 
treatment regimen were not associated with new WHO stage 4 disease or death while 
sex, prior WHO stage 3 or 4 disease, lower baseline CD4 and study arm (clinical 
monitoring only) were associated with an increased risk. There was no association with 
liver fibrosis measured by FIB-4 in a model restricted to participants in Uganda (data 
not shown). 
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Table 50: Factors associated with risk of new WHO stage 4 or death in a Cox 
regression model 
   Events Adjusted 
HR 
  
  N n % 95% CI p 
Site Entebbe 1,020 229 22.5   0.81 
 JCRC 1,297 337 26.0 1.06 0.89 to 1.25  
 Harare 998 257 25.8 1.05 0.87 to 1.27  
Sex Male  1,160 323 27.8   0.05 
 Female  2,155 500 23.2 0.86 0.75 to 1.00  
Age group 18-30  532 136 25.6   0.63 
 30-35  795 203 25.5 0.99 0.79 to 1.23  
 35-40  848 219 25.8 1.03 0.83 to 1.28  
 40-45  608 143 23.5 0.90 0.71 to 1.15  
 45-50  313 64 20.4 0.84 0.62 to 1.14  
 >50  219 58 26.5 1.07 0.78 to 1.47  
WHO Stage Stage 2 672 104 15.5   <0.001 
 Stage 3 1,864 485 26.0 1.56 1.26 to 1.94  
 Stage 4 779 234 30.0 1.67 1.31 to 2.12  
Baseline CD4 <50  1,109 396 35.7   <0.001 
 50-99  784 186 23.7 0.64 0.54 to 0.76  
 100-149  759 139 18.3 0.49 0.40 to 0.60  
 150-199  759 102 13.4 0.42 0.34 to 0.52  
HBsAg Negative 3,007 731 24.3   0.02 
 Positive 308 92 29.9 1.30 1.04 to 1.62  
Anti-HCV Negative  3,175 786 24.8   0.95 
 Positive  77 19 24.7 1.04 0.66 to 1.64  
 Not done 63 18 28.6 1.07 0.67 to 1.72  
Log ALT  3,315 823 24.8 0.97 0.69 to 1.36 0.85 
Log Platelets  3,315 823 24.8 1.42 0.99 to 2.05 0.06 
Drug TDF  2,468 652 26.4   0.08 
 ABC  300 54 18.0 0.76 0.57 to 1.01  
 NVP  547 117 21.4 0.87 0.71 to 1.06  
Monitoring LCM  1,656 359 21.7   <0.001 
 CDM  1,659 464 28.0 1.29 1.12 to 1.48  
 
The incidence of a new WHO stage 4 event or death was 5.8 per 100 patient years in 
those HBsAg negative and 7.6 per 100 patient years in those HBsAg seropositive 
(p=0.02). The IRR was such that those HBsAg seropositive had a higher incidence of 
new WHO stage 4 event or death than those HBsAg seronegative in those treated with 
TDF (IRR 1.47, 95% CI 1.15 to 1.87) but a not in those treated with ABC (IRR 0.95, 
95% CI 0.25 to 2.58) or NVP (0.75, 95% CI 0.35 to 1.43) though the difference in IRR 
did not reach statistical significance (p=0.12) (Table 51). 
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Table 51: Incidence of new WHO stage 4 event or death by HBsAg status and 
drug treatment 
  Drug Non-TDF vs. TDF 
  TDF ABC NVP IRR 95% CI 
HBsAg 
 
Neg 6.0 4.5 5.7 0.88 0.73 to 1.05 
Pos 8.8 4.3 4.3 0.48 0.25 to 0.86 
HBsAg pos vs. neg 
 
IRR 1.47 0.95 0.75   
95% CI 1.15 to 1.87 0.25 to 2.58 0.35 to 1.43   
Incidence rates are shown per 100 participant years. 
Participants in the LCM arm of DART had a higher incidence of an event if HBsAg 
seropositive (IRR 1.46, 95% CI 1.04 to 2.00) but in the CDM arm the association with 
HBsAg was not statistically significant (IRR 1.19, 95% CI 0.86 to 1.61) (Table 52) and 
again the difference in IRR was not significant (p=0.27). 
Table 52: Incidence of new WHO stage 4 event or death by HBsAg status and 
monitoring strategy 
  Monitoring CDM vs. LCM 
  LCM CDM IRR 95% CI 
HBsAg 
 
Neg 4.9 6.7 1.36 1.17 to 1.58 
Pos 7.2 8.0 1.11 0.72 to 1.71 
HBsAg pos vs. neg 
 
IRR 1.46 1.19   
95% CI 1.04 to 2.00 0.86 to 1.61   
Incidence rates are shown per 100 participant years. 
In participants with detectable HBsAg, there was no significant difference in risk of new 
WHO stage 4 event or death by HBV DNA result (p=0.51, adjusted analysis) (Figure 
51).  
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Figure 51: Cumulative probability of new WHO stage 4 event or death by baseline 
HBV DNA status 
 
ND: HBV DNA not detected. BLQ: HBV DNA detected below the level of quantification. 
Low DNA: HBV DNA <2,000 IU/mL. High DNA: HBV DNA >2,000 IU/mL. 
Similarly there was no difference in risk by HBeAg status (p=0.89, adjusted analysis) 
(Figure 52). 
 Chapter 8: Clinical progression Page 178 of 240 




 Chapter 8: Clinical progression Page 179 of 240 
8.3.3 Death 
387 (11.7%) of 3,315 patients (337 HBsAg seronegative, 50 HBsAg seropositive) died 
over a median follow-up of 5.1 years (IQR 4.6 to 5.5 years).  
The cumulative probability curves are similar to those in the previous analysis, in that 
most of the difference in mortality between those HBsAg seropositive and seronegative 
occurred within the first year (Figure 53). 
Figure 53: Cumulative probability of death by HBsAg status 
 
 
The risk of death appeared unaffected by HBsAg status during the first 12 weeks of 
follow-up but diverged sharply between 12 and 24 weeks (Figure 54). 
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Figure 54: Cumulative probability of death by HBsAg status (first 48 weeks) 
 
 
Overall 71 (18.3%) out of 387 deaths occurred between 8 and 24 weeks (inclusive) 
after treatment initiation. By HBsAg status, 14 (28%) out of 50 deaths in HBsAg 
seropositive participants and 57 (16.9%) out of 337 deaths in HBsAg seronegative 
participants were during this period.  
The IRR and aHR for HBsAg on mortality are shown over the first 48 weeks in Table 53 
and over the whole of follow-up in Table 54. [Fig] and Figure 56 show the aHR for the 
initial 48 weeks and for the whole of follow-up respectively. In the analysis examining 
the whole of follow-up, the only period during which the hazard was different by HBsAg 
status was from 0 to 48 weeks. Within the first 48 weeks, the only period with a 
statistically significant effect was between 12 and 24 weeks. As in the analysis of new 
Stage 4 event or death, we examined a plot of the hazard curve over time to try to 
determine the timing of the effect of HBsAg on mortality but this did not provide any 
further information. 
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Table 53: Incidence rate and adjusted hazard ratios for HBsAg on death over the 




IRR 95% CI P aHR 95% CI p 
0 to 12 1.51 1.10 to 2.04 0.01 1.33 0.68 to 2.62 0.41 
12 to 24 1.56 1.09 to 2.19 0.01 3.00 1.40 to 6.42 0.01 
24 to 36 1.40 0.93 to 2.04 0.09 2.46 0.82 to 7.36 0.11 
36 to 48 1.35 0.87 to 2.03 0.15 1.20 0.27 to 5.37 0.82 
Incidence rates were calculated using participant-weeks. 
 





IRR 95% CI p aHR 95% CI p 
0 to 48 1.68 1.05 to 2.57 0.02 1.78 1.15 to 2.77 0.01 
48 to 96 0.81 0.25 to 2.00 0.70 0.89 0.35 to 2.26 0.81 
96 to 144 0.72 0.14 to 2.25 0.63 0.77 0.23 to 2.52 0.66 
144 to 192 1.36 0.42 to 3.46 0.51 1.29 0.50 to 3.36 0.60 
192 to 240 2.20 0.82 to 5.08 0.08 1.93 0.82 to 4.54 0.13 
240 to 288 2.76 0.80 to 7.72 0.07 2.30 0.82 to 6.39 0.11 
 Incidence rates were calculated using participant-weeks. 
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Figure 55: Adjusted hazard ratio for HBsAg on death over the initial 48 weeks 
 
Figure 56: Adjusted hazard ratio for HBsAg on death over the whole of follow-up 
 
 
Over the whole of follow-up, HBsAg-positivity was associated with a 51% (95% CI 11 to 
105%; p=0.009) higher mortality in an adjusted Cox regression analysis (Table 55). 
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Sex, age, site, anti-HCV status, baseline ALT, baseline platelet count and drug 
treatment regimen were not associated with death while WHO stage 3 or 4 disease, 
lower baseline CD4 and study arm (clinical monitoring only) were associated with an 
increased risk. Restricting to participants in Uganda, FIB-4 also did not have an effect 
(data not shown). 
Table 55: Factors associated with risk of death in a Cox regression model 
   Deaths Adjusted 
HR 
  
  N n % 95% CI p 
Site Entebbe 1,020  111 10.9   0.79 
 JCRC 1,297  164 12.6 1.01 0.79 to 1.30  
 Harare 998 112 11.2 0.93 0.70 to 1.23  
Sex Male  1,160  155 13.4   0.29 
 Female  2,155 232 10.8 0.89 0.72 to 1.10  
Age group 18-30  532  54 10.2   0.38 
 30-35  795 104 13.1 1.30 0.93 to 1.80  
 35-40  848  95 11.2 1.16 0.83 to 1.63  
 40-45  608  78 12.8 1.33 0.93 to 1.90  
 45-50  313  28 8.9 0.98 0.62 to 1.57  
 >50  219  28 12.8 1.44 0.91 to 2.30  
WHO Stage Stage 2 672  44 6.5   0.002 
 Stage 3 1,864  222 11.9 1.60 1.15 to 2.22  
 Stage 4 779  121 15.5 1.92 1.34 to 2.75  
Baseline CD4 <50  1,109  194 17.5   <0.001 
 50-99  784 87 11.1 0.65 0.50 to 0.83  
 100-149  759  65 8.6 0.52 0.39 to 0.69  
 150-199  663 41 6.2 0.39 0.28 to 0.55  
HBsAg Negative 3,007  337 11.2   0.009 
 Positive 308 50 16.2 1.51 1.11 to 2.05  
HCV Ab Negative  3,175 376 11.8   0.35 
 Positive  77  7 9.1 0.76 0.36 to 1.60  
 Not done 63 4 6.3 0.53 0.20 to 1.43  
Log ALT  3,315 387 11.7 1.25 0.77 to 2.02 0.37 
Log Platelets  3,315 387 11.7 1.43 0.85 to 2.41 0.18 
Drug TDF  2,468 310 12.6   0.40 
 ABC  300 28 9.3 0.89 0.60 to 1.32  
 NVP  547 49 9.0 0.82 0.60 to 1.12  
Monitoring LCM  1,655  166 10.0   0.007 
 CDM  1,659  221 13.3 1.32 1.08 to 1.61  
  
The incidence of death in those HBsAg seropositive was 3.6 per 100 patient years 
compared to 2.4 per 100 patient years in those HBsAg seronegative (p=0.009). The 
IRR for HBsAg seropositive vs. seronegative did not differ by initial antiretroviral drug 
regimen (p=0.99) (Table 56). 
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Table 56: Incidence of death by HBsAg status and drug treatment 
 
Drug treatment Non-TDF vs. TDF 
TDF ABC NVP IRR 95% CI 
HBsAg 
Negative 2.5 2.1 2.0 0.81 0.61 to 1.06 
Positive 3.9 3.1 2.9 0.77 0.34 to 1.56 
IRR 1.53 1.47 1.45   
95% CI 1.07 to 2.14 0.29 to 4.83 0.55 to 3.25   
Incidence rates are shown per 100 participant years.  
In participants in the LCM arm, the incidence of death was 2.0 deaths per 100 patient 
years in those HBsAg seronegative but 3.5 deaths per 100 patient years in those 
HBsAg seropositive while in the CDM arm the respective incidence rates were 2.8 
deaths per 100 patient years for HBsAg seronegative and 3.8 deaths per 100 patient 
years for HBsAg seropositive participants. However, while there was a trend towards 
monitoring being effective (i.e. a lower rate of death in the LCM arm) in HBsAg 
seronegative participants, the difference between the IRR in each arm did not reach 
statistical significance (p=0.27) (Table 57). 
Table 57: Incidence of death by HBsAg status and monitoring strategy 
 
Monitoring LCM vs. CDM 
LCM CDM IRR 95% CI 
HBsAg 
Negative 2.0 2.8 1.41 1.13 to 1.76 
Positive 3.5 3.8 1.07 0.59 to 1.93 
IRR 1.76 1.34   
95% CI 1.10 to 2.71 0.84 to 2.03   
Incidence rates are shown per 100 participant years.  
Restricting the analysis to those with detectable HBsAg, there was a trend towards 
higher risk of death in those with HBV DNA greater than 2,000 IU/mL (Figure 57). 
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Figure 57: Cumulative probability of death by baseline HBV DNA status 
 
ND: HBV DNA not detected. BLQ: HBV DNA detected below the level of quantification. 
Low DNA: HBV DNA <2,000 IU/mL. High DNA: HBV DNA >2.000 IU/mL. 
However, in a Cox regression model controlled for age, sex, drug, site, monitoring, 
baseline CD4, WHO stage, liver fibrosis (using API) and anti-HCV (not shown), the 
trend was not significant, (p=0.15). 
Similarly there was a trend to higher risk of death in those with detectable HBeAg 
(Figure 58). However this was not significant in an unadjusted Cox model (HR 1.4; 
p=0.29) and the effect disappeared in an adjusted model that also included age, sex, 
drug, site, monitoring, baseline CD4, WHO stage, API and anti-HCV (HR 1.0; p=0.98). 
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Figure 58: Cumulative probability of death by baseline HBeAg status 
 
 
8.3.3.1 Cause of death 
Deaths were classified as definitely/probably due to HIV, definitely/probably due to 
drug and a third group not known/uncertain/unlikely to be due to HIV or drug (which 
included participants given codes uncertain HIV/drug, unlikely HIV/drug, not 
known/insufficient information, uncertain HIV/not drug and uncertain drug/not HIV). 
The distribution of deaths did not differ between HBsAg seropositive and seronegative 
participants (p=0.14) (Table 58). 
Table 58: Classification of death 
 HBsAg positive HBsAg negative 
p 
Category n % n % 
Definitely/probably HIV 16 32.0 162 48.1 0.14 
Definitely/probably drug 4 8.0 15 4.5  
Uncertain 30 60.0 160 47.5  
Total 50 100.0 337 100.0  
 
A cause of death could be assigned in 270 (80.1%) HBsAg seronegative and 39 
(78.0%) HBsAg seropositive participants. Primary or secondary causes of death 
included liver-related events in 12 (4.4%) and 3 (8%) respectively (p=0.42) (Table 59). 
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Table 59: Liver-related causes of death by HBsAg status 
Cause of death HBsAg negative HBsAg positive Total 
Liver failure 10 2 12 
Sepsis/liver failure 2  2 
Hepatocellular carcinoma  1 1 
Total 12 3 15 
 
Of the 15 liver-related deaths, using the classification in Table 58, the deaths of 3 
participants were reported as “Definitely/probably drug” related (all HBsAg negative, 
two with “Liver failure” and one with “Sepsis”). The other 12 were reported as 
“Uncertain”.  
As stated above, the additional risk of death associated with HBsAg was statistically 
significant only between 0 and 48 weeks and from Figure 54 it appears this effect 
mostly occurred between 8 and 24 weeks after treatment initiation. Of those who died 
between 8 and 24 weeks after starting HAART, cause of death was recorded for 13 
HBsAg seropositive and 47 HBsAg seronegative participants. Of these, 2 HBsAg 
negative participants died of liver failure. The HBsAg seropositive participants who died 
during this period died of: neurological disease (1 meningitis, 1 epilepsy, 1 transverse 
myelitis, 1 indeterminate), infections (1 cryptosporidium, 3 of sepsis, 1 miliary TB), 
cancer (1 solid tumour, 1 CNS lymphoma), 1 anaemia and 1 of COPD. 
There was no significant difference between the last ALT count before death in those 
HBsAg seropositive compared with those HBsAg seronegative (Table 60) or both with 
baseline ALT (p=0.59) (Figure 59).  
Table 60: Last ALT before death by HBsAg status 
HBsAg Median IQR Range p 
Negative 26 15 to 42 3 to 1802 0.59 
 Positive 24 15 to 41 4 to 1615 
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Figure 59: Distribution of ALT at baseline and before death in HBsAg 
seronegative and seropositive participants 
 
 
In those who died in the first 24 weeks after treatment initiation, the majority had 
normal ALT and very few had an ALT greater than 5 times the ULN (Table 61). 
Table 61: Last ALT before death in those who died within 24 weeks of treatment 
initiation 
  ALT > ULN ALT > 5x ULN 
HBsAg N N % P N % P 
Negative 112 26 23.2 0.77 
 
2 1.8 0.35 
 Positive 19 5 26.3 1 5.3 
  
There was also no difference between the last CD4 count before death in those HBsAg 
seropositive compared with those HBsAg negative (Table 62).  
Table 62: Last CD4 count before death by HBsAg status 
 HBsAg positive  
HBsAg Median IQR Range p 
Negative 86 22 to 169 1 to 830 0.66 
Positive 87 33 to 235 1 to 399  
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8.4 Discussion 
8.4.1 CD4 count at baseline and over time 
We found no difference in baseline CD4 count between those positive or negative on 
testing for HBsAg. There was also no difference in the rise in CD4 after treatment 
initiation. This latter finding is in agreement with most previously published data [74, 75, 
79, 80, 82, 84-86]. However a recently published study in Tanzania found lower CD4 
counts at baseline (median 101 vs. 116 cells/mm3) and smaller rises in CD4 at 6 (71 
vs. 77 cells/mm3, p=0.46) and 12 months (143 vs. 158 cells/mm3, p=0.05) of follow-up 
in those HBsAg seropositive [199]. It was a large study with 1,079 coinfected and 
16,460 HIV-monoinfected patients starting ART. The authors stated that their study 
was the first to show such effects of HBsAg status on CD4 count on ART and 
suggested that previous studies may have included too few patients and that the result 
is real, perhaps due to coinfection leading to CD4 cell death via either activation or 
splenic sequestration. Indeed some of the earlier studies did show a non-significant 
higher CD4 rise in those HBsAg seronegative [74, 80, 84, 85] but in one that included 
178 HBV coinfected and 2,781 HIV monoinfected patients there was no difference [86]. 
Another recent study (from Ghana) also found an association between a positive 
HBsAg status and lower CD4 rise, with HBsAg-positive patients having a 2 cells/mm3 
smaller increase per month over 36 months [96]. This study included 143 coinfected 
and 228 monoinfected patients. Of particular note that study found HBsAg was 
associated with higher baseline CD4 count (133 vs. 119 cells/mm3, p=0.08). It may be 
that differences in baseline and rise in CD4 exist but that DART was not powered to 
detect them. However it appears that if any such associations are real the differences 
are small and perhaps not clinically important. 
8.4.2 Clinical progression 
In this study, all patients were treated with at least one drug with activity against HBV 
and 75% with dual therapy, i.e. 3TC alone or with TDF. Despite this, HBsAg positivity 
was associated with an increased rate of progression to death and to the combined 
end-point of WHO stage 4 HIV disease and death. Most of this excess risk appeared to 
occur within the first year after treatment initiation. In fact the risks were similar very 
early after treatment initiation, then diverged for a period of weeks and then were again 
similar, but with a suggestion of a difference between 192 and 240 weeks. An 
explanation of the lack of difference early on could be that sicker individuals with HBV 
coinfection were excluded from study entry. In fact there were no deaths of HBsAg 
seropositive individuals for almost a month after initiation. After about one year HBV 
will be suppressed in the majority of coinfected participants (chapters 3 and 6) and 
there may have been some improvement in liver fibrosis [306] and so perhaps the 
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effect of HBV minimised. The apparent difference later in follow-up may be related to 
participants changing to second line therapy. However the analysis of the changing 
hazard over time is based on only 29 deaths in HBsAg seropositive individuals during 
the first year and so should be interpreted with caution. 
As discussed by Walker, the risk of death was low immediately after entry to DART and 
rose to a maximum between 30 and 50 days after study entry [307]. This was likely to 
be because patients at high risk of imminent death were excluded. Other possible 
causes suggested for an initial increase in the risk of death after HAART initiation 
included deaths due to drug toxicity or IRD or a delay in HAART having an effect. It is 
impossible to determine to what extent these play a role. Drug toxicity has been 
reported to cause death in the presence of liver flare. However few deaths in DART 
were reported as being due to liver disease and we did not find evidence of a rise in 
ALT before death. IRD has been reported against HBV [308] and the timing of the rise 
in risk of death does fit with a process occurring during immune reconstitution, in that 
IRD most often occurs during the first 90 days of treatment [309]. There is no 
indisputable definition of IRD but one commonly used includes: (i) onset after 
antiretroviral initiation or change, (ii) a rise in CD4 cell count by at least 50 cells/mm3 or 
by a factor of 2 or a decrease in HIV RNA by at least 0.5 log copies/mL, (iii) an 
inflammatory process and (iv) lack of an explanatory infectious cause of the signs and 
symptoms observed [310]. In trying to explain the incidence of death after treatment 
initiation in DART we are limited in that all participants recently started treatment, HIV 
RNA data is not available and we have limited information on infectious conditions. 
However we can likely exclude IRD against HBV in hepatocytes since so few of those 
who died in the first 24 weeks had raised ALT at death and there was no difference in 
ALT by HBsAg status. CD4 count was measured in DART but it has been suggested 
that CD4 rise may not be relevant in IRD since restoration of immune function may not 
be directly related to CD4 cell count in plasma [311]. Studies of IRD related to other 
conditions such as TB or cryptococcal disease have attempted to identify other factors 
in blood that may be related, such as IL-6, IFN-γ, TNF-α and others [312]. Crane found 
CXCL-10 and soluble CD30 to be associated with liver inflammatory flares after starting 
antiretroviral treatment [202] and suggested that such flares are due to IRD [313]. 
Andrade examined biomarkers of inflammation in HBV/HIV coinfected patients and 
identified increased D-dimer, IL-6 and soluble CD14 as associated with mortality while 
increased I-FABP was associated with a lower risk of death [314]. The same study 
identified increased ALT and IL-10 at baseline as associated with a liver flare in the first 
4 months on ART and increased CCL26 associated with a lower risk of flare. Testing 
for such immune markers has not been performed on the DART population. Liver 
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biopsy would also be very useful to determine whether drug toxicity or IRD were 
involved in deaths but DART participants did not have liver biopsies [310]. 
Despite the higher risk of death in those with HBsAg there was no evidence of an 
increase in death due to liver disease. This is surprising in light of the greatly increased 
rate of liver-related death demonstrated in the Multicentre AIDS Cohort Study (MACS) 
[118]. However there are significant differences between the MACS and DART 
populations. HIV-positive patients in the MACS study included individuals on and off 
HAART and with higher CD4 counts and the whole of the MACS study period 
examined was prior to the introduction of TDF. In addition, our lack of finding an 
increase may be related to low numbers; there were 61 liver-related deaths in the 
MACS study but only 15 in the current one.  
We did not find an association between baseline ALT and mortality or between 
baseline platelet count (which may be reduced in advanced liver disease) and 
mortality. This is in contrast to previous findings, for example in the Veterans Aging 
Cohort Study both ALT [315] and FIB-4 (which includes ALT and platelet count) [316] 
were associated with all-cause mortality. In addition we did not find a significant 
increase in ALT before death compared to baseline, which also suggests that few 
deaths were related to liver inflammation. 
However this study, in common with many others including the Tanzanian study 
referenced above [199], suffered from a lack of clarity in cause of death, in that in one 
fifth of deaths no cause of death was determined. This limits the validity of our findings. 
However there are inherent problems in cause of death analyses of HIV populations, 
as reviewed by Justice [317]. HIV has many effects, not only immunosuppression, but 
also including immune activation and inflammation, anaemia and thrombocytopaenia 
and interactions with infections such as hepatitis B. Other factors involved in risk of 
death include age, sex, smoking, alcohol, other comorbidity and drug toxicity and these 
may well not act independently of one another and of HIV-related factors. The added 
complication that many deaths occur away from health facilities make it even harder to 
record accurate causes of death. Thus, Justice argued for not performing cause of 
death analyses but rather analysing all-cause mortality.  
As noted in chapter 1, there is a risk that any association found between coinfection 
and mortality may in fact be due to confounding factors, as in the SMART study, in 
which although the risk of non-AIDS death was higher in those with HBV or HCV 
coinfection, such deaths were very rarely due to liver disease with the three most 
commonly stated causes being “unknown”, substance abuse and non-AIDS 
malignancy [97]. This may help explain why in the present study the rate of death was 
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higher in coinfected participants and yet the majority of deaths do not appear to be as a 
result of liver disease. This would be in keeping with the fact that we found that 
treatment with TDF did not eliminate this difference in risk. This is again in contrast with 
the Tanzanian study mentioned above, in which they found that HBV coinfection was 
associated with an increased risk of death only in those not treated with TDF [199].  
There was also no increase in risk of death in those treated with NVP (in all participants 
or in those coinfected with HBV) despite NVP being a well-recognised cause of liver 
toxicity and indeed being associated with an increased risk of flare in the current study. 
8.4.3 Benefits of routine laboratory monitoring 
The overall risk of death was reduced in the LCM arm, as described previously [259]. 
However we found no evidence that routine 3-monthly laboratory monitoring reduced 
the effect of HBV infection on mortality. In fact we found a trend towards laboratory 
monitoring reducing the risk of death only in those who were HBsAg negative. This 
contradicts the conclusions of the authors of the Tanzanian study who suggested that 
“HIV/HBV co-infected individuals clearly need to be monitored more closely” [199]. 
Monitoring can only be of benefit to individuals if clinical decisions are made as a result 
of such monitoring. Any benefit of monitoring that could be detected in DART may be 
partially obscured since grade 4 abnormal results were returned to clinicians regardless 
of study arm (LCM or CDM). However only 26 (0.8%) DART participants had a grade 4 
rise in ALT during follow-up (as described in chapter 6) and the majority of participants 
(54.0%) had normal ALT throughout follow-up while only 8.3% had a rise of ALT of 
greater than Grade 1 (2.5x ULN [181]). Of 80 participants with a flare (chapter 6), in 
only 25 (31%) were these flares followed by a change in treatment (18 of which were 
reported as being made due to liver disease) and 8 of these changes were 
interruptions after which the same regimen was restarted after a break of between 7 
and 43 days. Thus even when the result of a monitoring test was abnormal the test 
rarely resulted in a change in management. 
8.4.4 Conclusion 
HBV coinfection was associated with an increased risk of death in HIV-positive 
individuals on HAART. The reason for this increase remains unclear and may not be 
related to liver disease or immunosuppression. 
The use of TDF did not eliminate the increase in risk of death associated with HBV 
infection and so this analysis did not find evidence to support the use of more than one 
drug against HBV in coinfected patients, as recommended in guidelines [123]. 
We did not find evidence to support the use of routine monitoring of ALT. 
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9 Conclusions 
9.1 Epidemiology 
Of the 3,316 participants of the DART study, 1,829 (55.2%) had evidence of exposure 
to HBV and 308 (9.3%) were seropositive for HBsAg at study entry. Exposure was 
more common in Zimbabwe than in Uganda, in males than in females and with 
increasing age. HBsAg seropositivity was also more common in Zimbabwe and in 
males but age had no effect, either on the prevalence of HBsAg seropositivity in the 
whole population, or on the probability of having evidence of having cleared an 
infection if exposed. Of those with a positive HBsAg test result, 36.8% tested positive 
for HBeAg and 79.3% had detectable HBV DNA. HBeAg test results were more often 
positive in those with advanced HIV disease. As expected, DNA was more likely to be 
detected in plasma in participants with detectable HBeAg than in those without HBeAg 
and when detected to be at a higher level. Unlike HBeAg test results, DNA test results 
were not associated with stage of HIV disease. 
These results are in line with previously published prevalence of anti-HBc and HBsAg 
in Uganda and Zimbabwe (chapter 1, Tables 1 and 2). Data on the prevalence of 
HBeAg seropositivity in HBV/HIV coinfected individuals in Uganda and Zimbabwe is 
limited to 23 individuals in Uganda and 24 in Zimbabwe where the rates found were 
28% and 54% respectively [32, 48]. In a systematic review of viral hepatitis serology in 
sub-Saharan Africa, the prevalence of HBeAg in HBV/HIV coinfected individuals in 13 
studies was 17.1% (82/480) [20]. This review included the Ugandan study mentioned 
above [48]. 
However, put together with previous data, the results underline the fact that there are 
differences in HBV epidemiology not only between countries in sub-Saharan Africa but 
even between areas quite close together in the same country. These differences 
include variation in the proportion exposed and also in the outcome from exposure. 
Thus, in order for providers of HIV care to consider the importance of HBV coinfection, 
local epidemiological data is required since assumptions made about coinfection 
prevalence by extrapolating from data from elsewhere may well be inaccurate. 
9.2 Suppression 
A systematic review and meta-analysis of all available data describing HBV DNA 
suppression in HIV infected patients treated with TDF showed that 57.4% had fully 
suppressed HBV DNA at 1 year and the proportion suppressed increased over time to 
85.6% at three years. Suppression of HBV DNA to undetectable levels was more 
common at 1 year in those HBeAg seronegative, but at 2 and 3 years there was no 
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difference by HBeAg status. Suppression was durable, with very few patients 
experiencing breakthrough on treatment. There was no evidence that the proportion 
achieving suppression is increased when TDF is used with 3TC or FTC compared with 
when TDF is the only drug with activity against HBV. There was also no evidence that 
prior exposure to 3TC and/or FTC is associated with a lower probability of suppression 
when treated with TDF.  
DART included patients treated with 3TC as the only drug active against HBV. In the 
DART population we found similar results to those from the meta-analysis; half (51.2%) 
of those with quantifiable baseline HBV VL suppressed to undetectable after 48 weeks 
of treatment and two-thirds (68.6%) suppressed by the end of follow-up with no 
difference in suppression at 48 weeks between those treated with 3TC alone or with 
3TC in combination with TDF. Positive HBeAg status and baseline HBV VL >107 IU/mL 
were associated with failing to achieve an undetectable HBV VL. Maintenance of 
suppression once achieved was as likely in those treated with 3TC alone as in those 
treated with 3TC and TDF. In contrast to this lack of difference by treatment group, 
those treated with TDF who had not fully suppressed at one year were likely to go on to 
do so on continued treatment but none of those treated with 3TC alone who had failed 
to suppress at one year did so later.  
9.3 Flares 
Liver transaminase flares on starting ART were more common in HBsAg seropositive 
participants (HR 3.4) though in those treated with NVP, HBV coinfection was not 
associated with increased risk. 7 of 80 with a flare on first line ART died within a month 
of the flare. Only 1 of these 7 was HBsAg seropositive. Most flares on first line ART did 
not result in any clinical change and resolved spontaneously.  
Detectable HBsAg was also a predictor of flare on a switch to a second line ART 
regimen that did not contain TDF or 3TC (HR 4.5). Death was very common after such 
flares (50% of HBsAg seronegative and 75% of HBsAg seropositive participants, 
p=0.58) and liver failure a commonly cited cause although these results should be 
interpreted with caution as the absolute numbers were very low (3 deaths from 4 flares 
in HBV coinfected participants and 4 from 8 in HIV monoinfected participants) and 
deaths occurred up to 8 months after the onset of the flare. 
However HBsAg seropositivity was not a predictor of a flare when participants 
underwent 12-week structured treatment interruption and flares that did occur in such 
interruptions were not associated with death. 
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Laboratory monitoring strategy was not associated with a better clinical outcome in any 
of these scenarios. However any benefit of monitoring may have been obscured since 
results were returned to clinicians when grade 4 abnormalities were found. 
These somewhat contradictory results may be explained by the fact that (i) at study 
entry participants had advanced HIV disease and therefore a high risk of death, (ii) 
participants switching to second line may have done so as a result of a failure of first 
line therapy and thus be a population with a higher risk of death and (iii) subjects in the 
structured treatment interruption substudy were a selected group who had responded 
to treatment and thus were at a lower risk of death.  
9.4 Clinical Outcome 
There was no difference in CD4 count by HBsAg status, either at baseline or on ART. 
However HBsAg seropositive participants had a higher cumulative probability of 
reaching the two endpoints examined (progression to new WHO stage 4 event or death 
and progression to death) after treatment initiation. The difference between those 
HBsAg seropositive and those HBsAg seronegative appeared to occur within the first 
year of treatment, possibly after a lag of 2 months. The increased progression to new 
stage 4 event or death in those HBsAg seropositive was not significantly reduced in the 
laboratory monitoring strategy arm. However in HBsAg negative participants there was 
a reduced incidence in the LCM arm compared to the CDM arm. In HBsAg seropositive 
participants there was no reduction in progression in those treated with TDF compared 
to those treated with ABC or NVP. In fact the incidence of new WHO stage 4 disease 
or death was higher in the TDF group. However treatment allocation was not 
randomised or blind so this result may be a result of bias. 
Although all-cause mortality was higher, few deaths were recorded as due to liver 
disease and there was no evidence of more frequent liver inflammation at death (as 
measured by ALT) in those HBsAg seropositive compared to negative. In patients with 
advanced liver fibrosis the liver may be unable to produce enough ALT to have a high 
value and thus ALT may be misleading as a marker of inflammation. However platelet 
count at death was rarely very low, which suggests that few of the participants had 
advanced liver fibrosis or cirrhosis.  
9.5 Limitations 
The primary aim of this hepatitis substudy was to examine HBV virological suppression 
in coinfected participants of the DART study. One limitation of describing this 
suppression is that, as a result of time and resource constraints, in the majority of 
individuals we have HBV viral load measurements only at baseline, at week 48 and at 
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the end of first line therapy. In participants who had a detectable HBV VL at 48 weeks 
and an undetectable VL at the end of first-line therapy, HBV VL measurements at 
intervening points would allow us to better determine the time over which suppression 
occurs.  
In addition to showing the proportion of HBV/HIV coinfected individuals that achieved 
HBV virological suppression on ART we have also attempted to answer other 
questions relevant to the management of coinfection such as the effect of HBV-active 
treatment on progression. A better understanding would be gained if we were able to 
compare with a control group who received ART which did not have anti-HBV activity. 
However DART was a randomised controlled trial of monitoring strategy in which all 
participants received treatment with 3TC. We have compared participants treated with 
and without TDF although treatment allocation was not randomised. The study was 
performed in the absence of HBV testing and in a period when TDF was not routine. 
The latest guidelines for antiretroviral treatment from the World Health Organization 
state that TDF (with 3TC or FTC) should be included in first line regimens unless there 
are contraindications while AZT (with 3TC) is given as an alternative and ABC or D4T 
can be used in special circumstances [132]. 
One possible reason for failing to achieve virological suppression is poor adherence to 
therapy. DART participants had adherence assessed by a healthcare worker every 4 
weeks through the study. In the majority of cases of poor HBV VL response to 
treatment there was no association with poor adherence. However it may also have 
been informative to examine blood levels of ART in those who did not achieve an 
undetectable HBV viral load to estimate how many participants were exposed to sub-
therapeutic levels of drugs, whether through poor adherence or through drug 
interaction or malabsorption.  
Another explanation for virological failure is drug resistance. Mutations in the reverse 
transcriptase of HBV giving rise to resistance to 3TC are well recognised and 
characterised. On the contrary, mutations giving rise to resistance to TDF have not 
been consistently demonstrated. HBV resistance testing of baseline and on-treatment 
samples from participants in whom HBV DNA was detectable on treatment could 
demonstrate the contributions of both pre-existing and emergent viral resistance. Since 
the DART cohort contains a large number of HBV-coinfected participants treated with 
TDF and follow-up is long it would be a good population in which to look for the 
emergence of TDF resistance mutations. However there were only 10 participants 
treated with TDF that had HBV VL greater than 1,000 IU/mL after more than 48 weeks 
on treatment and so even in this large study, the absolute number of participants in 
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which to look for such resistance mutations is low. Sequencing will be performed but 
this represents further work beyond the scope of this thesis. 
In addition to not being able to compare patients treated with HBV-active and HBV-
inactive ART, our study would benefit from an HIV-negative control group. This would 
allow us to compare outcomes by HIV status. The published literature on HBV from 
resource-poor areas is more extensive in HIV-negative or HIV-untested than HIV-
positive populations. The degree to which this literature is directly relevant to HIV 
coinfected populations is unclear. The DART population all had advanced HIV disease 
with CD4 counts below 200 and so the relevance of our findings to individuals with 
higher CD4 count, including those with very high CD4 count who thus do not need 
immediate treatment, is also unclear. 
The outcomes we hope to avoid in HBV-infected individuals are liver failure and death. 
These become more likely as liver fibrosis progresses. In examining the issue of 
progression of liver disease this study would have greatly benefitted from a well-
validated measure of liver fibrosis. Paired liver biopsies have been used to determine 
fibrosis progression and biopsy is the gold standard measurement of liver fibrosis. 
However transient elastography (TE, FibroScan®) is being increasingly used in 
resource-poor areas as well as resource-rich ones. For example, in a study of 59 HBV-
monoinfected patients in Burkina Faso, TE has been shown to perform very well 
against biopsy (AUROC 0.87 to distinguish F0-1 from F2-4) [318]. However a study of 
117 HBV-monoinfected patients in Indonesia found TE did not perform any better than 
APRI (AUROCs: TE 0.72 vs. APRI 0.80 for F0-1/F2-4 and TE 0.87 vs. APRI 0.86 for 
F0-2/F3-4) [319]. Unfortunately, in DART ALT was tested routinely in all patients but 
AST was not. Thus we are unable to calculate APRI for all participants. 
Although this study benefitted from long follow-up of up to 5.8 years this may not be 
long enough to observe some benefits of treatment. Recent data from a study in HIV-
negative patients showed that a reduction in risk of HCC only became apparent 3.3 
years after initiation of TDF [320]. Thus longer follow-up may show increasing 
differences between those treated effectively and those not. However this study used a 
risk score equation developed and validated in Asian individuals (from Taiwan, Hong 
Kong and South Korea) infected with HBV without HIV coinfection, untreated for HBV 
and followed for a median of 12.0 years [321]. The authors cautioned against applying 
the model to HIV coinfected individuals and thus a model developed and validated in a 
sub-Saharan African coinfected population would be useful. The model in HBV 
monoinfection was developed using a cohort of over 3,500 and validated with a further 
1,500 individuals. P-values derived from the Cox model were small (generally <0.001) 
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so it may be possible to develop a model in a smaller cohort but the DART HBV/HIV 
coinfected cohort is only one tenth the size. Of more importance, the risk equation 
development cohort included 131 and the validation cohort 111 who developed HCC 
while in DART only 1 death was recorded as being due to HCC. The on-treatment 
cohort included 641 patients followed for 6 years and 13 developed HCC [320]. If we 
accept the observed rate of HCC in DART to be accurate any reduction in HCC rate 
will be of minimal benefit at best. 
HBV immunisation was introduced into childhood schedules in Zimbabwe in 2000 and 
in Uganda in 2002 and coverage is estimated at 95% and 78% respectively [37, 38]. 
Thus 4 years from now the first cohort immunised at birth will become young adults. 
This will clearly have dramatic effects on the disease burden due to HBV, but HBV 
coinfection will continue to be a major problem for decades to come for those already 
infected. There is no data on HBV incidence in sub-Saharan Africa and so it is hard to 
predict whether immunisation of HIV-positive adults (as recommended in UK guidelines 
[125]) would have a significant effect. Retesting HBV serology at the end of follow-up in 
those of the DART population who were negative for all HBV markers at baseline 
would allow an estimate of HBV incidence to be made, as well as an indication of the 
probability of HBV clearance or chronicity in this population. However the incidence of 
HBV can be expected to be low in the DART population, since a recent study showed a 
reduced incidence of 0.14/100py in HBV-susceptible HIV-positive MSM treated with 
TDF and 1.36/100py in those treated with 3TC/FTC, compared with an incidence of 
2.85/100py in those not treated with HBV-active drugs [322]. 
9.6 Change in clinical practice 
The vast majority of HBV/HIV coinfected patients starting antiviral treatment now will 
start a triple therapy ART combination that includes TDF and either 3TC or FTC, in line 
with treatment guidelines [124, 132, 134]. We found no reduction in clinical progression 
in those HBsAg seropositive participants treated with TDF compared to those treated 
with ABC or NVP (each given in combination with AZT and 3TC), which might have 
been expected if TDF was more effective against HBV. Thus, although HBsAg 
seropositive participants were more likely to progress and die than HBsAg negative 
participants it is not clear that knowledge of HBsAg status, in order to ensure treatment 
of HBV, offers any benefit. 
We found evidence that HBV coinfection increased the risk of flare on starting therapy 
but these flares were without clinical consequence and thus knowledge of HBsAg 
status would not affect outcome. Similarly knowledge of HBsAg status would not affect 
outcome in structured treatment interruptions undergone by participants with good CD4 
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count on stable ART. However, in participants switching to second line, HBsAg 
positivity was associated with a high risk of flare, and these flares were frequently 
associated with death.  
These results imply that, as far as liver transaminase flares are concerned, there is no 
clinical benefit in knowing HBsAg status on HBV/HIV dual-active treatment initiation or 
in stable participants with good CD4 response to ART undergoing STI but that it may 
be very important to determine HBsAg status before stopping HBV-active ART. These 
results support WHO guidelines which state that HBsAg testing at HIV diagnosis and 
before switching antiretroviral regimen at treatment failure is “desirable (if feasible)” 
[132]. The WHO guideline suggests that, when switching off TDF, patients could be 
treated with an “alternative drug for hepatitis B treatment (such as entecavir)”. 
A large proportion of individuals achieved HBV virological suppression regardless of 
treatment regimen and those treated with 3TC alone were as likely to remain 
suppressed as those treated with 3TC and TDF. However, in those that had not 
achieved an undetectable HBV VL at one year, treatment with TDF was likely to result 
in suppression later whereas treatment with 3TC never did. Thus a treatment strategy 
could be to treat with 3TC and test HBV VL at 48 weeks. Those that have detectable 
HBV VL should then switch to TDF while those that have achieved complete 
suppression can continue on 3TC as the only HBV-active treatment. The results of the 
meta-analysis show that suppression on TDF is not affected by prior 3TC exposure. 
However this strategy would rely on HBV VL monitoring which is unavailable in many 
resource-poor areas, including much of Africa. A cheap and reliable test that could 
distinguish between detectable and undetectable HBV VL could be enough to inform 
this strategy. New WHO guidelines advise that HIV VL testing should be used 
wherever possible but state that less than 20% of those on antiretroviral therapy in 
Africa have HIV VL monitoring [132, 323]. Recent cohort evidence from resource-
limited settings has supported the benefit of moving to HIV VL monitoring [324]. Point-
of-care tests for HIV VL are in development and such technological advances should 
facilitate the development of similar tests for HBV VL. HIV VL point-of-care tests may 
provide only a binary result (with a cut-off of perhaps 1000 IU/mL) which, in the case of 
HBV, could be useful in monitoring those with suppressed virus but not useful in 
determining the trend of HBV VL in those who have yet to suppress. 
In the absence of HBV VL testing, ALT could be used to monitor patients for HBV VL 
rebound on treatment. However we did not find rises in ALT associated with virological 
rebound in the participants in the DART study, suggesting that this strategy is not 
effective. 
 Chapter 9: Conclusions Page 201 of 240 
While clinical progression (to new WHO stage 4 disease or death) was higher in those 
with detectable HBsAg, it appears that in HBsAg-positive participants, routine 
monitoring (including testing ALT) does not affect clinical outcome. Overall, the DART 
study found there was a benefit from routine monitoring, although the benefit was small 
when comparing both groups with an untreated historical cohort and outcomes for both 
groups were comparable with those achieved in resource-rich areas [259]. It may be 
that routine monitoring does not need to include ALT. WHO guidelines suggest ALT 
testing only when patients are treated with NVP, and then only in certain populations at 
increased risk of liver flare [132]. 
The results of this DART hepatitis substudy suggest that treating with 3TC as the only 
HBV-active drug may be a reasonable strategy but that in these patients detection of 
virological failure at one year would indicate a need to switch to a more potent regimen. 
However both the substudy and the meta-analysis suggest that if patients are treated 
with TDF, patients who have not yet achieved full suppression of HBV VL at one year 
can reasonably be continued on the same regimen with an expectation of suppression 
occurring later. Thus it may be that testing of HBV VL in patients on TDF would not 
give any benefit in determining clinical practice. 
In summary, the following conclusions can be made of particular relevance to clinical 
practice: 
(1) HBV prevalence may vary widely between populations even in close 
geographical proximity. 
(2) Knowledge of HBV status infrequently influences clinical decision making. 
(3) Knowledge of HBV status is important if patients are to stop HBV-active 
treatment.  
(4) Clinicians should consider whether to continue HBV-active treatment in patients 
with detectable HBsAg when such drugs are no longer indicated for treatment 
of HIV. 
(5) HBV VL testing is of limited benefit in patients treated with TDF. 
(6) HBV VL testing may be useful to determine the need for treatment switch if first-
line HBV treatment is with 3TC alone. 
(7) Routine ALT testing is of limited use in guiding management.  
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Appendix 1 – Systematic review search strings 
ISI Web of Science 
Topic=((TS=hepatitis OR TS=hbv) AND (TS=hiv OR TS=human immunodeficiency 
virus OR TS=AIDS OR TS=acquired immunodeficiency syndrome OR TS=acquired 
immune deficiency syndrome) AND (TS=tenofovir OR TS=TDF OR TS=truvada OR 
TS=viread)) 
 
Timespan=All Years. Databases=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH.  
 
EMBASE & MEDLINE 
((exp HUMAN IMMUNODEFICIENCY VIRUS/) OR (hiv.ti,ab) OR (exp ACQUIRED 
IMMUNE DEFICIENCY SYNDROME/) OR (aids.ti,ab))  
AND  
((exp HEPATITIS/) OR (hbv.ti,ab) OR (hepatitis.ti,ab))  
AND  
((exp TENOFOVIR/) OR (exp TENOFOVIR DISOPROXIL/) OR (tenofovir.ti,ab) OR 
(tdf.ti,ab) OR 
(viread.ti,ab) OR (truvada.ti,ab)) 
 
[Limit to: Human and English Language] 
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Appendix 2 – Meta-analysis – Regression Stata code 
The following Stata command produced the estimates in the “overall” columns in Table 
10. 
xi: xtmelogit u i.prior i.con i.studytype || study: , or 
u 0 if not suppressed 
1 if suppressed 
prior 0 if not previously exposed to 3TC/FTC 
1 if previously exposed to 3TC/FTC 
con 0 if treated with TDF without concomitant 3TC/FTC 
1 if treated with TDF with concomitant 3TC/FTC  
studytype 1 if randomised controlled trial 
2 if prospective cohort study 
3 if retrospective cohort study 
study numbers 1-23 for the 23 studies included (Table 7) 
Estimates of effects within strata were obtained by selecting appropriate cases e.g. 
xi: xtmelogit u i.prior i.studytype if con==0 || study: , or 
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Appendix 3 – Results of meta-analysis – forest plots 
Figure 60: Meta-analysis – forest plots of study arms at year 1 
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Figure 61: Meta-analysis – forest plots of study arms at year 2 
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Figure 62: Meta-analysis – forest plots of study arms at year 3 
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Appendix 4 – Meta-analysis – Forest plot Stata code 
* HBV / HIV resistance studies 






set more off 
set mem 100m 
cap log close 
 
set scheme s2mono , permanently 
 
global drive H 
global data_dir     "$drive:\Documents\Thesis\Co-infection 
Review\Resistance\Stata\data" 
global log_dir      "$drive:\Documents\Thesis\Co-infection 
Review\Resistance\Stata\logs" 




log using "`r(datestamp)'_HBVHIV_meta_09_forest.log" , replace 
 
* Import from data directory 
**************************** 
cd  "$data_dir" 
insheet using "Table.2.1.csv" // NB includes group and overall totals 
rename firstauthor author 




gen con  =(with3tc =="Yes") 
drop source year prior3tc with3tc 
 
gen studyarm=_n 
label define sarm   /// 
 1 "Nelson"    /// 
 2 "Matthews"  /// 
 3 "Kosi"    /// 
 4 "Tan"    /// 
 5 "Group A"   /// 
 6 " "    /// 
 7 " "    /// 
 8 "Dore"    /// 
 9 "Bani-Sadr"   /// 
 10 "Stephan"   /// 
 11 "Nelson"   /// 
 12 "Schmutz"   /// 
 13 "Jain"    /// 
 14 "Matthews"   /// 
 15 "Nuesch"   /// 
 16 "Tuma"    /// 
 17 "Kosi"    /// 
 18 "Lee"    /// 
 19 "Tan"    /// 
 20 "Kuzushita"   /// 
 21 "Avhingsanon"   /// 
 22 "de Vries-Sluijs"  /// 
 23 "Rodriguez"   /// 
 24 "Engell"   /// 
 25 "Group B"   /// 
 26 " "    /// 
 27 " "    /// 
 28 "van Bommel"   /// 
 29 "Stephan"   /// 
 30 "Nelson"   /// 
 31 "Schmutz"   /// 
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 32 "Lee"    /// 
 33 "Kosi"    /// 
 34 "Tan"   /// 
 35 "Group C"   /// 
 36 " "    /// 
 37 " "    /// 
 38 "Marcelin"   /// 
 39 "van Bommel"   /// 
 40 "Stephan"   /// 
 41 "Nelson"   /// 
 42 "Peters"   /// 
 43 "Jain"    /// 
 44 "Gutiérrez"   /// 
 45 "Quiros-Roldan"  /// 
 46 "Tuma"    /// 
 47 "Lee"    /// 
 48 "Kosi"    /// 
 49 "Tan"    /// 
 50 "de Vries-Sluijs"  /// 
 51 "Engell"   /// 
 52 "Butt"    /// 
 53 "Group D"   /// 
 54 " "    /// 
 55 " "    /// 
 56 " "   /// 
 57 "All"   /// 
 58 " " 




* Make confidence intervals for each studyarm 
*   and get standard errors 
********************************************* 
foreach x of numlist 1 2 3 4 5 6 7 { 
 gen p`x'=s`x'/n`x' 
 gen l`x'=. 
 gen u`x'=. 
 gen se`x'=. 
 
 foreach y of num 1/58 { 
   if n`x'[`y']!=. { di n`x'[`y'] " " s`x'[`y']  
   qui cii n`x'[`y'] s`x'[`y'] , exact 
   qui replace l`x'=r(lb) if _n==`y' 
   qui replace u`x'=r(ub) if _n==`y' 
   qui replace se`x'=r(se) if _n==`y' 
  } 
   } 
} 
 
list s1 n1 p1 l1 u1 s2 n2 p2 l2 u2 s3 n3 p3 l3 u3 if  /// 
 author=="A" | author=="B" | author=="C" |  /// 
 author=="D" | author=="All", noobs 
 
* Draw forest plots 
******************* 
foreach x of numlist 1 2 3 4 5 6 7 { 
 twoway (scatter p`x' studyarm [fweight = n`x'] ,    /// 
  msize(vsmall) msymbol(square) )      /// 
  (rcap l`x' u`x' studyarm),       /// 
  ylabel(0 "0" 0.25 "25" 0.5 "50" 0.75 "75" 1 "100")  /// 
  yscale(alt)         /// 
  legend(off) ytitle("") xtitle("")      /// 
  xlabel(#58, labsize(vsmall) angle(vertical)    /// 
  valuelabel )         /// 
  xline(6.5 26.5 36.5 54.5, lcolor(black) lwidth(thin))  /// 
  graphregion(fcolor(white) lcolor(white))  
 graph export forest_y`x'.png , replace 
} 
 
cap log close 
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Appendix 5 – Results of meta-analysis – Funnel plots  
Figure 63: Funnel plots of standard error against proportion undetectable at one 
year – by analysis group 
  




 Group B Group D 
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Appendix 6 – HBsAg screening tests and repeat tests 
All 3,316 patients had a screening test for HBsAg; 610 (18.4%) were positive with the 
proportion positive being much higher at Entebbe (26.6%) and Harare (23.4%) than at 
JCRC (8.1%). Of these 610 with a positive HBsAg screening test, 605 had a 
confirmation test; 2 at Harare and 3 at JCRC did not. The proportion of those who had 
a positive screening test who subsequently had a positive HBsAg confirmation test was 
much lower at Entebbe (30.6%) than at either Harare (71.6%) or JCRC (81.0%). 
On subsequent testing, 35 of the 83 participants at Entebbe with a confirmed positive 
HBsAg result had either negative results for all other HBV markers (anti-HBc, anti-HBs, 
HBeAg, anti-HBe and HBV DNA), had positive results for both anti-HBc and anti-HBs 
with negative results for HBeAg and HBV DNA or, in one case, had positive anti-HBs 
but negative anti-HBc, HBeAg, anti-HBe and HBV DNA. When considered in the light 
of the suspiciously low confirmation rate in Entebbe, it was suspected that these could 
have been falsely positive HBsAg. Samples were sent to JCRC for repeat HBsAg 
testing; 27 tested negative and 8 tested positive. Those testing negative were 
reclassified as HBsAg in all subsequent analyses [Table 63]. 
Of the 56 participants at Entebbe with a final positive HBsAg result, 8 had had HBsAg 
retested and found to be positive at JCRC, 40 had a positive result for HBV DNA, 7 had 
positive anti-HBc without positive anti-HBs and 1 had positive HBsAg and negative 
anti-HBc but insufficient sample remaining for any other testing. Thus the final 
classification of Entebbe participants as HBsAg seropositive is believed to be reliable. 
Table 63: Patterns of results in Entebbe patients subsequently retested for 














Pos Neg  Neg Neg Neg 14 2 12 
Pos Neg Neg Neg Neg Neg 8 2 6 
Pos Neg Pos Neg Neg Neg 1 0 1 
Pos Pos Pos Neg Neg Neg 6 2 4 
Pos Pos Pos Neg Pos Neg 6 2 4 
Pos: positive. Neg: negative. 
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The three participants at JCRC all had detectable anti-HBc at baseline and were 
treated as HBsAg seropositive in all subsequent analyses.  
Of the two participants in Harare without a confirmation test, one was anti-HBc 
seropositive and one anti-HBc seronegative. The one that was anti-HBc seropositive 
was also tested for HBV DNA at baseline and this was detectable at a level of 976 
IU/mL. This participant was then considered HBsAg seropositive while the other was 
excluded. 
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Appendix 7 – HBV serology results combinations 
Anti-HBc HBsAg Anti-HBs HBeAg Anti-HBe Frequency 
 NEG NEG   3 
 NEG POS   1 
 POS  NEG POS 1 
NEG  NEG   1 
NEG NEG    1166 
NEG NEG  NEG NEG 12 
NEG NEG  NEG POS 1 
NEG NEG NEG   270 
NEG NEG NEG NEG NEG 6 
NEG NEG POS   26 
NEG NEG POS NEG NEG 1 
NEG POS    5 
NEG POS  NEG NEG 25 
NEG POS  NEG POS 2 
NEG POS  POS NEG 15 
NEG POS  POS POS 1 
NEG POS NEG NEG NEG 3 
NEG POS NEG NEG POS 1 
NEG POS POS   1 
NEG POS POS NEG NEG 1 
POS NEG    13 
POS NEG  NEG POS 3 
POS NEG NEG   533 
POS NEG NEG NEG POS 6 
POS NEG NEG POS NEG 3 
POS NEG NEG POS POS 1 
POS NEG POS   950 
POS NEG POS NEG NEG 5 
POS NEG POS NEG POS 7 
POS POS    19 
POS POS  NEG NEG 19 
POS POS  NEG POS 94 
POS POS  POS NEG 71 
POS POS  POS POS 4 
POS POS NEG   1 
POS POS NEG NEG NEG 4 
POS POS NEG NEG POS 18 
POS POS NEG POS NEG 10 
POS POS NEG POS POS 1 
POS POS POS   2 
POS POS POS NEG NEG 4 
POS POS POS NEG POS 5 
POS POS POS POS NEG 1 
Total     3316 
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Appendix 8 – My role 
I am responsible for the work that makes up this thesis. 
I carried out a review of the literature around HBV/HIV coinfection and wrote the 
background chapter, with a view to setting out the context of the research. 
In conjunction with my supervisors, I decided upon the analyses to be performed. I 
wrote the necessary Stata code to tidy the data and run the analyses. 
The meta-analysis arose from an attempt to review the published data on the 
suppression of HBV in HIV-infected patients treated with tenofovir. I decided upon the 
end point and treatment categories and extracted what data I could. Many studies 
presented data which did not quite fit the categories and so I contacted lead authors 
asking for further data. Some of this data came in the form I requested, fitting the 
analysis; some came in form of spreadsheets of results which I then had to convert into 
usable Stata files. I wrote the Stata code and performed the analyses and wrote the 
draft of the paper which I then circulated to the other authors and I then rewrote it 
incorporating their comments. I formatted and submitted it for publication. 
For the DART analyses, I first coordinated the testing of the samples. This involved 
1. Planning testing, ordering assays and organising their delivery. 
2. Communicating with laboratories to monitor progress.  
3. Receiving results in the form of excel spreadsheets, tidying and converting them 
into Stata format. 
4. Organising quality control provided by UKNEQAS. 
I presented partial results at meetings. 
I wrote the thesis and edited it after discussion with my supervisors. 
The PhD was funded by a Clinical Research Training Fellowship from the Medical 
Research Council, which paid my salary, fees and costs for the initial three years, 
extended to 4 by UCL (assay costs were funded by Gilead). Since my thesis was 
primarily one of analysis and had no lab-based component I felt I should study to 
understand how and why statistical tests are applied and how they work. To do this I 
attended lectures and practicals of 10 modules taken from the undergraduate statistics 
degree course. As I was registered for the MPhil/PhD I was unable to register for a 
statistics degree or diploma and so I did not sit the exams. 
 Appendices  Page 235 of 240 
Through being a member of the research department I also had the opportunity to be 
involved in other interesting studies, notably the analysis of HBV in UK CHIC and the 
analysis of HCV in the Gay Mens Sexual Health Survey.  
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Appendix 9 – Presentations and publications 
H. Price, D. Dunn, T. Zachary, T. Vudriko, M. Chirara, C. Kityo, P. Munderi, J. 
Hakim, C. Gilks, D. Pillay, R. Gilson, DART Virology Group 
Low risk of alanine aminotransferase (ALT) flares in HBV/HIV coinfected patients  
starting HAART in the DART Study 
7th International Workshop on HIV & Hepatitis Co-infection, 2011, Milan, Italy 
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H. Price, D. Dunn, T. Zachary, T. Vudriko, M. Chirara, C. Kityo, P. Munderi, J. 
Hakim, C. Gilks, D. Pillay, R. Gilson, DART Virology Group 
Potent HBV therapy and availability of laboratory monitoring fail to abrogate 
increased risk of death in HBV-HIV-co-infected individuals in the DART study 
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 2011, 
Rome, Italy 
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H. Price, D. Dunn, D. Pillay, T. Zachary, T. Vudriko, C. Kityo, P. Munderi, J. Hakim, 
C. Gilks, R. Gilson, and DART Virology Group 
Brief antiretroviral interruptions do not increase the risk of liver flares in HBV/HIV 
coinfected individuals on dual-active treatment  
20th Conference on Retroviruses and Opportunistic Infections, 2013, Atlanta, 
USA 
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Stephan, C., Tan, L., Gilson, R. 
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic 
review and meta-analysis.  
PloS one. 2013;8(7):e68152. 
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